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Malaria is a devastating parasitic disease in humans caused by species in the genus Plasmodium.
With over 100 million cases and at least 1.5 million fatalities each year, the disease accounts for
4-5% of all fatalities in the world. A recent increase in the number of malaria cases in South
Africa has imposed severe costs on the economy and public health.
Immunity to malaria is a multi-component system involving both B and T celllymphocytes.
Pc96 is a 96 kDa antigen identified in the mouse malaria model Plasmodium chabaudi adami. It
is known to be associated with the outer membrane of mouse erythrocytes infected with the
parasite and has shown protective roles in mice challenged with P. chabaudi adami. A specific T
cell clone has been identified that adoptively provides protection to athymic mice infected with
P. chabaudi adami. Antibodies raised against Pc96 identified proteins that induced the
proliferation of the protective T cell clones. At least four other antigens of different species of.
malaria share at least one cross-reactive epitope.
In an attempt to identify aPlasmodiumfalciparum homologue ofPc96, the amino-acid sequence
was used in a BLAST search of the P. falciparum genome database, identifying a 403 kDa
protein with a high degree of homology to Pc96. Sequence alignments indicated a region
spanning 90 amino acids in Pf403 that overlaps the Pc96 amino acid sequence. A 178 kDa
protein in P. yoelii yoelii (Pyy178) was shown to be highly similar to Pc96. Tvcell epitope
prediction programs identified putative T cell epitopes in Pc96 which appear to be conserved in
Pf403 and Pyy178. A casein kinase IT phosphorylation site was also identified in this region and
is conserved in both sequences. PCR primers were designed to amplify regions of the
MAL3P6.11 gene coding for Pf403 from P.falciparum genomic DNA. An 817 bp region in the
MAL3P6.11 gene was amplified. This codes for the region ofPf403 that shows high homology
to Pc96 and contains the conserved T cell epitopes and casein kinase phophorylation site. A
BamHI site was incorporated into the forward primer to facilitate in-frame ligation with cloning
vectors. The PCR product obtained was verified by restriction analysis using HindIII and EcoRI
sites within the fragment.
The 817 bp peR product was cloned into the pMOSBlue vector using a blunt-ended PCR cloning
kit, and transformed into MOSBlue competent cells. Recombinants were identified using the u-
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complementation system, and verified by PCR, plasmid DNA isolation, and restriction digestion
analysis. The insert DNA in pMOSBlue was cut out with BamHI and sub-cloned into the BamHI
site in the pMAL-C2x expression vector. Sequencing ofthe construct confirmed the identity of
the cloned insert and showed the sequence to be in frame with the malE gene coding for maltose
binding protein (MBP). The fusion protein, MBP-Pf32 .5, was induced and expressed as a 75 kDa
protein comprising of the 32.5 kDa region ofPf403, and MBP (42.5 kDa) and was detected by
anti-MBP antibodies, by western blotting. This recombinant protein has many applications for
further studies involving the characterisation of the Pf403 protein, and the determination of
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1.1 Biology of malaria
Malaria is a protozoan disease of the group Sporozoa (Brock and Madigan, 1994). The human
disease is caused by a parasite that has a highly specific requirement for man as a vertebrate host
and the Anopheles mosquito as a vector. Malaria is seen by many to be the most important and
influential disease in human history. It has played a significant role in the spread and development
of culture and evolution of man and is thought to have originated in Africa up to 30 million years
ago. The adaptive ness and success of the parasite as a pathogen indicates a long and close-knit
relationship with humans. The severity of the malaria problem is appreciated when one considers
that over 100 million malaria cases are estimated worldwide, with at least 1.5 million fatalities
each year. This accounts for 4-5% of all fatalities in the world (Brock and Madigan, 1994).
There are four species of malaria that cause fever in humans: Plasmodium vivax, P. ovale, P.
malariae, and P. jalciparum. The most lethal, Plasmodium jalciparum, is the most devastating of
these species, commonly present throughout the many regions of the world, causing serious
infection and cerebral malaria. Most of the deaths occur in young children and pregnant women in
the sub-Saharan African regions. Newborn infants in these affected regions suffer complications
from low birth weight caused by malaria infection during pregnancy. In most cases the patient will
survive the illness yet will be sick for 10 to 20 days, placing hindrance on work productivity and
education (phillips, 2001).
The early 1960's saw drastic anti-malarial campaigns having a large effect on the eradication of
malaria in many regions of the world, however modem times has seen an increase in the disease,
re-affecting many of the regions thought to have been cleared. Several factors have caused this
including recent wars and conflicts, a dramatic increase in migration from malarias areas, poor
health facilities in developing countries and general poverty. The global ban on
dichlorodiphenyltrichloroethane (DDT) prevented the total eradication of the disease from these
regions. In general the rapid increase in global temperatures together with drug resistance makes
effective control of the epidemic an emergent and immediate worldwide problem (Greenwood et
al., 1991). The distribution of drug-resistant malaria is shown in Figure 1.1.
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Figure 1.1 The worldwide distribution of chloroquine resistant Plasmodium falciparum.
One of the first goals of researchers is to rapidly develop new tools needed for the effective control
of the disease. During the early 1990's many efforts at solving the problem included different
approaches and strategies, such as the use of insecticide-impregnated bed nets. In more recent
times, efforts largely have been focused on molecular and genetic strategies targeting both the host
mosquito and parasite biology. The genetic biocontrol of the mosquito has been one of the main
angles for research into control. The increase in knowledge of the disease due to the availability of
the Plasmodium jalciparum genome, has led to the discovery of vital features of the immune
system with regard to the development of a protective vaccine against the disease (Collins and
Paskewitz, 1995).
Although progress has been made slowly in this field, the development of a human malaria
vaccine has proved to be a lot more complicated than previously believed. The immune
mechanisms involved in malaria infections have been extensively studied although complicated by
the extensive life cycle of the parasite, confining specific protective antigens to specific stages of
development and pathogenesis (Zavala et aI., 1985). Some of the malaria proteins with vaccine
potential, such as MSP-1 (malaria surface protein) have a high degree of antigenic variation
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between clones, protecting only against specific strains in specific regions. Others may possess
multiple copies of genes with different receptor specificities, altering the human host erythrocyte
through the control and regulation of these genes (Miller et al., 1994).
These challenges have indicated the need for a more multi-faceted approach towards the design of
a vaccine against malaria. Recombinant proteins, attenuated vaccinia viruses, and DNA vaccines
have been studied recently. Recombinant proteins derived from different antigens representing
different stages of parasite growth, offer possible solutions to immunization against the parasites
highly complex life cycles (Stanley, 1998). New techniques in the identification of potential
vaccine antigens, along with molecular cloning and protein expression systems have allowed many
promising research opportunities. The recent sequencing of the parasites genome has revealed a lot
more information both from the protein and gene perspectives (Gardner et al., 2002).
The four main species of malaria parasites causing disease in humans (P. jalciparum, P. vivax, P.
ovale and P. malariae) contain several unique features suited to the disease they cause. The
relapsing malarias caused by P. vivax and P. ovale can remain dormant in the liver for very long
periods (hypnozoite stage). This capability allows the parasite to survive in regions that contain
winters or periods where reproduction and transmittance is impossible. P. malariae is unique in its
ability to survive for many years at extremely low parasite densities in the infected host (Collins
and Paskewitz, 1995).
The plasmodial existence in the host involves a complex life cycle with three distinct phases in the
mosquito and two in the human (Figure 1.2). The parasite is first transmitted to humans through
the saliva of infected Anopheles mosquitoes, during a blood meal. Only a few hundred sporozoites
pass directly from the mosquito salivary gland system and into the blood stream of humans where
invasion of the liver takes place soon after infection (Phillips, 2001). The molecular basis for liver
cell invasion is not entirely known, however the recognition and attachment to the cells has been
shown to involve specific ligands on the outer sporozoite membrane such as circumsporozoite
protein (CSP). After several weeks in the liver, the parasite develops into what is known as the
schizont form (Oaks et al., 1991). The schizont contains several thousand 'daughter' parasites
known as merozoites, which are released from the liver into the blood where the infection and
invasion of erythrocytes occurs (Phillips, 2001). Some of the sporozoite structures can remain
dormant inside the liver cells for a number ofyears until they are reactivated and reinfection of the
red blood cells occurs (depending on the particular species). The merozoite matures inside the
infected erythrocyte forming a new schizont structure known to contain 8 to 32 new merozoites.
The erythrocyte eventually ruptures after roughly 48 hours releasing the merozoites into the blood
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stream where they are free and available to invade and infect other erythrocytes. It is at this point
in the life cycle that fever associated with the clinical effects of malaria occurs (Oaks et al., 1991).
The morbid ity and mortality of the disease only appears at this stage (Phillips , 2001). Figure 1.2
shows the malaria life cycle, in the Anopheles mosquito and human host.
HumanLiverStages
)
Figure 1.2 The life-cycle of the malaria parasite in man and the Anopheline mosquito host
http://www.cdc.gov/malaria/biology/life_cycle.html
Several of these new merozoites will develop into sexual structures known as gametocytes, and if
ingested by a mosquito then male and female gametes will fuse, forming a zygote. The zygote
elongates over the next 12 to 48 hours forming an ookinete, which penetrates the insect's stomach
wall and becomes an oocyst. This structure will enlarge over the next few days forming thousands
of sporozoites. When the oocyst ruptures, the sporozoites move to the mosquito salivary glands,
ready for the next cycle (Oaks et al., 1991).
The cycle takes approximately 7 to 18 days after gametocyte ingestion, depending on factors
related to the host-parasite combination and environmental conditions. A large proportion of these
developmental stages are haploid , apart from the zygote, which is diploid (Billingsley and Sinden,
1997). It is at this stage where meiotic cell division occurs allowing genetic recombination.
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1.2 Malaria control and diagnosis
The complexity of the malaria life cycle and the different stages of Plasmodium development
provide an opportunity for a range of control measures. The biology of the vector does not lend
itself to a simple or universal control method and the most effective form of control has been
insecticide like DDT. Parasite development involves long term survival within the mosquito host,
making the host vulnerable to insecticides before transmission of the parasite occurs. The
modification of breeding habitats, such as removal of swamps and breeding grounds for
Anopheles, has shown success in decreasing the disease in specific regions. Mosquito nets have
been impregnated with chemicals, and biological control agents have shown some success in
eliminating malaria from several regions (Collins and Paskewitz, 1995).
The prevalence of malaria in most of Europe and the USA declined in the early 1800's due to the
massive uprising of agriculture and the sudden elimination of many drainage systems and areas
such as wetlands and swamps. Eventually eradication of malaria in these regions was
accomplished by the availability of quinine, along with an increase in education and economical
status in the country, and better housing facilities. In the late 1940's the US Public Health Service
implemented large scale spraying with DDT and outbreaks were limited to infected migrants and
war veterans returning from infectious areas, such a Vietnam and the Middle East (Collins and
Paskewitz, 1995). This caused many to think that the total eradication of malaria as a worldwide
problem was a possible goal, with the use ofDDT to control the vector.
The Global Malaria Eradication Program was established in 1955 in order to defme specific
worldwide goals for the elimination of the disease and one goal was the reduction in infected
vector populations to such an extent as to interrupt further transmission and survival of the
parasite. In Sri Lanka malaria incidence was reduced from 2.8 million cases in 1946 to 17 in 1963,
yet when spraying was stopped an epidemic occurred in 1967 and a reintroduction of spraying was
ineffective due to resistance of the vectors to DDT. The disease caused more than half a million
cases by the end of 1967. By the early 1970's most resources were devoted to malaria control
instead of eradication and DDT was removed from the US market because of environmental
concerns. Agricultural spraying of insecticides for control of cotton and rice pests in El Salvador
caused resistance in mosquitoes to several new compounds (Collins and Paskewitz, 1995).
There are a number of species of host vector capable of transmitting the parasite, Anopheles
gambiae being the most common and abundant mosquito species. The insect primarily breeds in
temporary rain puddles and so control at the larval level is difficult. The removal of swamp and
6
en-catchment areas does reduce populations of mosquitoes but the removal of small puddles after
the rains is virtually impossible. In urbanized areas this control has been successful as the
mosquito prefers to breed in more accessible structures where control is easier (Collins and
Paskewitz, 1995).
Due to difficulty in the use of insecticides and the main environmental concerns that the chemicals
pose, a lot of research is now focussed on biological control agents for controlling the spread and
effect of malaria on specific populations. The most successful of these projects has been the use of
larvivorous fish in the control of Anopheles larval stages present in water sources. The use of the
North American fish, Gambusia affinis, in 3800 wells in India appeared to dramatically reduce
mosquito densities and biting rates by 75% due to a reduction in larvae. Environmental issues have
arisen due to the competition between G. affinis and indigenous fish in similar habitats. Several
other biocontrol agents such as pathogens and parasites have been studied. This is however
difficult due to the management and storage of these reagents, and successful use is proving
impractical in the field (Collins and Paskewitz, 1995). In several poor countries where malaria
poses a serious threat, the reduction and elimination of vector contact with the host has been the
most simple and straightforward approach through the use of repellents or physical barriers such as
bed nets. Bed nets are effective when impregnated with permethrin insecticides and produced a
70% reduction of clinical malaria in children though regions of Africa (Collins and Paskewitz,
1995).
In 1820, quinine was discovered in the bark of the South American Cinchona tree as an active
ingredient. A high demand for the new drug quinine resulted in a massive depletion of the wild
tree and soon after several Cinchona plantations were established. During World War 11, several
new compounds were discovered enabling the treatment and control of malaria infections, among
them chloroquine and atabrine. Chloroquine is thought to interfere with the polymerisation of
haeme molecules in the erythrocytes by the trophozoites due to the degradation of haemoglobin.
Haeme molecules are usually polymerised into granules called hemozoin, a non-toxic product. The
drug provided a cheap and effective solution for therapy yet resistance to chloroquine arose in the
early 1960's in South America and South East Asia, and spread through Africa in the 1980's
(Collins and Paskewitz, 1995). In 1989, strains of chloroquine resistant parasite infections were
discovered in Papua New Guinea and soon spread to the Indonesian side of the island, indicating a
spreading pattern and progression towards the rest of South East Asia (Baird, et al., 1991). Other
prophylactic drugs such as amodiaquine, pyrimethamine and proguanil have been used in
chloroquine resistant areas and antibiotics such as doxycyline have shown effectiveness (Collins
and Paskewitz, 1995).
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It is now believed that a number of different approaches shouldbe taken in vector control and
research towards eradication of the Anopheles mosquito has moved more towards transgenic and
genetic studies due to the development of drug resistance (Butler, 1997). The focus is now
transgenic mosquitoes that are incapable of spreading malaria, and the spread of these genes
involved in natural resistance throughout wild populations in the field. These genes are currently
being mapped using linkage studies with resistant strains of mosquitoes. A collaborated effort to
map the mosquito genome began in the late 1980's, which was of great benefit to these studies.
Other approaches include the engineering of mosquitoes with foreign genes conferring protection
against infection. The bigger challenge would be the introduction oftransgenic mosquitoes into the
environment. Engineered transposons can integrate and replicate into the genome of mosquitoes in
wild-type populations, which should result in the effective transfer of genes in the environment,
yet this is a controversial issue, as the safety of this procedure cannot be assured. The manipulation
and release of genetically altered organisms into the field may have several unknown detrimental
effects to the ecosystem and environment (Butler, 1997).
Malaria has become an increasing problem in South Africa over the last number of years. The
high-risk areas include the northern regions on Mpumalanga, and Northern KwaZulu-Natal,
including several of the game reserves alongside or near Mozambique (Kruger National Park).
Malaria cases have been reported as far south as Durban, and rapid control measures are needed
and an effective system in place for the prevention of further spread of the disease. In 1988, due to
drug resistance, various regions of the country such Mpumalanga and Northern KwaZulu Natal,
replaced the chloroquine drug with sulfadoxine- pyrimethamine (SP) for the successful treatment
and therapy of P. falciparum infections (Sharp and Le Sueur, 1996). In 2001, artemether
lumefantrine drugs replaced the pyrimethamine-based drugs, due to a rapid spread of SP resistant
malaria (Bredenkamp et al., 2001). Since then drug combinations including artemesinin
derivatives have shown success in therapy and a decrease in transmittance in regions of South
Africa due to the emergence of artemether lumefantrine resistance. The disease is seen as a huge
problem in South Africa, from a clinical point ofview, and in light ofHIV infection rate. Similarly
to other malarious regions in Africa and the rest of the world, a human malaria vaccine would be
the most effective method ofcontrol of the disease.
1.3 Immunology of malaria
Immune responses in humans leading to the efficient defense against disease-causing pathogens,
involves two separate mechanisms; humoral, and cell mediated immunity. All humoral
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mechanisms involve the action of antibodies and antibody-producing B cells and their respective
responses to infection. Cell mediated immunity is far more complex and involves the activation of
T cells leading to the intracellular and extracellular killing of malaria parasites (Clark, 1987). Cell
mediated immunity involves several attributes of the immune system including the interactions of
the B-lymphocytes and their antibodies within these cellular mechanisms. Cell mediated and
antibody responses in malaria infection are now seen as highly integrated functions. T cells appear
to function in promotion of protective antibody synthesis and as inducer cells in cell mediated
immune responses (Jayawardena and Murphy, 1982). The T-lymphocyte system plays an essential
role in re-infection immunity to malaria, in human populations with resistance in Africa. The
involvement of B cells in these infections is vital for the survival and resistance to chronic malaria
infections (Grun and Weidanz, 1981).
1.3.1 Humoral responses to malaria
Most research-based efforts into the design of human malaria vaccines has been based on the
initial observation that protection against the parasite is largely due to the involvement of the
humoral immune system and antibodies (Brake, et al., 1988). Originally it was thought that
antibodies were responsible for the phagocytic processes of parasitised erythrocytes by
macrophages during infection (Allison and Eugui, 1983). The role of antibodies has since been
studied more extensively, revealing more direct evidence. It has been shown that there are elevated
levels of antibodies during malarial infection in the sera from adult Africans. These antibodies
when transferred rapidly accelerated the recovery of African children from Plasmodium
falciparum infections (Cohen et al., 1961). In more recent studies, monoclonal antibodies have
been used to identify and defme stage-specific antigens and mechanisms for this immunity have
been analysed (Schofield et al., 1987).
There is growing evidence to suggest the role of immunoglobulin G (IgG) in protection against
malaria in humans. Human antibodies have been shown to efficiently inhibit in vitro P. falciparum
merozoite proliferation and the passive transfer of IgG have provided protection against
falciparum malaria in South American monkeys (Aucan et al., 2000). Some blood stage antigens
. may be the target of protective immunity and have been included in several vaccine trials in
humans. In particular ring-infected erythrocyte surface antigen (RESA), merozoite surface protein-
1 (MSP1) and merozoite surface protein-2 (MSP2) are of considerable interest as they have been
the targets of protective immunity in animal models and are recognised by naturally acquired
antibodies. These antigens consist of polymorphic and conserved B cell epitopes responsible for
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the elicitation of immune response (Aucan et al., 2000). More recent understandings of the
immune mechanisms during malaria infection have revealed an integration of the cell-mediated
responses, with regard to the involvement of T cells and their functions.
1.3.2 Cell Mediated Immunity
Mouse malaria models such as Plasmodium chabaudi adami and P. yoelii yoelii (both genomes
have been sequenced recently), have provided vast amounts of information about the immunology
of malaria infection. DNA sequencing has proven highly successful in the production of several
significant discoveries into the involvement of cell mediated mechanisms, and immunology in
general. Manipulation of the mouse immune system such as the removal of B and T cell
components has provided the basis for much new knowledge gained. B cells in mice can be
disabled by the continuous treatment of the mice with goat anti-mouse immunoglobulin M (IgM)
serum (Roberts and Weidanz, 1979). The mice were totally incapable of producing any antibody,
as indicated by their failure to elicit responses against standard antigens such as sheep
erythrocytes. The involvement of B cells in infections was assessed using these models. Mice also
can be rendered T cell deficient (athymic) and have been used extensively in this field to study the
dependence of the mice on an intact thymus and cell mediated immune system.
Grun and Weidanz (1981) have shown that B-cell deficient mice challenged with P. chabaudi
adami, resolved their infections in a similar manner to that seen in immunologically intact mice.
The ability of B cell deficient mice to show immunity against parasite infection indicates that cell
mediated immunity plays a significant role. The complexity of immune reactions involved in these
experiments was demonstrated by challenge with exogenous parasites P. berghei and P. yoelii,
producing fatal infections in B cell deficient mice. This suggests that different mechanisms of
immunity exist in different species and perhaps more than one immune mechanism is required for
resistance of infection with certain plasmodial species (Grun and Weidanz, 1981). Cell mediated
mechanisms of immunity were further studied using T cell deficient mice subjected to infection
with P. chabaudi adami. The failure of athymic (T cell deficient) mice to resolve P. chabaudi
adami infections shows that the development of immunity to P. chabaudi adami infection IS
dependent on an intact thymus-dependent system (Grun and Weidanz, 1981).
It is possible that certain T cell epitopes on plasmodial antigen are the primary targets for
protective cellular immune responses. These molecules can be seen as potential antigens and
should be investigated for their potential as immunizing agents (Brake et al., 1988). Multiple ·
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antigen peptides containing potential and known B cell epitopes were coupled to T cell epitopes
from tetanus toxin. The tetanus toxin is known to produce a strong cell mediated response. This ,
coupled to non-ionic block copolymer adjuvants, has shown an improved protective response in
malaria (Wang et al. , 1995) .
In comparison to B cell epitopes, T cell epitopes are far more difficult to identify. Plasmodium
protein antigens containing specific B cell epitopes can be identified systematically and with
relative ease, yet this does not apply to T cell epitopes. A solution to this has been the development
of protective T cell clones that are then used for identification of antigenic epitopes in fractionated
proteins or DNA libraries. T cell clones were obtained from volunteers immunized with irradiated
sporozoites, and were subsequently used to identify specific epitopes within antigens such the
circumsporozoite (CS) protein (Calvo-Calle, 1997). T cell clones have been able to provide
adoptive protection against malaria in mouse models (Brake et al., 1986). One of these clones
identified (CTR2.1), along with two subclones, was shown to effectively transfer protection to
athymic nude mice infected with P. chabaudi adami. The clones were also shown to secrete IL-2
and interferon y (IFN-y), when stimulated with plasmodial antigen. This may suggest a role of
these clones in the initiation of clonal expansion leading to further activation of host immune
mechanisms, and the production of anti-parasitic factors. These studies indicated that it was
possible that T cell epitopes were recognised on the surface of infected erythrocytes, causing the
eventual immune response seen in malaria infection (Brake et al., 1988). When athymic mice were
infected with the CTR2.1 T cell clone, they produced a polyclonal IgG antibody response against a
number of Plasmodium chabaudi adami antigens, as seen in euthymic mice. Due to the fact that
the T cells were of a single clonal type, belonging to a specific subset, it may be that they provide
help to a variety of B cell types, producing the array of antibodies seen in the sera. Due to the
limited specificity of the T cell clones, it may be that there are several antigens present in the
parasite containing the same or a universal T cell epitope, activating B cells to produce antibodies
against these antigens (Goldring et al., 1989).
Recent studies have shown a role for extrathymic T cells in protection against malaria in the P.
yoelii mouse model. Although in the P. chabaudi adami model, in which athymic mice did not
recover from challenge infection, in the P. yoelii model they did. It was proposed that the
participation of extrathymic subsets of T cells played a role. These T cells participate in an innate-
type immune system, associated with autoantibody producing B-1 cells (Kaiissar Mannoor et al.,
2002). This indicates how differently immune systems control the infection for different species of
malaria and there are many factors that lead to cell mediated immunity. Infections with
Plasmodium vinckei petteri, P. chabaudi chabaudi, and Babesia microti, in B cell deficient mice
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appeared to exhibit a similar immune reaction as in normal mice. This further indicates the
participation of the cell-mediated arm of immunity in resolving these species infections (Cavacini
et aI., 1990).
Current research on gamma delta T cells suggests the possibility of a protective role (Elloso et a!',
1994). These have been studied in murine models and have been found to function independently
of antibodies and B cells (Van der Heyde et a!., 1995). The T cell receptor of gamma delta is
expressed on a small proportion of peripheral lymphocytes and may participate as non-MHC
restricted cytotoxic cells against intra-erythrocytic parasites (Ho et al., 1990). During infections
with P. chabaudi in mice, the 'Yo T cell populations increase in B cell deficient mice. These T cells
were shown to produce IFN-'Y when exposed to P. chabaudi parasites, indicating the possible
involvement of macrophages. Recently 'Yo T cell deficient gene knockout mice were used to show
the involvement of these cells in the pathology mouse of malaria infection (Seixas et aI., 2002).
There have been several explanations as to how the participation of T cells in the immune system
leads to the recovery from infection. Antibody-independent mechanisms may involve the role of
activated macrophages. During erythrocytic cycles of growth, systemic release of pro-
inflammatory cytokines is directed either by soluble malarial toxins or the stimulation ofT cells by
parasite antigens (Miller et al., 1994). The specific non-antibody mediators released from host
leukocytes include gamma interferon, tumour necrosis factor (TNF) and reactive forms of oxygen.
TNF production by monocytes is facilitated by T cells and sensitizes neutrophils and macrophages
to agents that cause them to secrete super-oxide compounds involved in the killing of pathogens.
It is likely that malaria-dependent activation of T cells and phagocytes leads to both disease and
killing of parasites (Miller et al., 1994).
Reactive forms of oxygen and TNF are seen to play a related role in these mechanisms. Clark has
shown that parasitaemia in P. chabaudi adami infected mice has been enhanced by ingestion, by
the host, of free radical scavenger compounds such as butylated hydroxyanisole (Clark, 1987).
Other researchers have reported that in vivo administration of TNF inhibits the survival of mouse
malaria. The disadvantage in comparison to antibody mediated immunity is that overproduction of
TNF by the host may be detrimental to survival and transmittance of the parasite due to the effects
of TNF on the host. Symptoms associated with TNF match those seen during chronic infection of
the disease and changes due to TNF toxicity in human malaria include symptoms such as
headaches, fever, myalgias and nausea. This has also shown to occur in similar reactions seen in
cancer patients receiving recombinant TNF infusions (Clark, 1987). Antibodies raised against TNF
12
have also been shown to inhibit the appearance of malaria infection symptoms in the pathology of
P. berghei without inhibiting parasitic growth (Grau et al., 1987).
1.4 Vaccination against malaria
The current control of malaria lies mainly in the use of anti-vector approaches and antimalarial
drugs. However both the Anopheles vector and the malaria parasite are becoming increasingly
resistant towards these measures taken and this is seen asa major problem in regions of the world
where malaria poses a problem This has shown the need for the development of a more long term
control measure such as the development of a human malaria vaccine (Collins and Paskewitz,
1995). Several studies over the last 50 years have shown that the concept of vaccination against
malaria may prove a useful tool in control of the disease (Holder, 1999). Humans that have been
continuously exposed to malaria infection eventually develop immunity to the disease. It was
found that immunization with antibodies from these individuals causes a dramatic reduction in
blood stage parasitaemia (Cohen et al., 1961). Furthermore, the inoculation of live attenuated
parasites into humans and animals before challenge infection leads to protective roles in these
models (Mitchell et al., 1975). The development of a protective vaccine will involve the
incorporation of the immune systems involved in acquiring natural immunity, as seen in exposed
populations. Identification of the components of this protection, will allow insight into the
development of a protective vaccine. Subunit and multi-component vaccine candidates have
shown to partially protect against infection, yet with limited success. Another factor creating
difficulty in vaccine development is the antigenic variation between different geographically
located parasites causing different levels of protection to arise (Ranjit and Sharma, 1999).
1.4.1 Sporozoite stage vaccination
Protective immunity in malaria has been acquired by the immunization of the person with
radiation-attenuated sporozoites in many animal and human models (Chen et aI., 1977). The
protection is highly effective against large doses of infectious sporozoites and appears to be
species and not strain specific. The introduction of these disabled whole parasites provides a
complete range of natural antigens to the immune system. After the introduction of sporozoites
from the mosquito liver cell invasion takes place. There are only two main proteins expressed at
this stage involved in the invasion of liver cells. Antibodies specific against the surface proteins of
the sporozoite can neutralise and prevent liver cell invasion (Holder, 1999). The infected liver cell
has been identified in this way as a main target for sporozoite induced protection. This recognition
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leads to cytotoxic T cells and killing of the infected hepatocyte. The T cells can also be stimulated
to produce cytokines such as y-interferon (Holder, 1999). It is known that this diversity shown in
the T-cell dependent immune responses mediate this protection and CD8+ T cell and IFN-y-
mediated immune responses should form the basis of vaccine design in the stages before
erythrocyte invasion, which cause the main symptoms and pathogenesis of the disease (Doolan
and Hoffman, 2000).
One of the main focuses of the development of a subunit synthetic peptide vaccine was based on
reproducing similar immunity to that achieved using attenuated sporozoites, and has involved one
of the expressed proteins at this stage, the circumsporozoite protein (CSP) (Targett, 1995). The
protein was discovered in the rodent model of infection with P.berghei, and was soon cloned
producing recombinant CSP (Dame et al., 1984). This protein was previously shown to be a major
component of the sporozoite surface membrane (Herrington et al., 1991).
Cell mediated and humoral immune responses have been shown to be protective in rodents and
nonhuman primates targeted to the CS protein (Calvo-Calle et al., 1997). The success in CSP lies
in the inclusion of relevant T cell and B cell epitopes in the development of synthetic vaccines.
The repeat region of CSP has been shown to contain a B cell epitope (NANP) 3 that can elicit
specific sporozoite neutralising polyclonal and monoclonal antibodies (Zavala et al., 1985). This
(NANP) 3 region was incorporated into a synthetic peptide, conjugated to tetanus toxoid as a
protein carrier, and formed the first synthetic peptide malaria vaccine to undergo phase I, and
phase II clinical trials (Herrington et al., 1987). The parasite-specific antibody responses were low
and the repeat sequence was unfortunately poorly recognised. In protective immunity, T cells
expressing the CD8+ antigen are required. This lead to investigations involving the transfer of T
cells recognising specific epitopes contained in CSP, into mice. This passive transfer lead to a
increased degree of protection against challenge, proving that CD8+ T cells are directly involved in
the response (Romero et a!', 1989).
It has since been realised that the use of irradiated attenuated sporozoites in providing long term
protection is a direct result of the parasite producing infection in the hepatocytes. This induces a
set of immune effector mechanisms mediated by cytokines and antibodies to various malaria
antigens other than CSP (Targett, 1995). Gene expression studies of the malaria sporozoite stage
revealed nearly two thousand expressed sequence tags involved in host cell invasion, providing a
new handle for the development of pre-erythrocytic vaccines (Kappe et al., 2001); The tandem
repeat region of CSP has also been cloned into plasmid vectors and expressed as recombinant
proteins in Escherichia coli. When injected into mice this protein induced high titres of antibodies
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that react with the CSP protein on live sporozoties , blocking in vitro invasion of hepatoma cells.
Immunization with vaccinia and influenza virus constructs expressing B cell or CD8+ T cell
epitopes of CSP or oral immunization with P. jalciparum CSP eo-expressed in Salmonella typhi
have also been extensively investigated (Targett, 1995). One of the most interesting approaches
included a DNA vaccine trial using DNA encoding the CSP, which caused induction of cytotoxic
T cells and antibody responses providing good protection in monkeys (Sedegah et al., 1994). The
protozoan parasite Toxoplasma gondii causes strong cell-mediated immunity as well as non-
specific resistance against other pathogens and turnors. For this reason the circumsporozoite
protein of Plasmodium yoelii was engineered into T. gondii in order to create a stronger immune
response against CSP. The CSP proteins were successfully expressed on the surface of T. gondii
and high levels of anti-CSP antibodies were elicited. These results established a possible vaccine
vehicle for the induction ofCD8+-dependent cell-mediated immunity (Charest et al., 2000).
Hill and colleagues have pursued a different approach to induction of protective cytotoxic T cell
responses by vaccination. They have shown that human leucocyte class I antigen (HLA-Bw53)
and an HLA class II haplotype (DRB1*1302-DQB1*0501) is associated with protection from
severe malaria. These haplotypes are common in humans throughout most of west African but rare
in other racial groups. In this population they account for a reduction in disease incidence with
similar proportions to the sickle cell variant. This data strongly supports the view that
polymorphism of major histocompatibility complex (MHC) genes has evolved through time
through natural selection by infectious agents (Plabanski and Hill, 2000). A search of pre-
erythrocytic stage antigens for potential HLA-Bw53 epitopes revealed peptides in the liver stage
antigen-1 (LSA-1). These epitopes were recognised by cytotoxic T cells from Gambian subjects
with the identical class I antigen. The study involved 6 different haplotypes common in both
African and Caucasian populations, revealing several epitopes in 4 pre-erythrocytic stage antigens
ie. CSP, LSA-1, thrombospondin related anonymous protein (TRAP) and sporozoite threonine and
asparagine rich protein (STARP) (Targett, 1995).
In a number of vaccine trials, it is often seen that the overall effectiveness of the vaccine is
lowered by the genetic restrictions imposed by the various HLA types . Vaccines such as these
should ultimately contain multiple protective CD8+ T cell epitopes restricted by diverse MBC
class I alleles, accounting for the genetic differences seen in populations in infectious areas.
Another problem that reduces the effectiveness of vaccines is the genetic differences in the
structure and antigenicity of the proteins used. The circumsporozoite protein showed heterogeneity
in the. repeat region and phenotypically different proteins were found in different strains and
geographically located parasites (Rosenberg et al., 1989). Doolan and colleagues (1996) found a
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way to prevent this effect of genetic restriction of protection against malaria using DNA
immunization with multi-gene representatives of the CSP. .
Specific proteins have been shown to be required for sporozoite gliding motility and aspects of
liver cell invasion and are part of a family of proteins found in the micronemes of invasive stages
of apicomplexan parasites. These proteins are trans-membrane proteins and studies were
performed investigating their role in cell invasion. Antibodies were effectively raised against these
putative antigens, however they are not expressed in sufficient amounts on the cell surface for
effective recognition and blocking by the immune system (Gantt et a!., 2000).
The advance in the technology of proteomics and genomics, along with more powerful methods of
DNA sequencing, have allowed more detailed studies on the sporozoite stage, and the expression
of proteins. cDNA Libraries were constructed, from the salivary gland sporozoites of the P. yoelii
yoelii model (Kappe et al., 2001). A total of 1972 expressed sequence tags (ESTs) were generated
from the construction of the library, enabling all expressed proteins in this stage to be evaluated.
Metabolic pathways and protein expression, thought not to occur during the sporozoite stages were
identified, such as key enzymes in the shikimate pathway. Proteins were more effectively studied
in the context of cell invasion. New insights into protein expression during the sporozoite stage
were gained and various adhesion ligands were discovered which had potential for formulating a
pre-erythrocytic based vaccine.
1.4.2 Merozoite stage vaccines
Most of the clinical symptoms of the disease are produced in the erythrocytic stage of the malaria
life cycle. This shows that this stage should offer several vaccine candidates aimed at either
clearing infection or reducing the detrimental effects of the disease. Red blood cells infected with
P. jalciparum have been shown to disappear from peripheral blood circulation as the intra-
erythrocytic parasite develops into the schizont. This is due to the binding or adherence of the
infected cells to microvascular endothelial cells (Miller et al., 1994). This phenomenon is known
as and often produces a lethal condition that in most cases leads to death. Cerebral malaria causes
sequestration of red blood cells, which has been shown to be associated with the occurrence of
knob formation on the surface of infected erythrocytes. A large antigenic variant surface protein
called P. jalciparum erythrocyte membrane protein 1 (PfEMP1) was shown to represent specific
ligands with host cells receptors CD36, thrombospondin (TSP) and intercellular adhesion molecule
1 (ICAM-l) (Baruch et al., 1995).
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There are several proteins whose coding sequences belonging to the var gene family, including the
gene for PfEMP1. This allows the P. falciparum parasite to express multiple forms of the protein,
which contribute to the success of the parasite as a pathogen. These variant proteins have the
ability to evade secondary disease, by the expression of different forms of proteins, avoiding
detection by antibodies previously raised against proteins such as PfEMP1. This has been studied
in several models including simian, murine and human malaria species indicating that antigenic
variance in the surface of infected red blood cells has been linked to the lengthened persistence of
infection, and the reestab1ishment of disease. Antibodies raised against specific forms of the
PfEMP1 have shown to block adherence to CD36 in infection with the same isolates. This has
paved the way for several important studies on vaccination against merozoite stage malaria
(Baruch et al., 1995). These antibodies did not reduce the adherence to other receptors such as
thrombospondin yet this study provided the molecular basis towards detailed studies on merozoite
involvement in cerebral malaria.
The merozoite surface protein-1 (MSP-1) is a 180 to 210 kDa protein and has been found to elicit
effective levels of immunity . This antigen is located on the surface of P. jalciparum merozoites
and a successful vaccine against asexual blood stage malaria may be based on this protein.
Immunization with native or recombinant forms of MSP-1 has partially protected Aotus and
Saimiri monkeys against P. jalciparum. Po1yclona1 and monoclona1 antibodies raised against
MSP-1 have been shown to exhibit inhibitory effects on the growth of the parasites. Antibodies
from human sera, affinity purified to MSP-1, inhibit parasite invasion in vitro and vaccinated mice
elicits complete protection against a lethal challenge infection (Daly and Long, 1993). Vaccination
of Aotus monkeys with two forms of MSP-1 provides protection against lethal challenge with P.
jalciparum malaria parasites (Egan et al., 2000).
Protein P126 has been associated with the release of merozoites from mature schizonts, and has





hour of a 42-hour erythrocytic cycle before being stored inside a parasitophorous
vacuole. This antigen could be involved in a successful subunit vaccine due to its re1atedness to
those antigens in several strains of P. jalciparum and similarity in the amino acids in this region
(Bhatia et al., 1987). Monoclona1 and polyc1onal antibodies specific for p126 are effective in the
inhibition of the growth of the parasite in vitro (Chulay et al., 1987) and can induce partial
protection against challenge in various species of monkeys (Banie et al., 1998).
A 155-kDa protein was identified on the surfaces of infected read blood cells due to the
recognition of specific modifications of the erythrocyte in comparison to uninfected cells (Perlman
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et al., 1984). The protein was termed Pfl55lRESA (ring-infected erythrocyte surface antigen) and
is involved in merozoite invasion (Walin et al., 1992). The sequence of the protein contains sets of
blocks of tandemly repeated amino acid sequences mainly in the carboxy terminal (C-terminal)
and central regions. These are repeatsof the peptide (EENVEHDA) and (EENV) (Kabilan et al.,
1988). Antibodies raised against RESA have been shown to specifically inhibit the rate of parasite
growth in vitro, showing the potential of this protein as a possible vaccine candidate (Collins et al.,
1986). Large proportions of human anti-Pfl55 antibodies are directed against epitopes formed by
these sequences, and have shown to be conserved between different isolates of P. falciparum.
Intact Pfl55 protein has lead to the in vitro proliferation, interleukin-2 (IL-2) release, and
interferon-y production in T cells specific to this antigen in infection. This antigen, indicating that
the protein contains T-helper cell stimulating epitopes, induced T cell-dependent anti-Pf155
antibodies. The identification of these epitopes would contribute towards the development of a
subunit vaccine against the merozoite blood stage (Kabilan et al., 1988). Synthetic peptides
corresponding to known epitopes ofPf155IRESA induce production ofparasite-specific antibodies
in vitro and were successful in verifying these epitopes (Chougnet et al., 1991). This protein was at
first believed to be associated with the micronemes and rhoptries of merozoites but has now been
localised to dense granules in the apical end of merozoites by immunofluorescent techniques.
During the process of erythrocyte invasion, the protein is expressed, released and transported to
the red blood cell membrane due to interactions with the cytoskeleton structures , functioning in
cell irivasion by the parasite (Ruangjirachupom, 1991).
A 96-kDa protein associated with the surface membrane of malaria infected mouse erythrocytes
was identified to produce protective properties in P. chabaudi. Monoclonal antibodies against
Pc96 identified cross-reacting antigens in P. falciparum (155 kDa), P. vivax (222kDa) and P.
cynomolgi (200 kDa). A specific monoclonal antibody against the protein Pch105 recognises Pc96
(Wanidworanun et al., 1989). Topographical location of Pc96 was further studied by
immunofluorescent microscopy verifying that the protein is located in the surface membrane of
infected erythrocytes. Further studies involved the elucidation of epitopes by mapping studies,
identifying 3 distinct binding sites for the monoclonal antibodies. The fact that four different
antigens in different species of malaria share the same, or similar topographical locations, along
with at least one cross-reactive epitope indicates that the epitope is included in a conserved and
functional region of the protein specific for the biology of the parasite . Pf155 and Pv222 share a
cross-reacting epitope with Pc96, suggesting the potential of Pc96 as a vaccine candidate
(Wanidworanun et al., 1989). The cross reactivity with Pf155IRESA suggests that the P.
jalciparum protein may contain similar T cell epitopes to Pc96. In view of the protective T cell
clones that Pc96 stimulated, ·producing antibody responses against multiple parasite antigens
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elicited in athymic mice challenged with P. chabaudi adami (Goldring, 1989), an investigation
into similar functions in P. falciparum would be worthwhile.
1.4.3 Sexual stage vaccination
The female Anopheles mosquito ingests gametocyte parasites in the blood, which develop
infection in the midgut, with the formation of zygote, ookinete and oocyst stages (Figure 1.2). A
few proteins studied on the surface of gametocytes, have been indicated in there role in blocking
parasite development. This has opened up a relatively new area of vaccine research known as
transmission blocking immunity (Holder, 1999). The effect of blocking transmission would
prevent infection in the gut of the mosquito, and would prevent the spread of disease and drug
resistant parasites through human populations (Stowers, 2000). Antibodies raised against antigens
expressed during these stages, can block the development of the parasite. Pfs230 and Pfs48/45 are
proteins identified to be expressed in the gametocyte stage of P. falciparum, and have been
unsuccessful in the initiation of immune responses. The main objectives ofa transmission blocking
vaccine, involves an antigen that induces significant amount of antibodies in the host. Upon .
ingestion of the blood by the mosquito, the antibodies disrupt the development of the parasite in
the gut, effectively preventing transmission. The fact that only a fraction of the thousands of
parasites ingested must be eliminated, as apposed to the millions, present in the human host system
as asexual erythrocytic-stages, allows the more efficient and rapid clearance of parasites (Duffy
and Kaslow, 1997).
One of the more promising candidates for a transmission blocking vaccine is Pfs25, an antigen
expressed on the surface of P. falciparum zygotes. This protein is a cysteine rich antigen of a 25
kDa mass which is made up of four domain-like tandem epidermal growth factors (EGF) which
are anchored to the surface of the parasites (Stowers, 2000). Immune responses to zygote surface
antigens such as Pfs25 are not induced in the host as they are only expressed in the mosquito
vector. Recombinant forms of Pfs25 have been shown to induce strong transmission-blocking
immunity in various models studies including rodents and monkeys (Targett, 1995). One such
recombinant protein, TBV25H, which was secreted by Saccharomyces cerevisae can induce
complete transmission-blocking antibodies (Stowers, 2000).
Pfs28 is a 28-kDa protein of the late-stage ookinetes and similarly to Pfs25, consists of EGF like
domains. Pfs28 is also considered a major potential vaccine. Pgs28 is the avian parasite (P.
gallinaceum) analog of Pfs28 and was used to show that polyclonal antibodies against Pgs28 block
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the transmission ofparasites by completely inhibiting the transformation from ookinetes to oocysts
in vitro in a similar mechanism to that of Pfs25. Due to the fact that the two antigens both block,
parasite development in the same stages, it was proposed that the two could act together as a
transmission blocking vaccine. It was subsequently found that pooling the two antigens had little
effect as a vaccine, but the fusion of the two to form a recombinant chimeric protein produced a
potent transmission-blocking vaccine (Gozar et al., 1998).
A different approach was taken whereby antigens from the mosquito midgut, involved in
interactions with the parasite, were targeted. Polyc1onal and monoc1onal antibodies against the
midgut inhibited the development of the parasite. Plasmodium jalciparum and Plasmodium vivax
were prevented from transport across the midgut reducing infection. The survival of the mosquito
was also affected by a reduction in egg laying capacity, across a wide range of Anopheles species
(Lal et al., 2001).
1.4.4 Synthetic multivalent vaccines
The development of multivalent vaccines involves the hybridisation of different proteins from a
number of different asexual or sexual blood stage antigens for the effective protection against
infection. These antigens combine their immunogenic properties and each component induces a
particular partial protective immune response, that when combined, protects a range of host
populations (Holder, 1999). The antigen must contain properties that initiate effective immune
response, taking into account factors such as antigenic variation. The delivery mechanisms used
must also serve to present the antigens in a form that stimulates the required components of the
immune system. As in the case of recombinant proteins, the development of better adjuvants for
human use is a priority, and much success has been seen in the field of DNA vaccines (Holder,
1999). Of equal importance is much-needed research into the development of accurate assays for
determining the nature of the protective immunity. A number of these have shown success in the
evaluation of immune responses in humans exposed to natural infection such as the inhibition of
sporozoite invasion assay. This has allowed the determination of the extent of hepatocyte invasion
in the presence ofblocking antibodies (Holder, 1999).
One of the most promising multivalent vaccines was the synthetic polypeptide SPf66 vaccine. This
contained antigens based on pre-erythrocyte and the blood stages of Plasmodiumjalciparum This
chimeric protein was one of the first multivalent vaccines of this type to be tested for it potential as
a human vaccine. The monomer unit making up the vaccine is a chemically synthesised peptide of
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45 amino acids containing sequences from three separately expressed asexual-blood-stage antigens
of 83, 55 kDa and 35 kDa, linked by (PNANP) motifs derived from the circumsporozoite protein
ofP.falciparum (Alonso et al., 1994).
Shi et al. (1999) have designed a recombinant protein coding for short peptide sequences from the
sporozoite antigens CSP and SSP2, LSA-1, and the merozoite antigens MSP-1 and MSP2. RAP1
and AMA1 (rhoptry proteins), EBA175 (microneme protein) and a gametocyte protein (Pfg27)
was also included into the structure of the vaccine. In total the construct is made up of twelve B
cell epitopes, six T cell epitopes and three cytotoxic T lymphocyte epitopes derived from a total of
nine P. falciparum antigens. The antibodies were raised against several constituent peptides in
sporozoites, liver stage, blood stage and gametocytes, and native proteins in the blood stage, as
determined by immunoelectron microscopy (Shi et al., 1999). The antibodies raised against this
vaccine were successful in inhibiting sporozoite invasion and antibody-dependent cell inhibition
assays, but on the whole were inactive in transmission blocking assays (Holder, 1999).
A potential universal T cell epitope for use in a malaria vaccine must ideally be capable of eliciting
humoral and cell-mediated immunity in individuals of diverse HLA types, ie. a large amount, if
not all, MHC class IT molecules. A recent study involved the use of a synthetic polyoxime malaria
vaccine containing Plasmodium falciparum B cell and universal T cell epitopes, eliciting immune
responses throughout a diversity of HLA types (Nardin et al., 2001). This vaccine, termed
(TIB)9MAP contains the (NANP)3 B cell epitope synthesised in tandem with a T cell epitope (TI)
defmed using CD4+ T cells of a P. falciparum sporozoite-immunised volunteer. The single tri-
epitope peptide is linked at four oxime bonds to lysine residues forming the structure used in these
experiments (Nardin et al., 2001).
Through most of the multivalent vaccine candidates studied, very few have elicited powerful
protection to humans against infection. Whether these recombinant multivalent approaches are the
solution, or single antigen vaccines remains to be seen. Knowledge of the immune system
involved in parasitic infection has increased significantly over the years and has shown that cell
mediated responses play a role. Whether or . not T cells are solely responsible for antibody
responses to potential antigens, they are being more carefully considered for inclusion in vaccine
constructs. The problem of genetic variance between the expressed antigens in heterogenous
parasites and the diversity of HLA haplotypes in human populations requires the need for a
universal epitope, common to many species, to be used in a vaccine.
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1.4.5 Nucleic acid vaccines
DNA vaccines are seen as third generation vaccines, and are based purely on the genetic features
of the parasite. Protective immunity resulting from DNA vaccination was first achieved in 1993,
during studies involving the influenza virus, in particular the influenza A nucleoprotein which
provided protection in mice (U1mer et al., 1993). DNA vaccination involves the delivery of a
plasmid bearing the pathogen DNA and a strong eukaryotic promoter into an organism used for
immunization, followed by endogenous expression by the host and the induction of an immune
response against the protein. The advantages to this system are that the plasmid DNA persists in
the tissue for long periods of time, enabling the control of immunization times. The proteins
expressed by the DNA vaccine p1asmids, closely resemble eukaryotic structures, as apposed to
recombinant proteins synthesised in prokaryotic expression systems such as E. coli (A1arcon et aI.,
1999).
The first experiments involving DNA vaccines against malaria were those conducted by Sedegah
et al. (1994) where a plasmid encoding the circumsporozoite protein was used in attempts to
immunise mice against lethal P. yoelii parasites. Although the sera showed limited inhibitory
activity against the parasites, the titres of antibodies were increased after immunization. It was
found that only a fraction of the antibodies raised against CSP were specific to previously defined
antigens, accounting for the lack of sufficient antibodies capable of inhibiting the parasite. Despite
this, there was evidence for a cell-mediated response, as a high percentage of mice were protected
against infection, due to the action of the T cells on the infected liver cells (Sedegah et al., 1994).
This indicates that DNA vaccines can effectively be used for the generation of protective cell
mediated responses, providing the DNA encodes previously characterised T cell epitopes such as
the esp. They can also be used in a multivalent format, expressing many antigens at the same
time, and overcoming genetic restrictions imposed by the host.
A tool has been developed known as expression library immunization (ELl). This has been used in
conjunction with DNA vaccine based methods of investigating protective features in malaria
infection. It was shown that mice could be protected against Mycoplasma pulmonis infection with
cloned genomic DNA, represented by pools of thousand of p1asmids (Barry et al., 1995). This
technique was adopted for studies on the mouse malaria model Plasmodium chabaudi adami,
showing that 63% protection was achieved in challenged mice, previously vaccinated with plasmid
pools. This allows the successful screening of the malaria genome, to identify possible sequences
that contain protective features in infection (Smooker et al., 2000).
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1.5 Objectives of this study
Pc96, a protein associated with the membrane of Plasmodium chabaudi infected mice
erythrocytes, showed several immunogenic and protective properties (Wanidworanun et al., 1989).
Mice immunized with Pc96 were partially protected against further infection, indicating the
potential of the antigen in the development of a vaccine. Monoclonal antibodies against Pc96 were
used to identify cross-reacting antigens in other malaria species, identifying the Pfl55 RESA
antigen previously studied (Perlmann, 1984). However, the availability of sequence data
representing both P. yoelii and P. jalciparum genomes (PlasmoDB) provides a new method of
identifying homologous proteins to Pc96 in these species, possibly containing similar epitopes.
Pc96 was identified to contain certain T cell epitopes, using a specific protective T cell clone that
previously was shown to provide adoptive protection in mice challenged with P. chabaudi adami
(Brake et al., 1988). Antibodies raised against Pc96 identified proteins that induced the
proliferation of the protective T cell clone.
The presence of homologous proteins in different malaria species was evaluated by the screening
of protein databases with the protein sequence ofPc96 (Chapter 3). These searches were also used
to determine the structure and possible function of the proteins . In this study a 178 kDa protein in
Plasmodium yoelii yoelii (Pyy178) and a 403 kDa Plasmodium jalciparum protein (Pf403) was
identified using the sequence data from these genomes that contain regions of extensive similarity
to the Pc96 antigen. The presence of potential T cell epitopes was evaluated, in order to determine
possible involvement in similar protection to that provided by Pc96. The identification of these
proteins and the relative sequence comparisons, are described in Chapter 3.
The molecular cloning of Plasmodium jalciparum open reading frames has allowed malaria
proteins to be studied effectively by the construction of recombinant proteins. In order to further
study these proteins, their immunological significance, and respective functions in the malaria
parasite , the proteins must be expressed, to allow further biochemical experimentation. The E. coli
cloning systems pGEX and pMAL have shown success in several studies involving recombinant
proteins. Due to the homology of this region in Pc96, Pyy178 and Pf403 , as determined by
multiple sequence alignments (ClustalW), it is highly likely that the region represents either a
functional or structural domain, conserved between multiple species of malaria. The T cell
epitopes identified in Chapter 3 to be highly conserved in these three proteins, indicate that further
cloning and expression of this region, would be worthwhile in identifying the region and its
possible involvement in protection against Plasmodium jalciparum in humans, similarly to that
seen with the Pc96 protein in Plasmodium chabaudi adami infection. Chapter 4 describes the
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design of a strategy for cloning the region of Pf403 that shares this homology with the Pc96
antigen. Ultimately, a series of overlapping regions in the Pf403 protein in Plasmodium falciparum
will be cloned and expressed in E. coli using these expression vectors. The first, and most relevant




Chemicals used in this study were in most cases manufactured by Roche (Mannheim,
Germany), Merck (Darmstadt, Germany) or Sigma (St Louis, USA). The
nitrocellulose used for western blotting (Hybond™ -C, 0.45 micron), and the T4 DNA
Ligase, was obtained from Amersham Lifesciences (Cleveland, USA). The nylon
membrane used for binding nucleic acids was from Osmonics Inc (Minnetonka,
USA). Ampicillin antibiotic, Taq Polymerase was purchased from Roche (Mannheim,
Germany) . The Agarase Tenzyme for degrading low-melting point agarose was from
Sigma (St Louis, USA) . Restriction enzymes used in this study were from Promega
(Madison, USA) as well as the Klenow enzyme (DNA polymerase I large fragment).
The pMOSBlue blunt ended cloning kit was purchased from Amersham Biosciences
(Buckinghamshire, UK).
The Digoxigenin (DIG) Oligonucleotide 3'-end Labelling Kit with the terminal
transferase enzyme, dATP's, the DIG-ddUTP molecule, and the anti-Digoxigenin
antibody with alkaline phosphatase conjugate for detection, was from Roche
(Mannheim, Germany). Purified plasmid DNA was isolated using the Nucleobond"
AX kit. This was purchased from Macherey-Nagel (Duren, Germany).
The oligonucleotide primers for PCR were all synthesised at the University of Cape
Town, by the Biochemistry Department synthetic laboratory. Isolated Plasmodium
jalciparum (3D7) genomic DNA was provided by Professor Christian Doerig
(INSERM, Paris).
DNA sequencing was performed by Mariaan Ponsie in the Molecular Biology Unit,
using the ABI PRISM® 3100 Genetic Analyser, with the BigDye® Terminator v3.1
Cycle Sequencing Kit.
Distilled water (dist.H20 ) was obtained from a Milli-RO® 15 purification system and




2.1.1 Database screening for proteins similar to Pc96
The nucleotide sequence of Pc96 was translated into six reading frames using the
on1ine Translate software (DNA to protein) at ExPaSy (http://us.expasy.org). The
predicted amino acid sequence of Pc96 was used in a series of database searches with
the on1ine BLAST (Basic Local Alignment Search Tool) version 2.2.6. The database
used for BLAST searches was on the NCBI (National Center for Biotechnology
Information) website (http://www.ncbi.nlm.nih.gov/BLAST).This database is known
as the nr database, containing links to GenBank and many other sources combining a
huge range of different biological sequence data. This method is a highly sensitive
database-searching tool, for the identification of proteins and analysis of sequence
similarity. Comparisons of the query sequence and the sequences in the databases
provide a measure of similarity or percent identity. BLAST reports results as an
output of statistics and scores based on the matches it has found, involving algorithms
responsible for locating similar strings within vast amounts of data at high speed
negating the need to systematically compare sequences (Altschu1 et al., 1997).
The E value depends on the score of the alignments based upon factors such as the
lengths of database searched and properties of the query sequence. The E values for
the hits allow interpretation of results. Scores below 0.01 occur by chance rarely, and
so is a reasonable indication of homology. Even higher scores seen (le-50) provide
extremely high confidence that the query is comparib1e to that of selected targets in
the database searched. PSI-BLAST (Position Specific Iterated - Basic Local
Alignment Search Tool) was used with the Pc96 query sequence. This relies on
gapped local alignments, building and iteratively refining patterns and profiles
constructed from the alignments made. These profiles are used to re-search the
database, with additional sequences identified in each cycle. This leads to the
identification of sequences that may share homology with the query sequence but did
not achieve a match using the original BLAST searching algorithm. Despite its
increased sensitivity, care must be taken in using this algorithm for the annotation of
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unknown protein sequences, as the profile generated can often mislead the alignments
and provide false homologous hits (Baxevanis, 1998).
2.1.2 Prediction of T cell epitopes in Pc96
In order to evaluate the presence of any putative T cell epitopes on Pc96, online
epitope prediction software was used. There are two programs available on the World
Wide Web that allow unrestricted predictions, BIMAS (http://www-
bimas.dcrt.nih.gov/molbio/hla_bind/) (parker et al., 1994) and SYFPEITHI
(htlp://www.syfpeithi.de) (Rammensee et a!', 1999). These programs involved the
recognition of T cell epitopes, due to chemically related amino acids in specific
positions, corresponding to that of known MHC ligands. This allowed for the
definition of a peptide 'motif for every MHC allele (Falk et al., 1991). SYFPEITHI
uses motif matrices previously obtained and deduced from refined motifs based on
single peptide analysis exclusively of natural ligands. Binders for various mouse,
human and rat MHC class I molecules are compared according to the presence of
primary and secondary anchor amino acids and other chemically similar residues. The
predicted amino acid Pc96 sequence was used in the epitope prediction program
SYFPEITHI, for naturally processed MHC class II epitopes, and I for a variety of
HLA-types (Rammensee et al., 1999).
2.1.3 Multiple sequence alignments of Pc96 and similar proteins using
CLUSTALW
The CLUSTALW algorithm provided by the European Bioinformatics Institute (EBI)
on the WWW has been widely used for the comparison of conserved amino acid
sequences either between homologous proteins or domains, or between different
species (Thompson et a!., 1996). The algorithm is based on the idea of progressive
alignment, creating a series of pairwise alignments using the query sequence. A
distance matrix . is calculated based on these initial alignments, reflecting the
relatedness of sequences. Pc96 and proteins matched using BLAST, were compared
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in multiple and pairwise sequence alignments to investigate homology and identify
regions within the sequences that have regions of similarity.
2.1.4 Comparison of structural features of Pc96, Pyy178, Pf403
The program PREDICT7 version 1.2 (Carmenes et aI., 1989) was used to determine
structural properties of Pc96 and related proteins such as hydropathy, flexibility,
surface probability, and antigenicity. Due to the fact that hydrophobic residues are
located within the globular protein structure, and hydrophilic on the outside, exposed
and interacting with water, an algorithm was designed by Hopp and Woods (1981) to
represent this feature. Each amino acid is assigned a numerical value of
hydrophilicity, which is averaged along the sequence of the protein, producing a plot
of these trends. Flexibility, or sequence mobility, provides structural clues as to the
nature and movement within the protein. Functional activity can often be assigned to
these conformational variations. Regions of highest mobility exist often on the most
highly accessible segments, usually on the surface of the molecule (Karplus and
Schulz, 1985). Surface probability measures the proteins contact to solvents. Features
of the protein such as buried residues can determine the surface regions of globular
proteins (Janin, 1979). Antigenicity plots are based on the amino acid composition of
regions of the protein and show a probability of the region being antigenic, due to
previous characterisation of known antigens (Welling et aI., 1985). Due to the fact
that these plots generate data specific to structural aspects of the protein, they were
used primarily to compare homologous regions of interest in the identified protein
homologues.
2.1.5 Identification of putative motifs and patterns from the PROSITE profile
library and generation of similar 3D structures using 3DPSSM
The PROSITE analysis program was used with the query protein sequence to scan a
profile library (Sigrist et aI., 2002). The PROSITE profile library used for searching is
an ExPASy database that is a collection of biologically significant motifs or sequence
patterns. Due to the fact that some proteins are large and contain many domains and
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functions, protein functional classifications are based mostly on domains rather than
complete proteins . Pc96 and other similar proteins were used to screen the PROSITE
database. Certain functional domains contain sets of conserved regions of amino
. acids, and the occurrence and positions of these regions along the length of a protein
sequence, in relation to certain alignment features can be used to create a signature of
the domain, allowing the identification of these patterns within query sequences.
These signatures are a reflection of the 3-dimensional conformation of the domain,
and can be used to assign function to regions of un-characterised proteins, providing
the profile of that region is a significant match.
The 3-dimensional structure and function of protein sequences was also determined
by analysis with the 3D-PSSM (Three Dimensional - Position-Specific Scoring
Matrix) server. The server contains a database with known protein structures, which
are compared to the query sequence and scored on a basis of compatibility. Factors
such as secondary structure elements, and probability of occupying various states of
hydrophilicity, in relation to overall shape are analysed (Kelley et al., 2000). Entries
in the PROSITE database make up the so-called BLOCKS database, used to identify
families of proteins. This is not a comparison of the sequence itself, due to the fact
that homologous proteins may not share sequence similarity. A block relates to
motifs, or conserved stretches of amino acids conferring specific function to the
structure of a protein. Individual proteins may contain several blocks in similar
combination, corresponding to specific structure or function. The query sequence is
aligned against all blocks in the database at all available positions. A score is derived
from alignments using the position-specific scoring matrix (PSSM), taking into
account matches at given positions and the probabilities of amino acids occupying
specific positions in the block (Baxevanis, 1998).
2.2 Immunochemical techniques
2.2.1 Western blotting
This technique relied on the use of specific .antibodies for the identification and
characterisation of proteins separated by sodium dodecyl sulfate-polyacrylamide gel
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electrophoresis (SDS-PAGE) and transferred electrophoretically to nitrocellulose.
Nitrocellulose is a matrix with a high affinity for protein. The method used in this
study was that of Towbin et al. (1979), with minor modifications. The transfer buffer
included methanol to enhance the binding of protein-SDS complexes to the membrane
(Goodenham, 1984). The unoccupied sites on the membrane were blocked with non-
fat milk. Antigens transferred onto the nitrocellulose binds to primary antibody, which
in turn binds to secondary antibody specific for the primary antibody.
The secondary antibody contains a detection system with labelled enzyme
horseraddish peroxidase (HRPO). HRPO catalysed a reaction involving a
chromogenic substrate, forming a visual, insoluble precipitate. These effectively
labelled specific bands bound to the nitrocellulose.
2.2.1.1 Materials
10% Cm/v) SDS. SDS (10 g) was dissolved in 100 m1 dist. H20 with gentle heating if
necessary.
Blotting buffer. Tris (27.23 g) and glycine (64.8 g) were dissolved in 3.5 litres of
dist.Hjf) and methanol (900 ml) was added. The volume was made up to 4.5 litres in a
large beaker. Prior to use, 10% (m/v) SDS was added (4.5 ml).
Tris buffered saline CTBS; 20 mM Tris, 200 mM NaCl, pH 7.4). Tris (2.42g) and
NaCI (11.69 g) were dissolved in 950 ml of dist.Het), adjusted to pH 7.4 with He1,
and made up to 1 litre.
1% Cm/v) Ponceau S. Ponceau S (0.1 g) was dissolved in 1% (v/v) glacial acetic acid
(100 ml).
Blocking solution [5% Cm/v) non-fat milk powder]. Low fat milk powder (5 g) was
dissolved in TBS (100 ml).
0.5% Cm/v) BSA-TBS. Bovine serum albumin (0.1 g) was dissolved in TBS (20 ml).
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4-chloro-I-naphthol substrate solution [0.06% Cm/v) 4-chloro-1-naphthol, 0.0015%
(v/v) H2ilil 4-chloro-1-napthol (0.03 g) was dissolved in methanol (10 ml). 2 ml of
this solution was diluted to 10 ml with TBS, with the addition of 30% hydrogen
peroxide (4 !-Ll).
2.2.1.2 Method
After SDS-PAGE had been performed on duplicate gels, one gel was used for staining
as a reference for the blot, and the other was used for blotting onto nitrocellulose. The
nitrocellulose was cut to a size similar to that of the SDS-PAGE gel and floated on
blotting buffer to soak. Six pieces of Whatman No. 4 filter paper were cut slightly
larger than the nitrocellulose. A sandwich was constructed (Figure 2.1) with blotting
buffer to avoid the entrapment of air bubbles that can disturb the blotting pattern.
Two white Scotch-Brite pads, filter paper and the nitrocellulose and gel were
positioned as seen in Figure 2.1. The sandwich was placed into a plastic support, into
the western blotting apparatus and immersed in cold blotting buffer. The
nitrocellulose was kept on the anodal side of the gel and blotting was achieved at 200
mA for 16 h. The blotting tank was placed in a larger container of ice. Blotting buffer .










Figure 2.1 Arrangement of nitrocellulose sandwich prior to electro-transfer of
protein. 1 - Scotch Brite pads; 2 - 3 x filter paper; 3 - SDS-PAGE gel; 4 _
nitrocellulose membrane.
The gel was removed and stained with Ponsceau S (l0 ml) in a glass petri dish to
ensure that protein transfer had occurred. The nitrocellulose was removed and rinsed
with dist H20 until the dye is removed. The nitrocellulose was air-dried for 1.5 h. The
membrane was then blocked for 1 h with 5% (m/v) low fat milk powder in TBS. It
was then washed in TBS (3 x 5 min), followed by a 2 h incubation with primary
antibody in 0.5% BSA-TBS. A washing step was repeated (3 x 5 min) and followed
by incubation in secondary antibody with HRPO enzyme conjugate in 0.5% BSA-
TBS for 1 h. 4-chloro-l-naphthol substrate solution (lO ml) was used as a substrate
for the development of the chromogenic reaction.
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2.2.2 Screening for recombinants using DIG nucleic acid hybridisation and
detection
The Roche (Mannheim, Germany) Digoxigenin (DIG) Oligonucleotide 3'-end
Labelling Kit was used to label oligonucleotide primers with the modified nucleotide
analogue, digoxigenin-labelled dideoxyuridine-triphosphate (DIG-ddUTP), for the
detection and screening of recombinant plasmid DNA. The enzyme terminal
transferase is used to enzymatically label the 3'-OH termini of the oligonucleotide
primer, incorporating a single DIG-ddUTP. The enzyme depends on C02+ ions for its
function and incorporates the DIG-ddUTP as a modified substrate. Only a single
nucleotide is added to the 3' terminus of the oligonucleotide due to the chain-
termination effect of this analogue.
The labelled oligonucleotides can then be detected by the specific high affinity
binding of an antibody/alkaline phosphatase conjugate to the digoxigenin molecule.
The alkaline phosphatase is then used to catalyse the indicator reaction with BCIP and
NBT. The reaction products are insoluble purple-blue precipitates, which directly
adhere to the nylon membrane. Figure 2.2 shows the structure of DIG-ddUTP
(Schmitz et al., 1991).
This technique can be applied to many fields of molecular biology, in particularly
diagnostic and forensic applications. Labelled probes can be used to screen complex
gene libraries, restriction site mapping of cloned DNA, gel shift assays and various
other in situ hybridisation techniques. For the purposes of this study, the
oligonucleotide primers used for polymerase chain reaction (PCR) were labelled and
used to probe DNA for detection of the PCR product in the form of insert or
recombinant DNA (Schmitz et al., 1991).
33
o
Figure 2.2 Structure of digoxigenin-Iabelled dideoxyuridine-triphosphate (DIG-
ddUTP) (Schmitz et al., 1991).
2.2.2.1 Materials
5 x Reaction buffer OM Potassium cacodylate; 0.125 M Tris-CI; 125 mg/ml Bovine
Serum Albumin, pH6.6).
CoCl2 solution (25 mM CoCl61
DIG-ddUTP solution 0 mM DIG-dUTP) .
dATP solution 00 mM dATP)
Terminal transferase (50 U/1l1 in 0.2 M Pottasium cacodylate, 1 m M EDTA, 200 mM
KCI; 0.2 mg/ml Bovine serum albumin; 50% glycerol [v/v]; pH 6.5)
10% (m/v) SDS. SDS (10 g) was dissolved in 100 m1 dist H20 with gentle heating if
necessary
100 x Denhardt's solution (2% Ficoll; 2% polyvinylpyrrolidone; 2% Bovine serum
albumin) Store at -20°C in 10 ml aliquots.
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20 x SSC (3 M NaCl; 300 mM sodium citrate; pH 7). NaCl (175.3 g) and Na
Citrate.Zl-l-O (88.23 g) was dissolved in dist H20 (900 ml). The pH was titrated to 7.0
with HCl and the volume was made up to 1 litre. The solution was autoclaved to
sterilise prior to use.
2 x SSC (0.1% SDS). 10 % SDS (1 ml) was combined with 20 x SSC (10 ml) and
made up to 100 ml with dist.H20.
0.2 x SSC (0.1% SDS) 10% SDS (1 ml) was combined with 20 x SSC (1 ml) and
made up to 100 ml with dist.H20.
Hybridisation solution (6 x SSC; 5 x Denhardt's solution; 0.5% SDS). 20 x SSC (30
ml), 100 x Denhardt's solution (5 ml) andlO% SDS (5 ml) were diluted with dist H20
(60 ml).
Buffer 1 (0.1 M Tris-CI; 0.15 M NaCI; pH 7.5). Tris (12.11 g) and NaCl (8.76 g) was
dissolved in dist H20 (900 ml). The pH was adjusted to 7.5 with HCI and the made
up to 1 litre with dist.Hg),
Buffer 2 Cl % Blocking solution). The blocking reagent (vial 6 of the DIG Nucleic
Acid Detection Kit) was dissolved to a final concentration of 1 % (w/v) in buffer 1,
with gentle heating ifnecessary.
Buffer 3 (0.1 M Tris-Cl; 0.1 M NaCl; 50 mM MgCh; pH 9.5).
Tris (12.11 g), NaCI (5.84 g), and MgCh (4.76 g) were dissolved in dist H20 (900
ml). The pH was adjusted to 9.5 with HCI and made up to 1 litre with dist.Hjf),
Anti-Digoxigenin-AP, Fab fragments (Roche, Germany).
Colour substrate solution nitroblue tetrazolium salt (NBT) solution (45 JlI) and 5-
bromo-4-chloro-3-indolyl phosphate, toluidinium salt (BCIP) solution (35 ul) was
combined with buffer 3 (10 ml).
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2.2.2.2 Method
Crude preparations of DNA from each colony were obtained using the same method
as per Section for colony PCR screening (Section 2.3.7). Colonies resulting from the
transformation reactions were streaked onto sterile LB agar plates previously
supplemented with ampicillin (100 ug/ml) and numbered. After sufficient overnight
growth at 37°C, a portion of each colony was transferred to sterile dist H20 (50 ul)
and vortexed to resuspend the colony. The samples were boiled for 5 min to lyse the
cells and centrifuged briefly to remove contaminating cell debris. The supernatant,
containing both chromosomal and plasmid DNA was transferred (30 Ill) to a sterile
microfuge tube.
Reaction components were combined in a sterile microfuge tube as described on
Table 2.1, for the enzymatic transfer of the digoxigenin compound to the 3' terminus
of the oligonucleotide.
Table 2.1 Reaction components for oligonucleotide tailing with DIG-ddUTP
Reaction component Volume (Ill)









The above reactions (Table 2.1) were mixed and incubated at 37°e for 15-30 min and
placed on ice. Hybridisation solution (100 Ill) was added and the mixture was stored
at -20oe. DNA samples were heat at 95-100oe for 15 min to denature the DNA.
These were immediately dotted onto a nylon membrane onto pre-marked pencil dots.
It was important not to let the sample cool before dotting, as they re-anneal and
hybridisation is not possible. The primers used to make the probe were dotted as a
positive control, and vector (pGEX, no insert) was dotted as a negative control, as the
probe is not specific to vector DNA. The positive control for the detection procedure
is DIG-labelled molecular weight markers. The membrane was then baked at llOoe
for 15 min to bind the DNA to the nylon membrane.
Hybridisation solution (10 ml) was added as a pre-hybridisation step and the filter was
incubated for 2 h at 37°e. The solution was removed and the probe (60 Ill) and
hybridisation solution (10 ml) was added and incubated at 37°e overnight. The filter
was removed and washed at 37°e with 200 ml 2 x sse, 0.1% SDS (2 x 15 min) then
200 ml 0.1 x sse, 0.1% SDS (2 x 15 min). The filter was air-dried for 5 min and was
washed for 1 min in buffer 1 (80 ml). The blocking step involved incubation at room
temperature with shaking for 30 min in buffer 2 (100 ml). After this step the filter was
washed briefly in buffer 1 (100 ml). The anti-digoxigenin-AP conjugate was diluted
(1:5000) in buffer 2 (4 III in 20 ml). The filter was incubated for 30 min with the
diluted antibody conjugate (20 ml). Non-bound antibody conjugate was removed by
washing (2 x 15 min) in buffer 1 (100 ml). The membrane was equilibrated for 2 min
in buffer 3 (20 ml). The filter was then incubated with the colour substrate solution
(10 ml) in the dark until the colour reaction developed.
2.3 Molecular biology techniques
2.3.1 Quantitation of DNA
Spectrophotometry was used for determination of the amount of DNA in solution.
Readings were taken at 260 nm and 280nm. The reading at 260nm allows the
concentration of the DNA to be calculated. An OD of 1 corresponds t050 ug/ml for
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double stranded DNA. A ratio of the readings at 260nm and 280nm provides an
estimate of the purity of the sample. If OD26o/OD28o values are significantly less that
1.8, quantitation of nucleic acid will be inaccurate (Sambrook et al., 1989). DNA
sample (5 Ill) was added to sterile TE buffer (495 Ill) in a 0.5 ml quartz cuvette. TE
buffer (0.5 ml) was used as a blank and readings were taken at 260 nm and 280 nrn.
DNA concentration (ug/ml) = A260 x 100 (dilution factor) x 50 ug/ml (OD of 1)
2.3.2 Agarose gel electrophoresis of DNA
Agarose gel electrophoresis of DNA is a technique commonly used in molecular
biology for the study and analysis of nucleic acids. Agarose gels can be cast by
melting agarose in a buffer and allowing the solution to cool causing the compound to
form a matrix of uniform density. An electric field is applied across the gel and
negatively charged DNA molecules migrate towards the anode. The gel matrix acts
like a sieve, allowing fragments to migrate at a rate dependent on the length of the
molecule. Large molecules move through the gel with less efficiency than small
molecules due to the frictional hindrance provided by the agarose matrix (Sambrook
et al., 1989).
The fluorescent dye, ethidium bromide is used for visualisation of the DNA
fragments. The dye intercalates between the nucleotide bases in DNA and displays an
increased fluorescent activity compared to when in free solution. In this way, trace
amounts of DNA can be detected by including ethidium bromide in the gel and
electrophoresis buffer (Sambrook et al., 1989).
2.3.2.1 Materials
50 x TAE buffer (40 mM Tris-acetate, I mM EDTA, pH 8.0). Tris was dissolved in
800 ml dist. H20. Glacial acetic acid (57.1 ml) was added, and made up to 900 mls
with dist.Hjf). Ethylenediaminetetraacetic acid (EDTA) (18.612 g) was dissolved in
80 ml dist. H 20 , the pH was adjusted to 8.0 with glacial acetic acid and the solution
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was made up to 100 m1 with dist. H20. 0.5 M EDTA, pH 8.0 (100 m1) was combined
with tris-acetate solution (900 ml) to make all solution.
1 x TAB working solution. 50 x TAB buffer (20 ml) was diluted to 11 with dist. H20.
1% (rn/v) agarose. Agarose (0.3 g) was placed in a Erlenmeyer flask with 1 x TAE
buffer (30 ml). The solution was heated in a microwave oven, for about 1.5 min with
occasional mixing until all the agarose had visibly melted. Different % gels can be
used for different ranges of resolution (Table 2).
Gel-loading buffer Cl mM EDTA, 0.5% (rn/v) bromophenol blue, 50 % (v/v)
glycerol). EDTA (0.007 g) and bromophenol blue (0.1 g) were dissolved in sterile
dist. H20 (10 ml) and glycerol (10 ml) was added and thoroughly mixed.
1% Crn/v) Ethidium bromide. Ethidium bromide (0.2 g) was dissolved in dist. H20 (20
ml) and stored in a glass bottle wrapped in aluminium foil.
Tris-EDTA buffer (TE buffer; 10 mM Tris-HCI, 1 mM EDTA, pH 8.0). Tris (0.121 g)
and
EDTA (0.037 g) were dissolved in 90 ml dist. H20, adjusted to pH 8.0 with HCl and
made up to 100 ml with dist. H20.
2.3.2.2 Method
A dry perspex-casting tray (100 x 65 mm) was cleaned, dried and masking tape was
used to seal the open ends ensuring a closed mould for setting the agarose . A perspex
10 well comb was positioned in the casting tray. Once the molten agarose had cooled
to approximately 55°C, ethidium bromide (1 Ill) was added and thoroughly mixed in.
The warm agarose solution was poured into the casting tray, making sure that no air
bubbles were present. After approximately 20 min the masking tape and the perspex
well comb were removed and the casting gel with the set agarose was positioned in an
electrophoresis tank. 1 x TAB buffer was added to submerge the gel. Gel-loading
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buffer (Iul / 51ll sample) was added to the DNA samples prior to loading. The
glycerol in the buffer ensures that the DNA sample loaded is of a higher density than
the 1 x TAE buffer and will sink to the bottom of the wells. The bromophenol blue is
included so that the progress of the electrophoresis can be visualised. .
Electrophoresis was carried out at 100 V until the bromophenol dye moved out of the
wells and into the gel followed by 70;.80V for 1.0 - 1.5 h, or until the dye front
migrates sufficiently through the gel. The casting gel was removed from the
electrophoresis tank and examined in an ultraviolet transilluminator. Photography was
conducted through a red filter with a Polaroid® type 667 black and white instant
films. Table 2.2 shows the various percentage agarose gels that can be used to resolve
a wide range of sizes of nucleic acids (Sambrook et al., 1989).














2.3.3 Restriction endonuclease digestion of DNA
Restriction enzymes are those occurring III bacteria species forming a defence
mechanism against foreign DNA. 'Host-controlled restriction' was shown in the early
1950's when some strains of bacteria were immune to bacteriophage infection.
Bacteria were shown to produce an enzyme that degrades the phage DNA before
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replication and the synthesis of new phage particles occurs. The bacterium DNA is
protected by additional methyl groups that block the enzyme action (Brown, 2001).
Purified restriction enzymes enable the molecular biologist to cut DNA molecules in a
precise reproducible manner required for DNA analyses and gene cloning. Over 1200
different restriction enzymes have been characterized. There are three classes based
on mode of action: type I, IT and ill. Type I and ill have complex behaviour and have
a limited role in their use in molecular biology , while Type IT endonucleases play a
vital role in gene cloning. The enzyme binds specifically to double-stranded DNA at
specific sites or particular recognition sequences and cleaves the strand. Endonuclease
enzymes are able to break internal phosphodiester bonds within a DNA molecule.
Each restriction enzyme recognises particular unique hexanucleotide positions, which
are usually palindromic (Sambrook et al., 1989).
2.3.3.1 Method
The procedure is slightly different for each enzyme and was performed as per
manufacturer 's instructions. DNA (minimum 0.1 ug), 10 x restriction buffer (2 Ill)
and enzyme (1 U/llg DNA) were made up to 20 III with sterile deionised H20 in a
sterile microfuge tube. The enzyme should be added last so that it is correctly
buffered immediately. The volume of enzyme used cannot exceed 10% of the reaction
volume due to presence of glycerol in the enzyme storage buffer which can decrease
endonuclease activity. The sample was mixed by gentle finger tapping and pulse-spun
if necessary. The tube was incubated at the recommended temperature (usually 37°C)
for 2 hours to overnight. The reaction was stopped by heating at 65°C for 10 min to
inactivate the restriction enzyme. An aliquot of the reaction can be run on an agarose
gel (Section 2.3.2) to check the efficiency of the digestion.
2.3.4 Isolation of plasmid DNA (alkaline lysis)
The aim of this technique is the preparation of sufficient plasmid DNA for use in
subsequent experiments. The presence of plasmid DNA in an E. coli cell is
determined phenotypically by selectively isolating the plasmid DNA from cellular
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DNA and RNA and additional cellular components such as protein, which can often
contaminate and inhibit further downstream DNA manipulations. A number of
different methods for isolating DNA have been developed, the most common of these
being the alkaline lysis technique. The first step of plasmid isolation is lysis of the
host cells carrying the plasmid. This method utilises sodium hydroxide and sodium
dodecyl sulfate (SDS) for breaking open the bacterial cells. At this pH (12-12.6) the
chromosomal and linear DNA are denatured. An acidic acetate solution is then used to
neutralise the solution, and the chromosomal DNA forms an insoluble aggregate.
Along with protein-SDS complexes, these contaminants can be removed by
centrifugation. Due to its covalently closed circular nature, the plasmid DNA remains
in solution, in the cleared lysate. Further treatment of the solution such as ethanol
precipitation can be used to clean and concentrate the plasmid DNA for further
experiments such as cloning or sequencing. A scaled down protocol using these
techniques is known as the mini-prep technique (Sambrook et al. , 1989).
2.3.4.1 Materials
Ampicillin stock (5 mg/ml). Ampicillin (Roche) (50 mg) was dissolved in 10 nil
sterile dist.Hjt). The solution was filter-sterilised and stored at 4°C. Dilute 2 ml per
100 ml LB medium (100 ug/ml final concentration).
LB (Luria Bertani) Medium. Bacto-tryptone (10 g), bacto yeast extract (5 g) and NaCl
Cl 0 g) was dissolved in dist H20 (1 1) with heating. Media was dispensed into conical
flasks, stopped with cottonwool, and wrapped in tin foil. The media was sterilised by
autoclaving ( 1 hour at 121°C).
GTE solution (50 mM glucose, 25 mM Tris.Cl pH 8.0, 10 mM EDTA). Glucose (4,5
g) was dissolved in sterile dist H20 (450 ml) along with Tris (1.51 g) and EDTA
(1.86 g). The buffer was adjusted to pH 8.0 with HCl and made to 500 ml with
dist.H20.
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NaOH/SDS CO.2m NaOH, 1% SDS). NaOH (1.6 g) was dissolved in dist H20 (200
ml). 10% SDS (5 m1) was diluted with O.2M NaOH (45 ml). This solution was
prepared just before use.
3M Potassium acetate solution, pH 4.8. Anhydrous potassium acetate (58.89 g) was
dissolved in dist H20 (50 ml) combined with glacial acetic acid (50 m1). The mixture
.was left to dissolve for 1.5 h. The solution was titrated to pH 4.8 with glacial acetic
acid and adjusted to 200 ml with dist.Hif).
2.3.4.2 Method
LB medium (10 ml) containing appropriate antibiotic (eg. 100 ug/ml ampicillin) was
inoculated with a single bacterial colony of E. coli containing plasmid. The culture
was grown overnight at 37°C with vigorous shaking. Cells were pelleted in sterile
po1ypropylene centrifuge tubes, in the desktop Sigma 3K20 centrifuge (7250 x g; 5
min; 4°C) and the supernatant was poured off. The pellet was resuspended in GTE
solution (200 Ill) and left at room temperature for 5 min. The suspension was
transferred to a sterile microfuge tube. RNase A (2 Ill) was added. Freshly prepared
NaOH/SDS (400 Ill) was added to the sample and placed on ice for 5 min. Potassium
acetate solution (300 Ill) was added mixed thoroughly and the solution was placed on
ice for 5 min. A thick white precipitate of cellular debris and chromosomal DNA
forms on addition of this buffer. The precipitate was removed by centrifugation
(12000 x g; 5 min; 4°C). The clear supernatant (800 Ill) was carefully transferred to a
fresh sterile microfuge tube. Chilled isopropanol (600 Ill) was added to the sample
and this was placed at -20°C for 1 h. Plasmid DNA was pelleted by centrifugation
(12000 x g; 5 min; 4°C) and the supernatant was removed carefully from the pellet.
The plasmid DNA was washed twice with ice cold 70% (v/v) ethanol (0.5 m1) and the
pellet was eventually resuspended in sterile TE buffer (50 Ill). This preparation IS
stable at -20°C.
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2.3.5 Isolation of plasmid DNA (Nucleobond'" AX kit)
Nucleobond® AX is a silica based anion exchange chromotography system which
isolates plasmid DNA with extremely high levels of purity. The system is based on
the principle behind the alkaline lysis method (Section 2.3.4). Bacterial cells are lysed
by a NaOHlSDS solution, which denatures chromosomal DNA under the alkaline
conditions. The addition of potassium acetate results in a precipitate of cellular
compounds and chromosomal DNA. The plasmid DNA stays in solution and can be
purified using the Nucleobond® AX cartridge. The ion-exchange silica is secured
between inert filters in polypropylene cartridges allowing for the efficient separation
of nucleic acids . Impurities and contaminants are completely removed which
potentially inhibit further manipulations such as ligation or restriction digestion. The
plasmid DNA binds to the matrix at a low pH and ionic strength, and is eluted when
the pH is increased. The kit was used for preparative purposes, where the desired
mini-prep needs to be highly pure.
2.3.5.1 Materials
The following materials were supplied with the Nucleobond® AX kit. The plasmid
isolation was performed following manufacturers instructions supplied with the kit.
Buffer SI (50 mM Tris/HCI, 10 mM EDTA, 100 big RNase Alml, pH 8.0). The
lyophilised RNase supplied with the kit is dissolved in 1 ml buffer SI , then added to
the bottle SI. This buffer was stored at 4QC.
Buffer S2 (200 mM NaOH, 1% SDS).
Buffer S3 (2.8 M Potassium acetate, pH 5.1)
Buffer N2 [lOO mM Tris, 15% (v/v) ethanol, 900 mM KCI, 0.15% Triton X-lOO, pH
6.31. The solution was adjusted with H3P04 to pH 6.3.
Buffer N3 [100 mM Tris, 15% (v/v) ethanol, 1150 mM KCI, pH 6.31. The solution
was adjusted with H3P04 to pH 6.3.
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Buffer N5 [lOO mM Tris, 15 % (v/v) ethanol, 1000 mM KCl, pH 8.51. The solution
was adjusted with H3P0 4 to pH 8.5.
Nuc1eobond® AX po1ypropylene sterile cartridges.
Nucleobond® AX filters
2.35.2 Method
LB medium (30 ml) containing appropriate antibiotic (eg. 100 ug/ml ampicillin) was
inoculated with a single bacterial colony of E. coli containing plasmid. The culture
was grown overnight at 37°C with vigorous shaking. Cells were pelleted in sterile
polypropylene centrifuge tubes, in the desktop Sigma 3K20 centrifuge (5000 x g; 10
min; 4°C) and the supernatant was poured off. The pellet was carefully resuspended
in buffer 81 (4 ml). Buffer 82 (4 ml) was added and was mixed by inverting the
sample 6 - 8 times. The mixture was incubated at room temperature for no longer than
5 min. Chromosomal DNA was precipitated by the addition of buffer 83 (4 ml) with
gentle mixing by inversion and incubated on ice for 5 min. The white bacterial lysate
precipitate can be removed either by centrifugation (12000 x g; 25 min; 4°C) or by
filtration. The folded filter paper supplied with the kit was moistened with sterile dist
H2O and the lysate was filtered, collecting the flow-through in a sterile 10 ml
polypropylene tube. The cartridge was equilibrated by the addition of buffer N2 (2.5
ml). The filtered lysate was loaded onto the cartridge and allowed to flow through the
macroporous silica by gravity. The cartridge was then washed twice with buffer N3 (2
x 5 ml). The plasmid DNA was eluted with buffer N5 (5 ml) and collected in a sterile
polypropylene centrifuge tube. The plasmid DNA was precipitated with isopropanol
(3.6 ml) and centrifuged immediately (15000 x g; 30 min; 4°C). Before
centrifugation, the area where the plasmid DNA pellet is predicted to form was
marked with a pencil and the centrifuge tube was placed accordingly in the rotor. This
was to ensure that the position of the pellet is known and care can be taken to avoid
losing the DNA. The DNA was washed with chilled 70 % (v/v) ethanol (5 ml) and
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centrifuged (15000 x g; 10 min; 4°C). The ethanol was carefully removed and the
pellet air dried for 10 min and resuspended in water or TE buffer (50 Ill).
2.3.6 Purification and concentration of DNA from aqueous solutions
DNA can be effectively precipitated out of a solution using absolute ethanol, in the
presence of monovalent cations such as sodium ions. At very low temperatures (-
20°C), the DNA precipitate can be collected using centrifugation. The concentration
of the DNA is effected when the pellet is resuspended in a volume less that the
original sample (Brown, 2001).
2.3.6.1 Materials
3 M Sodium acetate, pH 5.5. Sodium acetate (40, 82 g) was dissolved in sterile dist
H20 (20 ml) and glacial acetic acid (50 ml). The solution was titrated to pH 5.5 with
glacial acetic acid and adjusted to 100 ml with sterile dist.Hjf).
2.3.6.2 Method
3 M sodium acetate was mixed in to 1/l0th volume. 2.5 Volumes of ice-cold 100%
ethanol was mixed in and left at -20cC for at least 1 h. The sample was centrifuged
(14000 x g, 25 min, 4°C). The supematant was removed carefully without disturbing
the pellet. The pellet was washed with 70% (v/v) ethanol (0.5 ml) by centrifugation
(12000 x g 5 min, 4°C). The ethanol is removed carefully and the pellet is left to air
dry for 10 min. The dry pellet was dissolved in sterile H20 if used in specific
enzymatic reactions or in TE buffer if stored indefmitely.
2.3.7 Colony PCR
PCR is a powerful tool with a variety of applications in disciplines relating to
molecular biology. The presence of an appropriate insert in a bacterial colony can be
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verified using a PCR technique. Amplification of insert DNA cloned into a vector,
using a crude preparation of the colony DNA as template, allows extremely quick
detection and characterisation of the construct. In preference, universal primers to the
vector are used for PCR, allowing the nature and size of the insert in the vector to be
characterised: Primers specific to the insert, in this case primers originally used to
amplify the insert can also be used to screen however care must be taken as false
positives can be generated. This arises due to amplification of non-cloned DNA
transformed into the competent cells, and is not a reflection of insert-containing
vector DNA. Although the DNA cannot replicate within the host, the sensitivity of
PCR is such that even trace amounts of insert DNA in a colony can be detected and
lead to a false positive. Therefore, when using insert-specific primers, care must be
taken in setting up the correct controls to safeguard against this occurrence (Alvarez
et al., 2002).
2.3.7.1 Materials
PCR reactions were performed as per Section 2.4.2
2.3.7.2 Method
The colonies tested were approximately I mm in diameter and were picked of the agar
media using a sterile toothpick, or flame-sterilised loop, and placed in sterile dist H20
(50 J-lI). The colony was vortexed thoroughly to ensure dispersion of the cells in the
water. The sample was boiled for 5 min to lyse the cells and denature the DNases, and
then centrifuged (8000 x g, 2 min, room temperature) to remove insoluble
contaminants that may interfere with the PCR reaction. The plasmid DNA present in
the solution was removed (10 ul) for use in the PCR reaction. PCR was performed
with the same reaction conditions and temperature cycles as described in section
2.4.2, for the amplification of the 817bp insert from Plasmodium falciparum DNA.
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2.4 Amplification of a 817 bp region in the Plasmodium falciparum
MAL3P6.11 gene by the Polymerase Chain Reaction
2.4.1 Design of oligonucleotides for PCR amplification of MAL3P6.11
In general, primers used in PCR are between 20 and 30 nucleotides in length,
allowing a high annealing temperature to be used. There is an increase in specificity
with longer oligonucleotides due to the occurrence of that specific sequence in the
target DNA. The primer length and sequence are highly important in designing
amplification. The melting temperature (Tm) of a nucleic acid hybrid increases with
increasing (G+C) content, and length. The annealing temperature used in the peR
cycle depends on the composition and length of the primer. An annealing temperature
(Ta).approximately 5°C below the lowest Tm of the pair of oligonucleotide primers
should be used (Innis and Gelfand, 1990). The length of a primer depends on its
(A+T) content. The higher the Tm of the primer, the more chance mismatch pairing
and non-specific priming occurring. However the primer should be complex enough
to decrease the likelihood of non-specific binding. Oligonucleotides were designed to
amplify regions of the MAL3P6.l1 gene in preparation for possible cloning into an
expression vector (pMAL-C2x).
Due to the fact that specific regions of the gene are to be cloned, it was possible to
introduce restriction site sequences onto the ends of the oligonucleotide primers. This
is based on the method described by Scharf et al. (1986) in which through PCR, these
sequences will become incorporated into the amplified product, which can then be
digested with the restriction enzyme to produce blunt or sticky ends, as so required.
Modifications at the 5' termini of oligonucleotides have little effect on the specificity
of the amplification ..
2.4.1.1 Materials
DNA sequence of MAL3P6.1l Obtained at PlasmoDB (The Plasmodium Genome
Resource) (http://plasmodb.org/). The Plasmodium falciparum 3D? database is
provided by The Institute of Genomic Research (TIGR).
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Primer 3
Online primer design software tool:
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3.cgi/primer3_www.cgi)
Amplify3 Primer design software tool, Dr Mitchell
2.4.1.2 Method
The online primer design software, Primer 3.0 was used to suggest possible primer
binding sites within the MAL3P6.11 gene. The program analyses DNA sequences and
selects oligonucleotide sequences suitable for PCR. The software takes into account
factors such as melting temperature and primer dimer characteristics. If specific
sequences are to be amplified, such as a region to be cloned, primers can be chosen
manually taking into account several important rules (lnnis and Ge1fand, 1990):
1 Primers should be between 17-28 base pairs in length
2 The base composition (G+C) should be 50-60%
3 The 3' end of the primer should preferably end in at least one G or C, to prevent
'breathing' of ends, and increase the efficiency of the primer.
4 Melting temperatures between 55-80°C
5 The 3' ends of the primers should not be complementary. Avoid the possibility of
causing primer dimers (hybridisation between oligonucleotide primers depletes
the reaction of available primers for template DNA amplification).
6 Avoid primer self-complementarity. Sometimes self-complimentary sequences
cause secondary structures such as hairpins.
Oligonucleotide pnmers were designed based on the above criteria, .to amplify
portions of the MAL3P6.11 gene. Due to the extremely low (G+C) content, suitable
positions for primer binding were generally limited. The primer design software
(Primer 3) provided possible binding sites for primers. This software predicts the most
probable and safe primer binding sites within a given sequence based on melting
temperature and primer dimer factors.
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Due to the fact that some primers were altered by the addition of restriction sites, they
were re-checked for primer-dimer formation with Amplify3.
<- - - - --- - - - - Open reading frame - Pf40 3 ------------->
1 2+3 4 5+6
Pc96
~----- Ov e r l a p ------>
Figure 2.3. Diagram showing MAL3P6.11 gene with positions of primers
designed: 1 - PfFORl, 2 - PfFOR2, 3 - PfFOR2(BamHI), 4 - PfREVl , 5 - PfREV2, 6
- PfREV2(SalI). Grey region shows overlap with Pca96, respective primers binding
sites is red.
The positions of the primers designed are shown in Figure 2.3. A set was designed to
amplify the entire gene (primers 1 and 4), the Pc96 overlap region (primers 2 and 4),
and the region of the overlap most similar to Pc96 (primers 2 and 3).
The restriction site chosen must not be present in the DNA target region, and so the
sequence of MAL3P6.11 was used in an online restriction enzyme site map generator,
Webcutter (http://www.firstmarket.com/cutter/cut2.html) .This provided a list and
position of all restriction endonuclease sites present in the gene. A BamHI restriction
site was designed into the sequence of the forward primer, PfFOR2(BamHI) and a
SalI site into PfREVI(SalI) (see Figure 2.3 and Table 2.3). BamHI and SalI sites do
not occur in the target sequence and so can be used for PCR cloning. The BamHI site
was designed to keep the translation of sequence in frame with the expression vector
protein. The SalI site does not have to keep frame, being at the C-terminus of the
protein.
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Table 2.3. Oligonucleotide primer sequences for peR of MAL3P6.1l. Restriction
sites BamHI and Sal! are underlined.
Primer no. 5'-3' sequence Primer name
1 tat gea tee ett teg tgg te PfFOR1
2 tag ata tta aea act ate ttg PfFOR2
3 gga tee aae tat ett gtt aat aat ett e PfFOR2(BamHI)
4 gtt gta egt ttt eeg tae cat e PfREV1
5 tat tta aaa ata tte aaa aag g PfREV2
6 gte gae tat tta aaa ata tte aaa aag g PfREV2(SalI)
Two additional primers, used for the amplification of a 717 bp region of the ACC
(acetyl-ccA carboxylase) gene from Plasmodium falciparum DNA were used as an
internal control for PCR. These are ACCXpfl (GCT AAT AAT GGG ATG GCA
GC) and ACCXpf2 (TTT GTG TAG TAC AAT CAC GAC).
2.4.2 Amplification of 817bp target region in the MAL3P6.1l gene from
Plasmodium falciparum genomic DNA
2.4.2.1 Materials
10 x PCR reaction buffer with MgCbClOO mM Tris-HC!' 15 mM MgCh, 500 mM
KC!, pH 8.3),
Roche CMannheim, Germany).
dNTP mixture (2.5 mM of each dATP, dCTP, dGTP, dTTP). TaKara Biomedicals
(Shiga, Japan).
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Tag DNA Polymerase (l VIIll), Roche CMannheim, Germany).
Primer 1: 5 !!M PtFOR2(BamHI) (5' ggatccaactatcttgttaataatcttc 3')
Supplied at 2 145.9 !-!M. 50!-!M primer stocks were made by diluting the primer stock
(10 Jl1) into sterile 1 x TE buffer (419 Ill). 5/lM stocks were made by diluting the
50flM stock (10 Ill) with sterile 1 x TE buffer (90 Ill).
Primer 25 gM PfREV1 (5 I gttgtacgttttctgaccatc 3')
Supplied at 2291.3 !-!M. 50!-!M primer stocks were made by diluting the primer stock
(10 Jl1) into sterile 1 x TE buffer (448 Ill). 5!-!M stocks were made by diluting the
50flM stock (10 Ill) with sterile 1 x TE buffer (90 Ill).
Plasmodium falciparum (3D7) genomic DNA. Isolated and provided by Prof.
Christian Doerig
2.4.2.2 Method
Reagents were set up in sterile PCR tubes to a total volume of 50 Ill, according to the
amounts shown in Table 2.4. The PCR tubes were kept on ice at all times and the Taq
polymerase enzyme was added last to the buffered reaction components.
Amplification was achieved using a Perkin Elmer GeneAmp 2400 Thermocycler
according to the following temperatures and times (as previously optimised for the
717 bp ACC amplification from Plasmodiumjalciparum DNA): 94°C for 5 min, 25
cycles of the following: 94°C for 30 sec (denaturation); 55°C for 30 sec (annealing);
noc for 1 min (extension), and noc for 7 min and finally to 4°C. PCR products
were analysed on a 1% agarose gel with appropriate molecular mass markers.
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Table 2.4. Components of PCR reaction used for amplification of 822bp region
from isolated Plasmodium falciparum DNA.
Reaction component
Sterile distilled H20
lax PCR reaction buffer with MgCh
dNTP mixture
Primer PfFOR2(BamHI) stock (5JlM)
Primer PfREV2 stock (5JlM)
Tag DNA polymerase











2.4.3 Optimisation of PCR reaction using a MgCh profile
The MgCh concentration in the PCR reaction mixture can be varied within a range of
0.5-5.0 mM in order to find the optimum. Mg2+ ions form a soluble complex with the
free dNTPs in the reaction mixture, which is vital for dNTP incorporation during
strand synthesis by DNA polymerase. They also stimulate the polymerase activity and
increase the T m of the primer/template hybrid. The final concentration of MgCh in the
reaction can have a dramatic effect on the yield and specificity of the amplification.
The optimum concentration is different for every PCR reaction, and so must be found
for each reaction using a MgCh profile. In general, low Mg2+ leads to low yields and
an inefficient reaction, whereas high Mg2+ often results in the accumulation of non-
specific products. Concentrations of 1.0 - 1.5 mM MgCh are usually sufficient, and
the profile is based around these values.
2.4.3.1 Materials
MgCI~ stock solution (25mM MgCb) Roche (Mannheim, Germany).
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10 x PCR reaction buffer without MgCh (lOOmM Tris HCI, 500mM KCI, pH 8.3),
Roche (Mannheim, Germany).
Other components as seen in Section 2.4.2
2.4.3.2 Method
The PCR reactions are set up as per section 2.4.2 (Table 2.4), but the 10 x PCR
reaction buffer without MgCh is used. This allows the MgCh to be added at varying
amounts. The amount of MgCh added was taken into account when making the
volume up to 50 III with sterile dist.Hg), Table 2.5 shows the amounts of MgCh
added for the profile. Products were analysed using agarose gel electrophoresis.






















2.5 Directional cloning of 817 bp PCR product into pGEX-4T-3
2.5.1 Clean-up of 817 bp PCR product
2.5.1.1 Materials
Components for PCR are described in section 2.4.2.
Chloroform: isoamyl alcohol CClAA)(24:1). Chloroform (240 Ill) was combined with
isoamyl alcohol (10 Ill) and stored at room temperature.
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2.5.1.2 Method
PCR amplification of the 8l7bp region in the MAL3P6.11 gene was conducted in a
100 III reaction volume as described in section 2.4.2. An aliquot (5 Ill) of the PCR
reaction was evaluated for purity and size on a 1 % agarose gel. (90 Ill) was added to
the remaining PCR product. The mixture was transferred to a sterile microfuge tube
and vortexed for 1 minute. The mixture was then centrifuged (12000 x g ; 1 minute)
and 2 III of the aqueous phase was transferred to a sterile microfuge tube. The PCR
product was quantitated at 260 and 280 nm using spectrophotometry before and after
the treatment to assess the clean up procedure. An aliquot (5 Ill) was checked on an
agarose gel for the efficiency of the CIAA treatment and yields obtained.
2.5.2 Klenow treatment and restriction digestion (Bamlll) of peR product
2.5.2.1 Materials
DNA Polymerase I Large (Klenow) Fragment (5U/Ill) (Promega, USA).
10 x BamHI restriction buffer (60 mM Tris-Cl; 1 M NaCl; 60 mM MgC12; 10 mM
DTT, pH7.5) (Promega, USA).
817 bp ClAA treated PCR product (500 Ilg/ml) As prepared in previous Section 2.5.1,
2.5.2.2 Method
The components described in Table 2.6 were added to a sterile microfuge tube and
incubated for 15 min at 30°C. The reaction was stopped by heating for 10 min at
75°C. BamHI (1111) was added to the reactions and incubated overnight at 37°C. This
reaction was again stopped by heating at 65°C for 15 min.
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Table 2.6 Reaction components for the blunt ending of PCR products using the
Klenow enzyme.
Reaction component
CIAA treated PCR product
Klenow enzyme (5 D/Ill)







2.5.3 Calculation of vector:insert ratios used for cloning 817 bp insert into
pGEX-4T-3
The amount of the insert DNA prepared after the klenow treatment and restriction
digestion (BamIll) reactions must maintain an appropriate vector:insert ratio for the
ligation reactions. A molar ratio of 1:5 (vector:insert) was chosen for the ligation
reactions. The amount of insert (817 bp) DNA to use per 50 ng vector (4900 bp) for
ligation was calculated according to the following equation:
Insert length (bp) x ng vector x molar ratio
vector length bp
ng insert
817 bp x 50
4900 bp
x 5.0 41 .68 ng insert
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Similarly, the amount of insert DNA to use in a ligation with a vector:insert ratio of
1:10 was calculated at 83.36 ng per 50 ng vector.
2.5.4 Ligation of 817 bp peR product into pGEX-4T-3 vector
2.5.4.1 Materials
817 bp Insert DNA (125 Ilg/ml) As prepared in previous Section 2.5.2 .
T4 DNA Ligase (Amersham Life Science, Inc, USA).
10 x ligation buffer (660 mM Tris-HCl, pH 7.6, 66 mM MgC12, 100 mM DTT, 660
!=tM ATP) (Amersham Life Science, Inc, USA).
BamHI/SmaI double digested pGEX-4T-3 DNA (50 Ilg/ml) (Amersham, Life
Science, USA) pGEX-4T-3 plasmid DNA was isolated from E. coli culture using the
(Nucleobondf AX kit) as described in Section 2.3.5. The purified DNA was digested
with BamHI and SmaI restriction enzymes (Section 2.3.3) in preparation for ligation
reactions.
2.5.4.2 Method
Ligation reactions were set up according to Table 2.7 in autoclaved microfuge tubes.
Before the addition of the 10x ligation buffer and the T4 DNA ligase, the reaction
mixture was heated at 65°C for 5 min then cooled on ice. The reaction was incubated
at 16°C overnight.
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Table 2.7 Reaction components for the ligation of 817 bp peR product into
BamHl/SmaI digested pGEX-4T-3.
Volume (ul)
Ligation reaction number 1 2 3 4 5 6
BamHI/SmaI digested pGEX-4T-3 (50 ug/ml) 1 1 1 1 1
817 bp Insert DNA (125 ug/ml) 0.3 0.3 0.6 0.6 0.3
10 x ligation buffer 1 1 1 1 1 1
T4 DNA ligase 1 1 1 1 1
Sterile dist.H2O 6.7 6.7 6.4 6.4 8 7.7
Total reaction volume 10 10 10 10 10 10
2.5.5 Preparation of competent E. coli DH5
The procedure developed by Cohen et al. in 1973, can yield competent cultures of E.
coli strains for transformation protocols. Based on previous observations, bacteria
treated with ice-cold solutions of CaCh, then heat shocked, can be transfected with
bacteriophage ADNA. The treatment induces a state of 'competence' in the bacteria,
in which they have the ability to take up DNA molecules derived from a variety of
sources. How these divalent cations induce this state, and the mechanism by which
plasmid DNA enters the cells is unknown. The method provides a means of obtaining
a high frequency of transformation, used routinely and efficiently for cloning
purposes (Sambrook, 1989). The protocol is essentially that of Cohen et al. (1973)
with minor modifications.
2.5.5.1 Materials
E. coli (DH5a) supE44 AlaeUI 69 (cp80 lacZ1MI5) hsdRl7 recAI endAI gyrA96 thi-I
relAI
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Glycerol stocks were previously prepared by combining E. coli culture (0,625 ml)
with sterile glycerol (0,375 ml). These were stored at -70°C.
LB agar medium. Bacto-tryptone (10 g), bacto yeast extract (5 g), NaCl (5 g) and agar
(15 g) was dissolved in dist H2O (1 1) with heating. The media was sterilised by
autoclaving (121°C for 1 h). Once the solution had cooled to about 50°C, the media
was aseptically poured into sterile petri dishes.
LB broth media See Section 2.3.4.1
Sterile 50 ml polypropylene tubes. The tubes were cleaned, rinsed, and the lids and
tubes were wrapped separately in tin foil. These were autoclaved at 121°C for 1 h.
0.1 M CaCh. CaCh.2H20 (1.47 g) was weighed and dissolved in dist H20 (100 ml).
Solution was autoclaved at 121°C for 1 h.
2.5.5.2 Method
Glycerol stocks of E. coli strain DH5a, were streaked onto LB agar plates, and
colonies were allowed to grow overnight at 37°C. A single colony was picked and
transferred aseptically to sterile LB broth (50 ml) and cultured overnight at 37°C. 500
III of this was inoculated into a further LB broth (100 ml) and grown at 37°C with
vigorous shaking (300 cycles / min) until the OD600 is 0.3 - 0.4 (the number of viable
cells per ml of culture should not exceed 108) . The growth of the culture was
monitored spectrophotometrically every 20-30 min. The cells (50 ml) were transferred
to two sterile (autoclaved), ice-cold 50 ml polypropylene tubes. The cells were cooled
by storage in the tubes, on ice for 10 min. The cells were recovered by centrifugation
(4500 x g, 10 min, 4°C) and resuspended in ice cold sterile 0.1 M CaCh (20ml). The
cells were again centrifuged (4500 x g, 10 min, 4°C) and carefully resuspended in 0.1
M CaCh (1 ml). Cells can either be used for transformation at this point or stored at
4°C (no longer than 3 weeks). Glycerol storage of these cells allows for much longer
storage, yet the transformation efficiencies decrease drastically after glycerol storage.
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2.5.6 Transformation of competent E. coli DH5a cells
2.5.6.1 Materials
E. coli DH5a competent cells. As prepared in section 2.5.5.
sac medium
pGEX-4T-3 test plasmid for transformation (0.2 ng/ul). Prepared by making a 0.2
ug/ml working stock of purified (Nucleobond'" AX kit) pMAL-C2x plasmid DNA
(Section 2.3.5).
2.5.6.2 Method .
Competent DH5a E. coli cells (Section 2.5.5) were aliquoted (20 ul) into sterile
microfuge tubes. The ligation reaction mixes (Table 2.2) (1 ul) were added directly to
the cells (20 JlI) and the sample was mixed gently. The test plasmid (pGEX-4T-3) for
transformation (1 ul) was used as a transformation control to assess the efficiency of
the DH5a competent cells. The tubes were left on ice for 30 min. sac media was
removed from -70°C and thawed. The cells were then heat-shocked for 90 seconds in
a 42°C water bath. The samples were rapidly placed on ice for 2 min and sac media
(80 ul) was added and gently mixed with the cells. The tubes were incubated at 37°C
for 1 h with rapid shaking (200-250 rpm) to allow the bacteria to recover and express
the antibiotic resistant marker encoded by the plasmid DNA. A hockey stick for
plating was made by heating and bending a Pasteur pipette, whose tip was sealed in a
flame. The transformations (50 ul) were spread onto the surface of the L-agar plates
aseptically, using 70%(v/v) ethanol to flame-sterilise the hockey stick. An additional
control transformation (5 ul) was also spread. The plates were incubated overnight,
inverted, at 37°C.
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2.6 Cloning 817bp PCR product into pMOSBlue vector
The pMOSBlue blunt ended cloning kit (Amersham Biosciences, UK) was used to
clone the 817 bp PCR product into the vector, pMOSBlue. Materials listed were partly
provided by the kit. The procedure was followed according to the kit manual.
2.6.1 Phosphorylation and klenow treatment of DNA fragments
The large fragment of DNA Polymerase I (Klenow Fragment) is DNA polymerase I
with its 5'-3' exonuclease activity removed, keeping the polymerase activity or the 3'-
S'exonuclease activity intact. The 5'-3' exonuclease activity degrades 5' termini of
primers bound to DNA templates and removes 5' phosphates that function in ligation
reactions (Klenow and Henningsen, 1970). The polymerase activity can fill in
recessed 3' termini , or degrade from free 3'-hydroxyl termini, polishing and blunt
ending DNA fragments (Sambrook et al., 1989).
Ligation reactions depend on the required 5'-phosphate residues at the termini of
DNA fragments for the formation of new phosphodiester bonds between two DNA
molecules. DNA molecules that lack the 5'-phosphate group can be prepared for
ligation by phosphorylation with bacteriophage T4 polynucleotide kinase. This
enzyme cata1yzes the transfer of the y-phosphate of ATP to the 5' terminus of DNA.
The phosphorylation and klenow reactions were performed simultaneously in this
experiment.
2.6.1.1 Materials
Positive control insert (4.5 ng/Ill). (Amersham Biosciences, UK)
817 bp PCR product (500 Ilg/ml)Prepared by CIAA treatment (Section 2.5.1).
10 x PK buffer (Amersham Biosciences, UK)
PK Enzyme mix (Amersharn Biosciences, UK)
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100 mM dithiothreito1 (DTT) (Amersham Biosciences, UK)
Sterile dist. HIO
2.6.1.2 Method
PK reactions were set up according to Table 2.8 and were incubated at 22°C for 40
min. The samples were centrifuged briefly to collect the contents at the bottom of the
tube. The reaction was heat inactivated at 75°C for 10 min. The reaction was cooled
on ice for 2 min and centrifuged briefly to collect the condensate.
Table 2.8 Components of PK reactions for cloning 817bp insert into pMOSBlue
Volume (Ill)
PK reaction number: 1 2 3 4 5 6
Control insert DNA 2 2
PCR aqueous phase 1 1 1
10 x Pk buffer 1 1 1 1 1 1
100mMDTT 0.5 0.5 0.5 0.5 0.5 0.5
PK enzyme mix 1 1 1 1 1
sterile dist.H2O 6.5 6.5 6.5 5.5 . 6.5 7.5
Final reaction volume 10 10 10 10 10 10
2.6.2 Blunt-end ligation of 817 bp insert to EcoRV digested pMOSBlue vector
2.6.2.1 Materials
T4 DNA ligase (4 units / Ill)
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EcoRV digested dephosphorylated pMOSBlue vector (50 ng / un
PK reactions from section 2.6.1
2.6.2.2 Method
Ligation reactions were set up as described on Table 2.9.
Table 2.9. Ligation reactions for cloning 817bp insert into 2887 bp pMOSBlue
vector.
Ligation reaction 1 2 3 4 5 6
linearised vector (50 ng) 1 1 1 1 1 1
PK reaction (1-6) 10 10 10 10 10 10
T4 DNA ligase 1 1 1 1 1 1
Total reaction volume: 12 12 12 12 12 12
The PK reactions (10 Ill) were combined with 1111 EcoRV digested pMOSBlue vector
according to the amounts indicated on Table 2.9. The T4 DNA ligase (l Ill) was
added last to the two samples and gently stirred with the pipette tip. The ligation
reactions (12 Ill) were incubated at 22°C overnight.
2.6.3 Preparation of LB agar plates for spreading pMOSBlue transformants.
2.6.3.1 Materials
LB-agar (500 ml), Tryptone ( 5 g), yeast extract (2.5 g), NaCI (5 g) and agar (7.5 g)
were dissolved in dist H2O (500 ml), in an autoclavable 1 I glass bottle with screw on
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lid, with heating. The dissolved media, and a magnetic stirrer bar was sterilised by
autoclaving (121°C, 1 h).
Tetracycline (12 mg/ml). Tetracycline (12 mg) was dissolved in 70%(v/v) ethanol (1
ml) and stored in the dark at -20°C. Dilute stock 0.1 ml per 100 ml L-broth (12 ug/ml
[mal concentration).
5-bromo-4-chloro-3-indolyl-~-D-galactoside (X-gal) substrate (40 mg/mn. Dissolve
X-gal (40 g) in dimethylformamide (DMF) (1 ml). Dilute 0.2 ml per 100 ml L-broth
(80 ug/ml final concentration).
O.lM isopropyl B-D-thiogalactopyranoside (IPTG). IPTG (0.238 g) was dissolved in
10 ml dist .Hjf). The solution was filter sterilised and stored in a sterile 15 m1 vial.
This was added to 0.3 mM final concentration in the media.
Ampicillin (5 mg/mn. Ampicillin (50 mg) was dissolved in dist H20 (10 ml). The
solution was filter sterilised and stored in a sterile 15 ml vial at -20°C. Dilute 1 m1 per
100 ml L-broth (50 ug/ml final concentration).
2.6.3.2 Method
LB agar (493 ml) was prepared and autoc1aved. The media was stirred using the
magnetic stirrer bar until it cooled down to approximately 50°C. Tetracycline (0.5
ml), ampicillin (5 ml), X-gal (1 ml), and IPTG (0.5 ml) were added aseptically and
mixed into the media. The LB media was poured into sterile 82mm plates until media
covered the base. The plates were left to cool and set before refrigeration, to prevent
condensation occurring inside the plates. Plates are stored inverted at 4°C.
2.6.4 Transformation of competent MOSblue E. coli cells
2.6.4.1 Materials
MOSBlue competent cells (component ofpMOSBlue blunt ended cloning kit)
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soe media (component ofpMOSBlue blunt ended cloning kit)
Test plasmid for transformation (0.2 ng!lll) (component of pMOSBlue blunt ended
cloning kit)
2.6.4.2 Method
Sterile microfuge tubes were pre-chilled on ice. A sample of MOSblue competent
cells was removed from -70De storage and thawed on ice. The cells were dispensed
into the sterile microfuge tubes (20 Ill). The ligation reaction mixes (Table 2.9) Cl Ill)
was added directly to the cells (20 Ill) and the sample was mixed gently. The test
plasmid (pMOSBlue)for transformation (1 Ill) was used as a transformation control to
assess the efficiency of the MOSblue competent cells.
The tubes were left on ice for 30 min. soe media was removed from -70 De and
thawed to room temperature. The cells were then heat-shocked for 40 seconds in a
42°C water bath. The samples were placed on ice for 2 min and room temperature
soe media (80 Ill) was added and gently mixed with the cells. The tubes were
incubated at 37De for 1 h with rapid shaking (200-250 rpm). A hockey stick was
made, and the cells were spread onto the LB-agar plates as per section 2.5.6.
2.7 Subcloning 822 bp fragment from pMOS817 into expression vector
pMAL-C2x
2.7.1 Purification of 822 bp insert from low-melting point agarose gel
Agarase I is isolated from Psuedomonas atlantica is an enzyme widely used in the
field of molecular biology for isolating DNA fragments of many sizes from agarose
gels (Burmeister and Lehrach, 1987). The enzyme is responsible for the degradation
of agarose to oligosaccharides, and so disrupting the agarose gel matrix. Once treated
and warmed, a gel will not reset upon cooling, allowing the DNA fragments to be free
from the agarose gel. Agarase I and the oligosaccharides, generally do not interfere
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with restriction enzyme digestion, and ligation. However the DNA can still be
separated from these contam.iri.ants using standard procedures (phenol extraction or
ethanol precipitation) (Burmeister and Lehrach, 1989).
Low melting point agarose contains hydroxyethyl groups that have been introduced
into the polysaccharide chain. This substitution causes the gel to set at approximately
30°C and to melt at 65°C. Due to the low melting-temperature, the agarose remains
fluid at 37°C, allowing various enzymatic manipulations to be carried out (ligation,
synthesis of probes, digestion with restriction enzymes, etc.). The use of the enzyme
agarase provides an extremely gentle method for the selective extraction and isolation
of DNA bands from gels.
2.7.1.1 Materials
Agarase I enzyme (Sigma-Aldrich, Inc., USA). Stored in 40 mM Tris HCI, 50 mM
NaCl, 50%(v/v) glycerol. One unit is the amount of enzyme that digests 100 ul of
melted 1% low-melting agarose to agaro-oligosaccharides in 1 h at 45°C.
25X agarase I buffer (0.75 M Bis-Tris, 0.25 M EDTA, pH 7.1).
Low melting point agarose
3 M sodium acetate pH 5.2. Sodium acetate (40, 82 g) was dissolved in sterile dist
H20 (20 ml) and glacial acetic acid (50 ml). The solution was titrated to pH 5.2 with
glacial acetic acid and adjusted to 100 ml with sterile dist.Hjf).
2.7.1.2 Method
The band of interest, identified by comparison to molecular markers, was cut from the
low melting point agarose gel and placed in a pre-weighed sterile microfuge tube. The
tube was weighed to determine the weight of the gel slice (100 mg of gel yields 100
~l melted gel). 0.04 Volumes of 25X agarase I buffer was added and the gel was
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melted at 65°C for 15 min. The sample was cooled to 45°C and the agarase I enzyme
was added (1 U of agarase per 100 III gel). This was incubated at 45°C for 1 h.
The DNA fragments were removed and concentrated from the sample by ethanol
precipitation. This was performed as per Section 2.3.6 with minor modifications as
follows. 0.1 Volume 3 M sodium acetate pH 5.2 was added to the melted agarose
solution and was incubated for 15 min on ice. The sample was centrifuged (12000 x g;
15 min, 4°C) to remove the oligosaccharides, and the supernatant was transferred to a
sterile microfuge tube. 3 Volumes of ice-cold 100%(v/v) ethanol was added and the
tubes were incubated for 1 h on ice. The samples were centrifuged (14000 x g, 25
min, 4°C) to pellet the DNA, which was air dried for 5 min and dissolved in dist.Hjt).
The DNA was quantitated using spectrophotometry (Section 2.3.1).
2.7.2 Ligation of 822bp fragment into pMAL-c2x
2.7.2.1 Materials
T4 DNA Ligase (Amersham Life Science, Inc, USA).
10 x ligation buffer (660 mM Tris-HCl, pH 7.6, 66 mM MgC12, 100 mM DTT, 660
!lM ATP) (Amersham Life Science, Inc, USA).
2.7.2.2 Method
pMAL-C2x Vector (1 ug) was used in a restriction digestion reaction (20 Ill) using
BamHI, in preparation for cloning as per section 2.3.3. Itwas ensured that complete
digestion had occurred, so as to minimise transformation of background colonies.
The amount of insert DNA to use for a vector:insert molar ratio of 1:5, was insert
(30.7 ng):vector (50 ng), as calculated in section 2.5.3. Table 2.10 shows the ligation
reactions performed for this experiment. The insert DNA prepared in the previous
section 2.6.1 was diluted toa 30.7 ug/ml working stock.
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Table 2.10 Ligation reactions for cloning 822bp BamID insert into pMAL-C2x
Ligation reaction 1 2 3 4 5 6
1 ul linearised pMAL-C2x (50 ug/ml) 1 1 1 1 1
1 III Insert DNA (30.7 ug/ml) 1 1 2 1
10 x ligation buffer 1 1 1 1 1 1
T4 DNA ligase 1 1 1 1 1
Sterile dist.H2O 6 6 5 7 8 7
Total reaction volume 10 10 10 10 10 10
2.7.3 Preparation of competent E. coli JMI03 cells
As performed in Section 2.5.5, but with the E. coli JM103 strain (supE thi-I endAl
hsdR4 sbcB15 strA !l(proAB) F'[traD36 pro.Ab" lacfllacZL1M15).
2.7.4 Transformation of competent JMI03 E. coli cells
The transformations were performed as described in Section 2.5.6, except the E. coli
JM 103 competent cells were used and the transformation efficiency was assessed
using pMAL-C2x test plasmid for transformation (0.2 ng/ul), which was previously
prepared by making a 0.2 ug/ml working stock of purified (Nucleobond'" AX kit)
pMAL-C2x plasmid DNA .
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2.8 Protein techniques
2.8.1 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was established in
1967 by Shapiro et al. The method is initially dependent on the interaction of the protein with
SDS. SDS is a detergent with a 12 carbon hydrophobic tail and a hydrophilic, sulfonic acid head
group. Proteins are first denatured in the presence of SDS by boiling. The SDS molecules interact
with the proteins causing the formation of rod-like complexes with a consistent ration of ea. 1.4
mg of SDS per mg of protein (Pitt-Rivers and Impiombato, 1968). The negative charge of the
SDS effectively masks that of the protein, causing all proteinlSDS complexes to contain the same
charge/mass ratio and an anodic migration (Weber and Osbom, 1969). While the charge
differences between proteins is masked by SDS, separation of proteins is due to differences in
size, therefore allowing effective separation based on size and estimation of molecular size.
SDS-PAGE is based on a discontinuous buffer system. This was developed where changes in the
properties of the buffers and the gels in a vertical slab layout, would maximise the resolution and
concentration of protein into defmed visible bands. Two different gels are used, a stacking gel
(large pore size) and a running gel (small pore size) (Omstein, 1964). Both gels contain Tris-HCl
buffer , but the buffer in the stacking gel is a lower pH than that in the running gel. In an electric
field, a sharp interface develops between the high mobility 'leading ion' (er) and glycine, the
less mobile 'trailing ion' . As the interface migrates downwards, protein molecules with mobilities
intermediate between cr and glycine become concentrated into a thin band. Protein molecules are
kept in this sharp interface by voltage gradients behind or ahead of the interface (Jovin, 1973). As
this interface reaches the change between the stacking and running gels the pH increases,
resulting in an increased mobility of the glycine trailing ion (the anodic mobility of glycine
increases with pH as the proportion of glycine ions increases). The interface overtakes the stack
. of proteins allowing separation to occur in a linear voltage gradient according to protein size. The
running gel therefore forms a small-pore sieve effect. The smaller the protein, the more rapid
migration towards the anode occurs (Dennison, 1999).
Polyacrylamide is a synthetic gel for electrophoresis that carries the advantage of being highly
reproducible. The pore size is easily controlled by adjustments in the proportions of acrylamide
and bisacrylamide, making up the synthetic polymer. Acrylamide is cross-linked by N,N'-
methylenebisacry1amide, by the initiation . of polymerisation . with N,N,N',N'-
tetramethylethylenediamene (TEMED). TEMED acts as a catalyst in the formation of free
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radicals from ammonium persulfate, causing polymerisation (Hames and Rickwood, 1981).
The Laemmli (1970) method of polyacrylamide gel electrophoresis has become one of the most
popular PAGE methods in use. However, for resolution of smaller proteins under 20 kDa, and
alternative method is used described by Shagger and Von Jagow (1987), called the Tricine
method. The estimation of molecular weight relies on reduction of the proteins as the disulfide
bridges may interrupt the protein structure and prevent formation of protein/SDS complexes.
Boiling in SDS not only denatures the protein but also dissociates the subunits of oligomeric
proteins. The molecular weights obtained by SDS-PAGE are therefore representative of the
subunits and not of the intact protein (Dennison, 1999).
2.8.1.1 Materials
Solution A: Monomer Solution [30% Cm/v) acrylamide, 2.7% Cm/v) Bis-acrylamideJ. Acrylamide
(73 g) and Bis-acrylamide (2 g) were dissolved and made up to 250 ml with dist H20 and stored
in an amber coloured bottle at 4
QC.
Filter through Whatman No. 1 filter paper before use.
Solution B: 4 x Running Gel Buffer (1.5 M Tris-HCL pH 8.8). Tris (45.37 g) was dissolved in
approximately 200 ml of dist.Hjf), adjusted to pH 8.8 with HCl and made up to 250 mL Filter
through Whatman No. 1 filter paper before use.
Solution C: 4 x Stacking Gel Buffer (500 mM Tris-HCL pH 6.8). Tris (3 g) was dissolved in 40
ml dist.Hjf), adjusted with HCl to pH 6.8 and made up to 50 mL This buffer was made up weekly,
because as a result of its poor buffering capacity at 2.1 pH units below its pKa at 4QC (Pharmacea
products catalogue), pH drift led to anomalous running patterns in non-reducing SDS-PAGE.
Filter through Whatman No. 1 filter paper before use.
Solution D: 10% (m/v) SDS. SDS (10 g) was dissolved in 100 ml dist H20 with gentle heating if
necessary.
Solution E: Initiator [10% (m/v) ammonium persulfateJ. Ammonium persulfate (0.2 g) was made
up to 2 ml with dist H20 just before use.
Solution F: Tank buffer [250 mM Tris-HCL 192 mM glycine, 0.1% Cm/v) SDS, pH 8.31. Tris (15
g) and glycine (72 g) were dissolved and made up to 5 litres with dist.Hjf). Prior to use, 2.5 ml
SDS stock (solution E) was added to 250 ml for use in the Mighty Small II apparatus.
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Solution G: Reducing Treatment Buffer [125 mM Tris-HCI, 4 % Cm/v) SDS, 20% Cv/v) glycerol,
10% (v/v) 2-mercaptoethano1, pH 6.81. Buffer C (2.5 ml), 10% SDS (4 ml) (solution D), glycerol
(2 ml) and 2-mercaptoethanol (1 ml) were made up to 10 ml with dist.Hjf).
Solution H: Non-reducing Treatment Buffer [125 mM Tris-HCI, 4 % Cm/v) SDS, 20% Cv/v)
glycerol, pH 6.81. Buffer C (2.5 ml), 10% SDS (4 ml) (solution D) and glycerol (2 ml) were made
up to 10 ml with dist.Hjt).
Stain stock solution [l% (m/v) Coomasie blue R-250]. Coomasie blue R-250 (1 g) was dissolved
in 100 ml of dist H20 by magnetic stirring for 1 h at room temperature. The solution was filtered
through Whatman No. 1 filter paper.
Staining solution [0.125% Cm/v) Coomasie blue R-250, 50% (v/v) methanol, 10% (v/v) acetic
acid]. Stain stock (62.5 m1) was mixed with methanol (250 ml) and acetic acid (50 ml), and made
up to 500 ml with dist.H jf),
Destaining solution I [50% (v/v) methanol, 10% (v/v) acetic acid]. Methanol (500 ml) was mixed
with acetic acid (100 ml) and made up to 1 litre with dist.Hjf).
Destaining solution IT [7% (v/v) acetic acid, 5% (v/v) methanol]. Acetic acid (70 ml) was mixed
with methanol (50 ml), and made up to 1 litre with dist.Hef),
2.8.1.2 Method
The Bio-Rad Mini-PROTEAN II® vertical slab electrophoresis unit was used for SDS-PAGE,
and was assembled as per manufacturer's manual. Glass plates, spacers, combs and casting stand
gaskets were washed thoroughly with soap water and cleaned meticulously with 70% ethanol.
The glass plates were .clamped, separated by the 1 mm spacers and running gel was poured into
the assembly using a 10 ml syringe with sterile needle. The gel was poured to a height leaving
space for the stacking gel. Dist H20 was overlaid to prevent inhibition of polymerisation by
oxygen. The gel was allowed to polymerise for 30 min to 1 h at room temperature. The gel had
set when the interface was visible between the gel and the water. The water is poured off the
running gel or carefully removed with a syringe. The stacking gel solution was poured in and the
gel comb was inserted to form the sample application wells.
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Table 2.11. Preparation of running and stacking gels of different acrylamide
concentrations (Laemmli, 1970).
Reagent Volume (ml)
Running gel (%) Stacking gel (%)
15 12.5 7.5 5 4 3
A 7.5 6.25 3.75 2.5 0.94 0.71
B 3.75 3.75 3.75 3.75 0 0
C 0 0 0 0 1.75 1.75
D 0.15 0.15 0.15 0.15 0.07 0.07
E 0.075 0.075 0.075 0.075 0.035 0.035
dist.H20 3.5 4.75 7.25 8.5 4.3 4.53
TEMED 0.0075 0.0075 0.0075 0.0075 0.015 0.015
Once set (30 min to 1 h at room temperature), the comb was carefully removed and the wells
rinsed with dist.Hjf), The clamps were placed onto the electrode apparatus and placed in an
electrode tank. Tank buffer (Solution F, with SDS) (250 ml) was poured into the upper and lower
electrode compartments.
The procedure for preparation ofprotein samples differs for different applications ofSDS-PAGE.
In general, for reducing SDS-PAGE, samples are combined with an equal volume of reducing
treatment buffer (solution G) and boiled for 5 min. A dye, bromophenol blue tracker dye (5 Ill)
which migrates with the buffer front was added to each sample before loading into wells.
Samples were loaded using gel-loading pipette tips into the set wells. After samples were loaded,
the gel unit was connected to a power pack and run at 18 mA per gel until the bromophenol blue
tracker dye in the sample is close to running off the gel. The power supply was disconnected, the
clamps removed and the plates were separated using a spacer. The gel was removed using gloves
and placed into staining solution for 4-to12 h. The staining solution was removed and the gels
rinsed with destaining solution I, until gel background is clear. Destaining solution II is used to
complete the stain and enlarge the gel. Gels were kept in plastic zip-seal backs and kept in
destaining solution IT until photographed or scanned.
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2.8.2 Induction and expression of GSTIMBP fusion proteins with IPTG
These protocols are similar to that of Sambrook et al.(1987) with minor modifications suited to
optimisation of expression systems. The induction is based on the chemical activation of the lacZ
gene with IPTG, during early exponential phase of E. coli culture. It is during this phase of the
growth cycle that E. coli is expressing proteins at an optimal level, due the availability of growth
nutrients, and the relative efficiency at which the cells divide. However these factors need to be
optirnised for each expression system, including the growth temperature at induction. An
advantage of chemical induction with IPTG is the relatively high amounts of expression that can
be obtained, even at low temperatures (20 - 30°C) .where in general, protein synthesis, rate of
growth and cell division is low. SDS-PAGE analysis following induction, is an effective way of
monitoring and detecting the levels of expression of a particular fusion protein, and provides a
platform for further analysis such as western blotting.
2.8.2.1 Materials
0.1 M isopropylthio-~-D-galactoside (IPTG). IPTG (0.238 g) was dissolved in sterile dist H20
(10 ml) and filter sterilised.
1 x SDS gel loading buffer [125 mM Tris-HCI, 4 % (m/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-
mercaptoethanol, pH 6.81.. Prepared as per Section 2.7.1, Solution G.
2.8.2.2 Method
E. coli cells containing the expression vector were initially streaked on an LB-agar plate (100
ug/ml Ampicillin) and grown overnight at 37°C in order to obtain single colony clones. Two
cultures of a single colony was grown in separate LB medium (10 ml) containing ampicillin (100
ug/ml) overnight at 37°C with agitation. Further LB broth media (20 ml) was inoculated with the
cultures (500 ul) and grown to an optical density (OD) of 0.6, as determined
spectrophotometrically (600 nm). This was achieved by measuring the density every 30 min,
against a sterile LB broth (1 ml) blank. At this point, one of the cultures was inoculated with
O.1M IPTG (3 ul per ml of culture) to 0.3 mM, taking into account the volume removed for
spectrophotometric analysis. These cultures were grown for a further 4 h to ensure the induction
of sufficient fusion protein for analysis using SDS-PAGE.
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Cellular protein extracts were prepared by centrifuging (15000 x g) for 1 min at room
temperature in a microfuge tube. The pellets were resuspended in 1 x SDS gel-loading buffer
(100 ul). Samples were boiled for 3 min and cooled on ice, followed by loading (5 ul) the wells of
a prepared SDS-PAGE gel for analysis of cellular protein. Cultured samples not induced were




IN SILICO DATABASE SCREENING WITH PC96 FOR CLASSIFICATION AND
FUNCTIONAL ASSIGNMENT
3.1 Introduction
The alignment of novel DNA and amino acid sequenceswith previously characterised coding or
amino acid sequences can provide important information about the identification of proteins. In
recent years, the explosive growth in biotechnology and information technology, and efficient
and automated sequencing methods have made it easier to characterise proteins based on their
sequences. If significant sequence similarity exists between the query sequence and a previously
characterised protein, much information can be acquired. The alignment of protein sequences can
show common underlying structural roles for the protein. Sequence comparison procedures
should be treated like any laboratory experiment taking care in the design of the particular
method, and the correct evaluation of results gained (Brenner, 1998).
Pc96, a 96 kDa membrane associated antigen in Plasmodium chabaudi adami, has shown
protective roles in infections of mice (Wanidworanun et aI., 1989). Monoclonal antibodies
against Pc96 identified cross-reacting antigens in P. jalciparum (155 kDa), P. vivax (222 kDa)
and P. cynomolgi (200 kDa). Because Pf155 and Pv222 share a cross-reacting epitope with Pc96,
this antigen was identified as a potential vaccine candidate. P. chabaudi adami infection in B-cell
deficient mice, activates aT-cell dependent mechanism which terminates acute malaria in a
similar manner to that seen in immunologically intact mice (Grun and Weidanz, 1981), indicating
. a significant role of cell mediated immunity. A protein was identified by antibodies raised against
Pc96 that caused the proliferation of specific T cell clones, responsible for providing adoptive
protection in a Plasmodium chabaudi adami infection. The identification of a similar protein in
Plasmodiumjalciparum with similar T cell epitopes, and the identification of the T cell epitope in
the sequence that may be responsible for a multiple antibody response would prove vital in the
design of cell mediated protection against human malaria. The ring-infected erythrocyte surface
antigen (pfl55/RESA) was thought to be the homologue of Pc96, based on cross-reactivity with
antibodies in P. falciparum. In these experiments, protein sequence and structural analysis
showed that Pf155IRESA is non-homologous to Pc96 and several othermalaria proteins shows
high homology in regions .
The sequence of the Plasmodium jalciparum genome has recently been made availability at
PlasmoDB (The Plasmodium Genome Resource) (Gardner et al., 2002). This allows the database
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to be screened for sequences similar to Pc96, thus providing an alternative approach to the
identification of possible homologues. An open reading frame was identified in the falciparum
PlasmoDB, coding for a 3394 amino acid protein predicted to be 403 kDa is size. BLAST
screening with the Pc96 protein showed Pf403 to contain an extensive region of sequence
similarity and similar secondary structure properties. Similar sequence similarities were found in
a 178 kDa protein identified in the Plasmodium yoelii yoelii database, Pyy178.In an ideal
situation, the BLAST search would have matched the Pc96 sequence to a full length, previously
classified protein with known characteristics and functions. Proteins identified as showing high
homology were previously not characterised, and were simply open reading frames within
malaria genome DNA sequences, with unknown function.
The evaluation of protein sequences and subsequent identification of putative T cell epitopes from
potential antigens has found many applications in the development of vaccines. Various strategies
are available that select putative peptide candidates based on algorithms . Further experiments can
be designed to verify the relevance of the epitopes (Schirle, et al., 2001) . Major histocompatibility
complex (MBC) molecules are involved in the presentation of these epitopes to cells of the
immune system. MBC class I molecules become associated with the peptides in the endoplasmic
reticulum, after which is transported to the cell surface where it is exposed to the immune system
for recognition by cytotoxic T cells. MBC class 11 ligands have more variety in their length (9-25
amino acids) and bind to MBC class IT molecules in the late endosomalllysosomal compartment.
The complexes are exposed on the cell surface, for recognition by CD4+cells. A T cell response is
mediated by the recognition of the peptide derived from protein antigen leading to T cell
activation . This has since become the most successful method for the identification of T cell
epitopes (Schirle, et al., 2001).
The specificity of other cell components of cellular immune response (TAP and proteasome) have
been applied as additional criteria to epitope prediction and the selection of appropriate T ·cell
epitopes. T-cell mediated immunity is initiated by a series of cellular processes due to the
recognition ofMBC-peptide complexes by the T cell receptor.
In this Chapter, a bioinformatics approach was taken, utilising the various malaria databases in
the search for proteins similar to the mouse malaria antigen, Pc96, and the possible identification
of protein structure and function. A 403 kDa protein in Plasmodium falciparum, and a 178 kDa
Pyy178 in Plasmodium yoelii yoelii, an alternative mouse model for malaria, showed extensive
regions of similarity to Pc96 and contained putative conserved T cell epitopes similar to that
found in Pc96. Features of these proteins such as hydropathy, flexibility and antigenicity were
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evaluated, and motifs and signature sequences were identified using the PROSITE database.
Further analysis was used to recognise the 3D structure of specific domain regions in Pf403 and
homologous proteins. Features recognised in the Pf403 sequence include a unique leucine zipper
patterns, along with the recognition of a Interferon-induced guanylate-binding protein I domain,
provide evidence suggesting the involvement of the protein in DNA binding. Other domains
highly similar to the Clostridium botulinum and C: tetani neurotoxins, and the Colicin la domain
(Membrane and cell surface protein) suggest a role in membrane association. Three unique
bipartite nuclear targeting sequence motifs indicate involvement of the protein in uptake and
accumulation in the nucleus.
3.2 Results
3.2.1 Identification of proteins with sequence similarity to Pc96 amino acid sequence
The nucleotide and predicted amino acid sequence of Pc96 was used in a number of database
searches using various BLAST algorithms designed to identify proteins with a high degree of
sequence similarity. The results of a BLASTP search using Pc96 as the query are summarised in
Table 3.1.
Table 3.1 Proteins with significant similarity to Pc96 identified using BLASTP
Significant hits with BLASTP
hypotheticalprotein (plasmodium yoeliiyoelii)
hypotheticalprotein C0760c - malaria parasite (Plasmodium
[alciparum)
E value GI accession number
2e-55 23481602
1e-21 7494250
Table 3.1 shows the two protein sequences identified the from GenBank database at NCBI. Only
proteins with sequence regions significantly homologous to Pc96 were chosen according to the
statistical E value reported by the software. The E-values for these matches show a high
significance, and an extremely low probability of these sequences being matched by chance.
Hypothetical protein (un-characterised open reading frame) in the Plasmodium yoelii yoelii
database (Pyy178) and hypothetical protein C0760c (Plasmodium falciparum) (Pf403) showed
the highest similarity to Pc96.
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Further analysis used the Pc96 sequence in the more sensitive and thorough algorithm,
position-specific iterated-BLAST (pSI-BLAST). Proteins with similar regions can be identified
using this search method, using profile data structures more sensitive to weak, yet significant
matches. The profile constructed after the first search is used in a second pass search of the
database, refming the profile. Table 3.2 shows ten database hits from the first PSI-BLAST
iteration of the profile. The two most high-scoring hits were again Pyy178 and Pf403, with E
values of l e-l l S, and 3e-29 respectively. Using this algorithm, Pyy178 showed a higher
probability ofbeing homologous to Pc96 than Pf403.
Table 3.2 Proteins with significant similarity to Pc96 identified using PSI-BLAST ·
Significant hits with PSI-BLAST E value GInumber
hypothetical protein (Plasmodium yoelii yoelii) 1.0e-115 23481602
hypothetical protein C0760c - malaria parasite (Plasmodium 3.00e-29 7494250
jalciparum)
hypothetical protein (Plasmodium yoelii yoelii) 0.0003 23482074
probable integral membrane protein PFB0710c - malaria 0.0003 7494364
parasite (Plasmodium jalciparum)
Plasmodium falciparum trophozoite antigen protein like 0.0005 17566482
family member (5U678) (Caenorhabditis elegans)
hypothetical protein (Plasmodium yoelii yoelii) 0.0009 23478292
fork head domain protein, putative (Plasmodium [alciparum 0.001 23619015
3D7)
myosin heavychain (Plasmodium yoelii yoelii) 0.002 23485072
lipase precursor GehM (Staphylococcus xylosus) 0.003 11493973
protein conserved (4F151) (Caenorhabditis elegans) 0.003 25145616
A BLASTP search with the hypothetical protein C0760c (Pf403) was performed to identify
similar proteins in GenBank. Only two hits were obtained, the hypothetical protein (Plasmodium
yoelii yoelii) (Pyy178) and another hypothetical protein tPlasmodiumyoelii yoelii) (Pyy84). As
can be seen, there were no hits of proteins with characterised functional domains, allowing easy
identification of the protein. Regions reported to be similar in these proteins showed a region of
the Pf403 protein to be similar to the Pyyl78 and Pc96 proteins, and a separate region to the
Pyy84 protein, indicating the presence of two domains, yet the function or identity of these
regions was not evident. The significance of these matches , were provided by E values for the
alignments are seen on Table 3.3.
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Table 3.3 Proteins with significant similarity to Pf403 identified using BLASTP
Significant hits with BLASTP
hypothetical protein (Plasmodium yoelii yoelii)
hypothetical protein (Plasmodium yoelii yoelii )










In order to identify proteins similar to Pyy178, the sequence was used in a BLAST search,
reflecting the similarity of Pyyl78 to Pf403. The only significant hit was again hypothetical
protein C0760c (Pf403), with an E value of 2e-n. No further proteins of any significance were
detected, that may identify the protein and its homologues. The database was screened using the
Pyy84 sequence, in order to further investigate the region of similarity, shared with Pf403. Due to
its conserved nature in these proteins from these two species, it is likely that this region forms a
particular function based on a domain or pattern. PSI-BLAST was used to identify other proteins
containing similar regions to Pyy84 (Table 3.4).
Table 3.4 Proteins with significant similarity to Pyy84 identified using PSI-BLAST'
Significant hits with PSI-BLAST
hypothetical protein C0760c - malaria parasite
(Plasmodium falciparum)
Uncharacterized protein [Methanopyrus kandleri AV19]
Unknown (protein for lMAGE:3614358) [Homo sapiens]
enterophilin-2L [Cavia porcellus]
membrane protein p120 - Mycoplasma hominis
kinesin-like 7; kinesin-like protein 2 [Homo sapiens]







Table 3.5 shows a summary of the malaria proteins identified using BLAST showing sequence
similarity.
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Table 3.5. Features of malaria proteins showing regions similar to Pc96
Protein GI accession Size (amino acids) Name Molecular weight (Da)
hypo thetica l protein (Plasmodium yoelii yoelii) 23481602 1523 Pyy178 178052.17
hypothetical protein C0760c - malaria parasite 7494250 3394 Pyy403 403158 .04
(Plasmodium jalciparum)
hypothetical protein (Plasmodium yoelii yoelii) 23484590 713 Pyy84 83779.93
Pc96 antigen (Plasmodium chabaudi adamiy Not deposited 942 Pc96 . 110054.92
The data obtained from the alignments of the BLAST hits, was used to construct a diagram,
showing and comparing the sizes and relative positions of the proteins in relation to the

















Figure 3.1 Positions of malaria proteins with homology to regions in Pf403. Pf403
(Plasmodium falciparumy; Pc96 (Plasmodium chabaudi adami), Pyy178 (Plasmodium yoelii
yoelii) and Pyy84 (Plasmodium yoelii yoelii) are shown in relation to amino acid number scale.
3.2.2 Prediction ofHLA-type T-cell epitopes in Pc96
The SYFPEITHI program (Rammensee et al., 1999) identified a number of putative T cell
epitopes in the sequence of Pc96 (Figure 3.2). In total, 17 peptides were predicted. A total of 7
HLA-type epitopes were identified. Of these peptides (ILKMFKLGSCYLYII), (LIKYKNFI) and
(LIKYKNFII) were shown to be conserved in Pf403 and Pyy178. As seen for Pc96 in mice
infected with P. chabaudi adami, Pf403 may contain T cell epitopes capable of eliciting an
immune response, directed against an array of P. chabaudi adami antigens. These epitopes
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conserved in Pf403 are of high interest. The 17 peptides identified by SYFPEITHI were used in
a BLAST search for short nearly exact matches of the Plasmodium falciparum malaria genome
(PlasmoDB). This identified malaria proteins also containing these specific epitopes. Table 3.6
shows the predicted T cell epitopes for Pc96 and lists the malaria proteins found to contain the
same epitope sequences. It was interesting to note that peptides (LIKYKNFI) and (LIKYKNFII),
which are virtually identical in Pc96, Pf403 and Pyy178, exhibit exact similarity to those
contained in a variety of other malaria proteins, as identified by the BLAST search for short
nearly exact matches.
FSVSSDHITL IKCNI LKMFK LGSCYLYIIN RNLKEI KI LF DKINSLEENI QSLNLFINNL 60
KDQNKNNEVI KINNEEQILQ LKNSLQNNEN CINNLNDNLK QKDEMNNSNI KNLI KYKNFI 120
I NLVHQTNVF LHIFKTMSTQ QVIQNSEYNQ LTQLLRKELD PYLNDSI MIS ELESKE KSDE 1 80
ANANNDLLNI PSTFSYENYE HIQIFTNKYN LIIERGQVSI FSDGKIKAPQ NEQTSTFFSN 240
ISSYFHNSNQ YNNTSNSKDA SENTPESPKD SQPQTYQEKE NEEESVRNDN GQMYSVEGNG 300
TDEEDYRDDL EEVEHDEDVE DEEREERDVR VEHDEDDDHD EHEERDEHGE LDEYDDHADH 360
VEHVESDEDD DHDDHDEHEE RDEHDELEEY DDHAGHIEHV EHDEDDEKSK ADGDTEVDED 42 0
ILSNNKEKEN QDVESYNEYN NDREEYENVS DSEKDEERSS IDNNYDEDHR DENETLQRYE 480
ENVIVENVDN LGE KELLPSN VESNVFENNY TSNDVNGNGI VPEVSEQNKV LDGDPI SNI N 54 0
YENI TTDI NI NTSNMQNEEN ISPPFSNKLE NNNST FVNGT TCSYMSEYEF NFFDKNDHPK 600
MKEAKKRKYH SDSEIVKQNN NNKTGYTKKK IRK ID HSYKF NNGD I PTEVV ENQIQ QN INF 660
NNLDNNYTNQ LFNNYYEEQK NKYELLDNI N KINQTYNSNN LDAPNDERND NENGNNSLMK 720
SDKESQNENK DDKAS DCYVI SSDDDAEVKD YDEEEDEAGE DDEDDDVKDY DEDESNEEI D 78 0
EGEEEEDEAD YEQFDSKGEI NSSVADEGEE SNSDDPDKDM I DYDEMDNAN GMKIEMKRTA 840
KLNVTI VNLN VMKAMLIVIK VMLIVMKVMK IVMKVTLI AM KATFDVMKAT LIMMKVI LVM 900
RRMTVVVIV T HI LQATTQMK IIKIKNQLLV LQHQMMVRMM DQ 942
Figure 3.2 Distribution of 17 putative T cell epitopes predicted in the Pc96 amino acid
sequence. (Epitopes are highlighted red and overlapping epitopes are highlighted in dark red).
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Table 3.6. T-cell epitopes predicted by SYFPEITffi for Pc96. Shows the epitope sequence,
HLA-type and other P.falciparum proteins containing the peptide.
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3.2.3 Multiple sequence alignments using ClustalW of protein regions with high
similarity to Pc96
Figure 3.3 shows the CLUSTALW alignment of Pc96 and Pf403 showing the high degree









--- - - - -- -------------------FSVSSDH I TLI KCNI LKMFKLGSCYLYI I NRNL 33
NNINNVNNINNVKNI VDINNYLVNNLQLNKDNDNI II I KFNILKLFKLGSCYLYIINRNL 24 00
: . .. * :* : ** **** : ***************
KEIKILFDKINSLEENIQSLNLFINNLKDQNKNNEVIKINNEEQILQLKNSLQNNENCIN 93
KE I QMLKNQILSLEESIKSLNEFINNLKNENEKNELI KINNFEEILKLKNNLQDNESCIQ 2460
***: :* :: * * ** * .*:* ** ** ** * *:: * : : * * : * * * ** * :** :** * . ** : **.** :
NLNDNLKQKDEMNNSNI KNLI KYKNFI INLVHQTNVFLHIFKTMSTQQVI QNSEYNQLTQ 153
NLNNYLKKNEELNKINVKN I FKYKGYI I HLIQQSNVFCKIFKHFNENKII DQSI INKL-L 2519
* * * : ** : : : *: * : * :* * - . * * * . * *. * . . * .*** : * * * : . : : : * :: * * :*
LLRKELDPYLNDSIMISELESKEKSDEANANNDLLNI PSTFSYENYEHI QIFTNKYNLII 213
YLKKSFDFYMYDSVIQEIRE- - - - - - - - - -NKNIIINQDFLTDEYFKHIQTFTKTCNVLI 2569
* : * . : * * : * * : : . * . :: * : :** * ** : . * . . *
Pc96
Pf403
ERGQVSIFSDGK-lKAPQNEQTSTFFSNI SSYFHNSNQYNNTSNSKDAS ENTPES PKDSQ 272
QRGYLSI LKDTNNDFFIQNKQSNQQGNQNGNHINMCN IYPDDEINVTADQQI FDGTENVQ 262 9









DNHLVNAFNNHNLLTNGNVKSDQINNETLERYEEN IIQNIYTNDNVDNNQVIEN INKILI 2749
: * : : .. : : : : * : * . : * : :: . :
Figure 3.3 Region of ClustalW multiple sequence alignment of Pc96 (Plasmodium
chabaudi adami), Pf403 (Plasmodium falciparum). * Shows exact amino acid matches, :
show conserved substitutions, and. denotes semi-conserved substitutions. Predicted T cell
epitopes are highlighted on Pc96).
Pc96 aligned with Pf403, shows the first 250 amino acids to be homologous, producing a
score of 973. To investigate and compare these sequences, pairwise alignments between
Pyy178 and Pf403 was performed using CLUSTALW (Figure 3.4). The alignment of
Pyy178 with Pf403 calculated an overall score of 2472. In this alignment it is evident that












:*:* **:*:. : : : : *
KDEYVSNLKMNLESSRMQLKDLCDQLEKGNLNEKKCNMKIQMLETKLXKEEKERKRYQIE
YQQFIHSLKANLENSRLELKELSNLNEKIQLSDEKNRMKITILEDKLFKNEKDKMKLQQI






***.**.: ::: ::: ****: : **:**.:* *:** *.:: * :: *::*:. **:**
EYIELLKKEKENVEKKFENTSEKYNEQINLNKKLTDDINLLISTHKEQVKVLNEQINILK
DYIKLIKKDKTNIQNEYNDLLEKYNEVVVKNNMLYNDMNVLLKEHKEEIFLLKENIKILQ


























































:***: **:::*:*: *::*::***.:**:*: ***:* :***::* ::*:*::**:*:*
Figure 3.4 Region of ClustalW multiple sequence alignment of Pyy78 (Plasmodium yoelii
yoeliis, Pf403 (Plasmodium falciparumy. * Shows exact amino acid matches,: show conserved
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DNNGDNGNN I VSEVGEENKLLGDN SVNHINYEN IKTDVAVNVDI DANTSNLQNEENI SPS
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* *** * ** : * .*** *. : * ** : ** *** ** *** : * :* * : * * * *** **: * **** * * * * *
VGEHDEDMLNDSKEKESSNIESYNEYNSNREEYVDVSDN DEEKEGDE FNYSNKEKSS IDN
DTEVDEDILSNNKEKENQDVESYNEYNNDREEYENVSDSEKD--- --- - ---EERSSIDN
FKELNENTTEPQKDTQI QTVQI SQEKQNEEENTKNENI I DTQVNNENYQI DALKNEEYND
YSVEGNGTDEEDYRDDLEEVEHDEDVEDEEREERDVRVEHDEDDDHDEHEERDEHGELDE
VEYTKKKMRKMNNSHKFTSRGTSDVTVESPTPQKLSEKLSEKLSEKLNGN IN GNINGDDN
TGYTKKK IRK IDHSYKFNNGD I PTEVVEN- - - - - - - - - - - - - - - - - - - -QIQQNIN FNNL
SK- -GELNSS ID DDSNSDDADKDM IDYDDIDNIN ENQNEEDSEVENEDDNNFLDE- - - - -
MKRTAKLNVT IVN-LNVMKAMLI VIKVML IVMKVMK IVMKVTL IAMKATFDVMKATLIMM
* . : * * : * * * : * . *
ENEDDENYASESFDNYYDEKK-KYEILENISKLNQACNNNNLDATSDGNNYAKKNEHNFL
DN- - - - NYTNQLFNNYYEEQKNKy ELLDNI NKI NQTyNSNNLDAPNDERN- DNENGNNSL
: * ** : . : * : *** :* :* * * *: * :* * . *: * *: * .***** * * :: * : * *
NYDESNCDKSNCEENETLQRYEENVIVENGNNLGEKELLTSNVESNLFENDDNNNDDNND
NYDEDHRD- - - - -ENETLQRYEENVI VENVDNLGEKELLPSNVESNVFENNYTSNDVN--
QSENQNEKQNENLS ENLSENLSEKQNENLSEKQNEKSNNFLSN-I SSYFQSSNKYNNAPT
TSTFFSNISSYFHNSNQYNNTSNSKDASENTPESPKDSQPQTYQEKENEEESVRNDNGQM
* . . . 0 * :* * : . :: .. ... . *. . . : . * : : * .
NKEKSNLNN FENNLLNIVS TFSCENYEHIQ I FTNKFNL I I ERGQFSILADSKIQ PSQNEK
SKEKSDEANANNDLLNI PSTFSYENYEHIQI FTNKYNLIIERGQVS I FSDGKI KAPQNEQ
**** : * : *: * *** **** ***** ** **** * : ** **** ** .. * * : : r • * * : .... *** ..
IKYKSFIINLVYQSNIFFHIFKNINKQKVIQNSIFNQLTQLR -KELDFYLNDSIMI SELE
IKYKNFIINLVHQTNVFLHI FKTMSTQQVI QNSEYNQLTQLLRKELDPYLNDSI MI SELE
**** .***** * : * :* :* :**** . : .. * :**** * : * * * * * * *** * ** **********
NLFINNLKDQHKNNEMIKINNEEQIV ELKNNLKNNENC INNLNDNLKQKDEMNN SNIQNL
NLFINNLKDQNKNNEVIKINNEEQILQLKNSLQNNENCINNLNDNLKQKDEMNNSNIKNL
* *** **** * *: * *** : * * * * **** *: : * * * .*: * * * * * ** * * * * **** * * * ** ** * *: * *
LNSSKNQFSVNSDH ITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDK IHSFEENIQSL
- - -----FSVSSDHI TLIKCNI LKMFKLGSCYLYI I NRNLKEI KILFDKIN SLEENIQSL

































Figure 3.5. Region of ClustalW pairwise sequence alignment of Pyy78 (Plasmodium yoelii
yoeliii, Pc96 (Plasmodium chabaudi adamh. * Shows exact amino acid matches, : show
conserved substitutions, and . denotes semi-conserved substitutions.
85
A score of 2435 resulted from the alignment of Pc96 with the Plasmodium yoelii yoelii, Pyy78
(Figure 3.6). It can be seen that the entire length of the Pc96 sequence is similar to a portion of
the Pyy178 protein. This indicates a high probability of these sequences being homologous. The
alignment shows several extended regions of sequence similarity. The full length of the Pc96




--VENDDNNNLNSSKNQEFSVNSDHI TLI KCNI LKMFKLGSCYLYI I NRN 5 8 0
------------------FSVSSDHI TLI KCNI LKMFKLGSCYLYI I NRN 32
NNVKNIV DI NNYLVNNLQLNKDNDNIII IKFNILKLFKLGSCYLYIINRN 2 3 99







LKEIKI LKDKIHSFEENI QSLNLFI NNLKDQHKNNEMIKI NNEEQI VELK
LKEI KILFDKI NSLEENI QSLNLFI NNLKDQNKNNEVI KI NNEEQILQLK
LKEIQMLKNQIL SLEESIK SLNEFI NNLKNENEKNELI KI NNFEEILKLK
**** .. * .. * * .** * -*** ****** : :: : : ** :***** * . * . . **
NNLKNNENCINNLNDNLKQKDEMNNSNIQNLIKYKSFIINLVYQSN I FFH
NSLQNNENCINNLNDNLKQKDEMNNSNIKNLI KYKNFI INLVHQTNVFLH
NNLQDNESCI QNLNNYLKKNEELNKINVKNI FKYKGY I I HLIQQSNVFCK










IFKNINKQKVI QNS IFNQLTQLR-KELDFYLNDSI MISELENKEKSNLNN 72 9
I FKTMS TQQVIQNSEYNQLTQLLRKELD PYLNDSI MISELESKEKSDEAN 182
IFKHFNENKII DQSIINKLLYLK- KSFDFYMYDSVI QEI RENK- - -- - - - 2 54 2




FENNLLNIVSTFS CENYEHI QIFTNKFNLIIERGQFSILAD SK-IQPSQN
ANNDLLNIPSTFSYENYEHIQIFTNKYNLIIERGQVSIFS DGK-lKAPQN




* :: * ** ** . * : : * : ** ** : * **
Figure 3.6 ClustalW multiple sequence alignment of Pyy178 (Plasmodium yoelii yoelil),
Pca96 (Plasmodium chabaudi adamiy and Pf403 (Plasmodium falciparum). * Shows exact
amino acid matches, : show conserved substitutions, and . denotes semi-conserved substitutions.
The alignment score for these three proteins was 5462. Pc96 shows homology from initial
amino acids in the sequence, while the similar region in Pyy78 spans from amino acids 532-729.
Pf403, being a much larger protein, is similar across a 221 amino acid region, from residues
2367 to 2589. From this multiple sequence alignment it can be seen that in these regions, there
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are stretches of highly conserved amino acids. From these results it can be seen that Pf403 is
more similar to Pyy78 than Pc96. The putative T cell epitopes, predicted in Section 2.1.2, are
indicated in the alignments, along with the casein kinase II phosphorylation site, shared between,
Pf403 and Pc96.
3.2.4 Secondary structure features of proteins similar to Pc96
The program PREDICT7 was used to calculate profiles based on secondary structure features
such as antigenicity, flexibility, hydropathy and surface probability , to further illustrate and
investigate the similarities between Pf403, Pc96 and Pyy178. Figure 3.7 shows these plots along
with the predicted T cell epitopes.
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Figure 3.7 Secondary structure features predicted for 250 bp region in Pca96, Pf403 and
Pyy178. A - Antigenicity plot (Welling et al., 1985); B - Flexibility plots (Karplus and Schultz,
1985), C - Hydropathy plots (Kyte and Doolittle, 1982); D - Surface probability plots (Janin,
1978). The position ofpredicted putative T cell epitopes are indicated in red.
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As can be seen for all profiles, the pattern of the plot is similar for the three proteins, for the
250 bp region of high similarity. The plots generated over theT cell epitopes show the nature of
the secondary structure , and indicate the similarities of the sequences containing the conserved
epitopes on Pf403 and Pyy178.
3.2.5 Motif and pattern recognition using PROSITE and domain analysis using 3D-PSSM
Table 3.7 shows the identification of PROSITE profiles for the proteins used in this study. These
. proteins contain regions of sequence similarity to that ofPc96. The N-glycosylation sites, protein
kinase C phosphorylation sites, casein kinase IT phosphorylations sites and tyrosine kinase
phosphorylation sites, are detected quite frequently within the sequences of these proteins. The
Leucine zipper pattern detected in all proteins except Pyy78, has previously been shown to play
a role in gene regulation. Although false hits have been identified in protein sequences known to
lack this motif, verification is usually obtained by the identification of DNA binding motifs. In
Pf403 there are three bipartite nuclear targeting sequences, increasing the likelihood of Pf403
playing a role in DNA binding or gene regulation. Although it may be difficult to draw any
structural or functional conclusions about these proteins, these consensus sequences comprising
of detected block motifs in the PROSITE database can be used for comparative analysis of 3D
structure, and the possible assignment of function for certain domains.
Table 3.7. The presence and number of motif and sequence patterns identified using
PROSITE for Pc96, Pf403, Pyy178 and Pyy84.
PROSITE pattern entry Pc96 Pf403 Pyy78 Pyy84
. N-g1ycosylation site 20 38 27 10
cAMP and cGMP-dependent protein kinase I 6 2 2
phosphorylation site
Protein kinase C phosphorylation site 9 16 26 6
Casein Kinase II phosphorylation site 24 49 35 14
Tyrosine kinase phosphorylation site 3 18 7 2
N-myristoylation site 2 6 8 8
Leucine Zipper pattern 2 1 1
Sulfonation 12 25 14 1
NUCLEAR Bipartite nuclear targeting sequence 3
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Tables 3.8 and 3.9 show the results of screening the 3DPSSM database with the four malaria
proteins under study (Pf403, Pc96, Pyy178 and Pyy84). This particular program recognises
certain combinations and positions of signature sequences and motif patterns from the sequence
and compares this to a database with a collection of known 3D structures. The statistical
relevance of the matches were reported as E values, reflecting the given probability of the
domain recognition pattern occurring by chance, based upon the initial alignments in the PSSM
algorithm. In general, E values below 0.1 are considered significant, and matches with values
below 1 can still be investigated.
In an attempt to recognise specific structural and functional domains, overlapping regions of
Pc96 and homologous proteins Pyyl78 and Pyy84 were submitted for fold recognition at the
3DPSSM site. This provided clues as to the identity of these regions within the proteins.
Analysis of Pc96 (Table 2.8) shows the identification of a region highly similar to the botulinum
neutoxin, and the yeast t-snare protein (ssol), a membrane protein. The Pyy178 protein sequence
was split into three regions, identifying the colicin la domain in the first, and the botulinum
neurotoxin in the second and third. The hydrolase domain was again found, similar to that of
phospholipase c beta and a region homologous to a hydrolase activator, proteasome component
y7, was identified. Pyy84 showed homology to Botulinum neurotoxin and interferon-induced
guanylate-binding protein I, a DNA binding protein.
These features compare to that of Pf403, indicating a similarity in the 3D structure of Pc96 as
well as the identified regions of sequence similarity. As can be seen on Table 3.9, a significant
match with Colicin la was obtained located in the first 500 residues of Pf403. This indicates the
possible role of Pf403 in biological membrane association as colicin la is involved in ion
channel forming in membranes and cell surfaces (Stroud et al., 1998). The interferon-induced
guanylate-binding protein 1, may also indicate DNA-binding properties. The domain that
showed the highest degree of structure recognition was the Botulinum neurotoxin catalytic
domain. This protein is a zincin metalloprotease, and is also involved in membrane association.
It is interesting to see the recognition of this domain, and that of colicin IA, in two specific
regions of Pf403. The hydrolase domain found in angiostatin , was recognised in the last 500
residues , along with translation initiation factor eIFla, a DNA-binding protein. Another putative
hydrolase domain was detected .in the first series of residues screened, similar to that of
phospholipase c beta.
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Table 3.8. 3D structure comparisons using 3DPSSM and identification of putative domains
in Pc96, Pyy178 and Pyy84.
E value of Protein Protein Name Description Organism
region
Pc96(l-480)
0.0 259 Botulinum neurotoxin serotype A Clostridium neurotoxins, Clostridium
catalytic domain - Zincin-like botulinum
metalloprotease
0.12 yeast t-snare protein ssol membrane protein Yeast
Pc96(481-942)
0.025 4 Botulinum neurotoxin serotype A Clostridium neurotoxins, Clostridium
catalytic domain - Zincin-like botulinum
metalloprotease
0.0597 GST-alpha-Na,K-ATPase crystal structure of the ankyrln
binding domain of2 alpha-
Na,K-atpase as a fusion protein
with glutathione3 s-transferase -
ankyrin binding.
Pyy178(1-488)
0.129 Colicin la Membrane and cell surface Enteric bacteria
protein - ion channel forming
0.329 Interferon-induced guanylate-binding c-terminal domain - binding of Homo sapiens
protein 1 guanine nucleotides
0.489 phospholipase c beta c-terminal - hydrolase enzyme
Pyy178(488-977)
0.000771 Botulinum neurotoxin serotype A Clostridium neurotoxins, Clostridium
catalytic domain - Zincin-like botulinum
metalloprotease
0.0487 yeast t-snare protein ssol membrane protein Yeast
Pyy178(977-l523)
0.00312 Botulinum neurotoxin serotype A Clostridium neurotoxins, Clostridium
catalytic domain - Zincin-like botulinum
metalloprotease .
0.052 proteasome component y7 hydrolase/hydrolase activator
Pyy84 (1-713)
0.171 Botulinum neurotoxin serotype A Clost ridium neurotoxins, Clostridium
catalytic domain - Zincin-like botulinum
metalloprotease
0 .64 2 Interferon-induced guanylate-binding c-termina1 domain - bindin~ of Homo sapiens
protem 1 guanine nucleotides - signa ling
protem
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Table 3.9. 3D structure comparisons using 3DPSSM and identification of putative domains
in Pf403 (Plasmodium falciparumi.
E value (region ofPf403) Protein name Description Organism
Pf403(1- 780)
· 0.042 Colicin la Membrane and cell surface Enteric bacteria
protein - ion channel forming
0.326 lnterferon- induced c-terminal domain - binding of Homo sapiens
guanylate-binding guanine nucleotides - signalling
protein I protein
0.445 phospholipase c beta c-terminal - hydrolase enzyme
Pf403(781-1560)
0.0000692 Botulinum neurotoxin Clostridium neurotoxins, catalytic Clostridium
serotype A domain - Zincin-like botulinum
metalloprotease
Pf403(1561-2340
0.0605 Colicin la Membrane and cell surface Enteric bacteria
protein - ion channel forming




0.0000688 Botulinum neurotoxin Clostridium neurotoxins, catalytic Clostridium
serotype A domain - Zincin-like botulinum
metalloprotease
Pf403(3121-3394)
0.254 Angiostatin hydrolase Homo sapiens
0.265 Translation initiation Nucleic acid binding - Cold shock Homo sapiens
factor eIF1a DNA-binding domain
These results together were used to construct a map of Pf403 and related proteins, according to
regions where putative domains of known 3D structure were identified. Figure 2.8 shows Pf403,
Pyy178, Pyy84 and Pc96, with the most significant matches obtained from the 3DPSSM analysis.
Both Pyy84 and Pyy178, two separate P. yoelii yoelii proteins showed homology to two separate
regions in Pf403, sharing similar comparisons to the 3D structures in these domains.
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Figure 3.8 Diagram showing domain regions identified by 3DPSSM analysis. Proteins A -
Pf403; B - Pyy84;C - Pc96; D - Pyy178. Structures identified by 3DPSSM shown on the diagram
are: Clcii (Colicin la) - shaded orange; D3btaa3 (Botulinum neurotoxin serotype A) - shaded
red; C140a (Angiostatin hydrolase) ; Clbg5 (GST-alpha-Na,K-ATPase) and Clfntb (proteasome
component y7 hydrolase activator); Didg3al (Interferon-induced guanylate-binding protein 1) _
shaded blue.
Due to the fact that two regions in Pf403, and regions in Pc96, Pyy84 and Pyy178 showed a
similar 3D structure to that of Botulinum neurotoxin serotype A, with comparatively high
estimations of statistical similarities , the 3D structure viewing software Rasmol was used to
generate structures of the protein (Figure 3.9). Both the backbone and ribbon structures were
shown, to emphasise features of the shape, and the positioning of helices and sheets making up
the protein.
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Figure 3.9. The 3 dimensional structures of the Botulinum neurotoxin domain,
identified by 3DPSSM. Images are shown as stereograms for 3D visualisation. Panel A
shows the ribbon structure and panel B, the backbone line structure.
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3.3 Discussion and conclusion
The assignment of function to an unknown protein from its sequence relies on the positive
identification of highly similar, previously characterised proteins. This technique has been
previously used by Merckx et al (2003) for the identification of cyclin related proteins in
the form of sequenced open reading frames in the Plasmodium falciparum sequence
database (PlasmoDB) (Gardner et al., 2002). Searches of sequence databases with the
predicted amino acid sequence of Pc96, identified several proteins containing regions of
extensive homology. Through variations of the BLAST algorithm, it was evident that all of
the highest scoring hits were other plasmodial proteins. Pf403 (Plasmodium falciparum)
and Pyy178 (Plasmodium yoelii yoelii) were hypothetical proteins found to contain regions
homologous to the Pc96 sequence.
Hypothetical proteins are based on the detection of open reading frames (ORF) within the
sequenced genomes, and properties of the proteins such as structure and function are
unknown. The extent of similarity between the plasmodial proteins was further analysed by
CLUSTALW pair-wise and multiple sequence alignment algorithms. Pyy178 showed the
highest similarity to Pc96. Pf403 is a much larger protein but contains a region spanning
several hundred amino acids with an extremely high degree of sequence similarity to that of
Pc96 and Pyy178. Pyy84 was subsequently shown to be similar to a different region in
Pf403.
The identification of T cells epitopes relied on the SYFPEITHI software for the selection of
a number of putative peptides within the Pc96 sequence. P. chabaudi adami infection in B-
cell deficient mice, activates aT-cell dependent mechanism which terminates acute malaria
in a similar manner to that seen in immunologically intact mice (Grun and Weidanz, 1981).
Due to the fact that the Pc96 protein was shown to contain T cell epitopes capable of
eliciting a protective immune response in the mouse malaria model Plasmoidum chabaudi
adami (Wanidworanun et al., 1989), these epitopes were evaluated and compared to the
Pf403 sequence. The identification of such epitopes in Pf403 is of interest, as there may be
a similar epitope in falciparum malaria capable of generating a multiple antibody response.
The fact that the epitopes were predicted using SYFPEITHI's algorithm of recognising
putative peptides, indicates that results are not conclusive, and further research and
evaluation is needed to verify the epitopes and their function within this antigen.
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Three epitopes predicted in Pc96 (ILKMFKLGSCYLYII), (LIKYKNFI) and (LIKYKNFII)
were shown to be conserved both in Pf403 and Pyy178 in a region of amino acids highly
similar between the three molecules. Multiple sequence alignments of this region showed
the similarity of the amino acids, and the secondary structure conformations reflecting the
nature of solvent exposure in this region to be similar. The epitopes were used in a BLAST
search of the P. falciparum genome database (PlasmoDB) in order to identify proteins
containing the same peptide. Due to the fact that the T cell clone, in the protective chabaudi
adami response provided help to a variety of B cell clonotypes, it is likely that the epitope
was contained in several other chabaudi adami malaria proteins. The two conserved
epitopes (LIKYKNFI) and (LIKYKNFII), and (YYEEQKNKY), were shown exist in a few
other Plasmodium falciparum proteins. The correct identification of T cell epitopes from
immunologically relevent antigens is a critical step in the development of.vaccines, and in
this chapter, the initial steps were taken for the selection of candidate peptides from the
sequence. Subsequent verification of their in vivo relevance will be necessary.
Scanning the protein sequences against a PROSITE database, identified several unique
features of the proteins similar to Pc96. N-glycosylation sites involve the attachment of
carbohydrate chains to proteins by N-linkages with the nitrogen atom of asparagine
residues. These proteins . (glycoproteins) form integral components of biological
membranes, lysosomal enzymes and the extracellular matrix (Karp, 1996). Potential N-
glycosylation sites correspond to the consensus sequence Asn-Xaa-Ser/Thr. The folding of
the protein plays an important role in the regulation of N-glycosylation. Several protein
kinase phosphorylation sites were found. cAMP- And cGMP-dependent protein kinases
share a preference for the phosphorylation of serine and threonine residues found close to at
minimum two consecutive N-terminal basic residues. Protein kinases are enzymes that
transfer phosphate groups to other proteins, involved in the regulation of a number of
activities such as hormone activation, cell division and gene expression. They play an
important role in cell signalling and the communication between cells and their
environment.
The presence of a unique leucine zipper pattern in Pc96, Pyy403 and Pyy84 may indicate
some role for the protein in gene regulation. This motif is present in many gene regulatory
proteins such as cAMP response element (CRE) binding proteins, CCATT-box and
enhancer binding proteins and various transcription factors. The motif consists of a
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repetition of leucine residues at every seventh position over a region of the sequence
including eight helical turns. Segments containing these periodic leucine residues are of an
alpha-helical conformation . The leucine side chains in the coil, interact with those from a
similar conformation on another polypeptide, causing dimerization and a coiled coil
structure of these two regions. The motifs consensus pattern is L-x(6)-L-x(6)-L-x(6)-L (
Landschulz et aL, 1988).
The presence of three bipartite nuclear targeting sequences in Pf403 further suggests a
DNA binding role. These patterns are present on proteins enabling the successful passage
through the nuclear membrane. Uptake of the protein by the nucleus depends on this signal.
Studies on the Large T antigen of SV40 in viruses have resulted in the identification of
sequences required for nuclear translocation (Dingwall and Laskey, 1996). The bipartite
nuclear targeting sequence is identified by two adjacent basic amino acids (Arg or Lys)
followed by a extended spacer region (10 residues) and three basic residues (Arg or Lys) in
the five following positions after the spacer. These motifs along with the leucine zipper
pattern, suggest strongly that Pf403 is involved in gene regulation and possibly DNA
binding .
3D structure analysis was performed using the 3DPSSM database for consecutive regions
of Pc96, Pf403, Pyy78 and Pyy84 in an attempt to identify the structure and possible
functions of the domain regions. The query sequences were deposited into the 3DPSSM
software which screens a library of known structures based on the spacing of patterns and
motifs. Two specific regions of Pf403 were identified to show high homology to that of a
Zincin-like metalloproteases closely resembling the catalytic domain of Clostridium tetani
and Clostridium botulinum neurotoxins. It is interesting to note that there are two of these
domains present, along with a comparison to two colicin la domains. There are seven
serologically different botulinum neurotoxins, involved in the inhibition of neurotransmitter
release from peripheral cholinergic synapses in nerve cells. Two regions in Pf403 and other
proteins studied contain 3D structure highly comparable to that of the catalytic domain of
the neurotoxin A metalloprotease. Colicin la is a hydrolase enzyme involved ion channel
formation in E. coli (Wiener et al., 1997). This structure is associated with biological
membranes.
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There were several attributes of Pf403 that indicated its possible role in DNA-binding. The
identification of a 3D structure similar to that of interferon-induced guanylate-binding
protein I (GBPI) indicates that this protein may be characterised by its possbile ability to
bind to guanine residues (GmP). GDP, and GTP). The presence of a unique leucine zipper
motif in Pf403 is also indicative of DNA binding. Together, the DNA binding properties
and membrane association comparisons, along with the high homology to the Zincin-like
metalloprotease, provide the basis for more detailed analysis and identification of Pf403
and related malaria molecules. The fact that no full-length protein was found conclusively
similar in primary structure and amino acid sequence indicates that the structure is unique
and novel in its conformation, possibly functional in malaria parasites and no other
organism. Further functional, structural and possibly enzymatic studies on these proteins
will rely on the availability of large amounts of protein. Due to the fact that isolation of
sufficient native protein from the malaria parasite is impractical and difficult, the genes can
be cloned and the proteins recombinantly expressed, allowing relatively large amounts of
the protein to be present for experimental evaluation. The subsequent chapters deal with the
molecular cloning of a region of the Pf403 gene, most similar to the Pc96 protein,
containing these putative T cell epitopes, and other features discussed. .
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CHAPTER 4
PCR-CLONING OF 817 BP REGION OF PLASMODIUM FALCIPARUM
MAL3P6.11 GENE
4.1 Introduction
The polymerase chain reaction is a highly useful technique in the field of molecular biology
for the in vitro amplification of DNA regions (Innis and Ge1fand, 1990). Oligonucleotide
primers complementary to the ends of a defmed region of template DNA are used in an
enzymic reaction involving DNA polymerase, deoxyribonucleotide triphosphates (dNTPs)
and a specific set of reaction conditions. Oligonucleotide primers are short, single-stranded
DNA molecules, also known as amp1imers. The primers are extended on single-stranded
denatured template DNA by the DNA polymerase enzyme. This results in double-stranded
copies of the target region generated in a repeating cycle of heating and cooling. The
template DNA is heat denatured in the range 93-100DC, forming single-stranded template
DNA. The temperature is lowered to hybridisation temperature allowing the primers to
anneal to their specific complementary regions on the template and then raised to extension
temperature for synthesis by the polymerase enzyme in a 5' to 3' direction. This is normally
repeated for at least 20 cycles copying the target DNA in an exponential manner (Mullis
and Fa100na, 1987).
The denaturation and annealing of oligonucleotide primers each cycle, requires polymerase
enzymes capable ofwithstanding the high denaturation temperature. To avoid having to add
fresh a1iquots of polymerase each cycle, a thermostable polymerase was isolated from
Thermus aquaticus (Taq). This has been a huge technological advancement, allowing
routine use of PCR in clinical and research laboratories. The availability of temperature-
cyclers has automated the reaction process eliminating the need for manual control of the
reaction (Brown, 2001).
The aim of these PCR experiments is to amplify regions of the MAL3P6.11 gene coding for
unique parts of the Pf403 protein, in preparation for further cloning into plasmid vectors.
Cloning of PCR fragments can be performed in a number of ways, depending on the vector
used and the cloning experiments to be performed. Blunt-end 1igation is when PCR
products are involved in a enzymatic reaction with the K1enow fragment of DNA
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polymerase which fills in, or cleaves single-stranded overhangs at the termini of a DNA
molecule; rendering the strand blunt-ended. The blunt fragments can then be ligated into
vectors cut with restriction enzymes forming blunt ends (Innis and Gelfand, 1990). Double
stranded PCR products are never blunt ended, and instead contain an additional adenine
nucleotide at the 3' termini caused by Taq polymerase. Thymine-Adenine (TA) cloning
takes advantage of this as the product is ligated into TA cloning vectors, which contain
thymine residues at the 5' ends (Holton and Graham, 1990). The disadvantage of these
methods is retaining an open reading frame if cloned into an expression vector. For this
reason, restriction sites can be incorporated into the sequence of the primer (Kaufman and
Evans, 1990). After PCR is performed, the product incorporates the restriction site into its
sequence, allowing restriction digestion to create terminal sticky-ends, and controlled in-
frame ligation with vector DNA. This method will be the primary approach for cloning
experiments in this study.
An initial cloning strategy involved the direct cloning of the PCR products into the
expression vector pGEX-4T-3. Due to several problems associated with direct cloning of
PCR fragments, the PCR products were cloned into the initial cloning vector, pMOSBlue.
The PCR product was cleaned and blunt-ended using the Klenow fragment of DNA
polymerase. The termini of the fragments were phosphorylated using polynucleotide kinase
and the modified strands were blunt end ligated intopMOSBlue using T4 DNA ligase. The
resulting construct is highly useful for further sub-cloning experiments involving other
vectors. The range of restriction endonuclease sites in the multiple cloning site of
pMOSBlue is extensive (Figure 5.1). An insert cloned into the EcoRV site allows a variety
of options for further cloning in many other vectors, including both prokaryotic and
eukaryotic expression systems. The 817 bp region recombined with this vector allows
further manipulations to be independent of PCR and growing up .bacterial cultures
containing the plasmid, allows batch amounts of the DNA to be obtained. PCR may
introduce mutations and mistakes into the DNA. In vivo amplification of the DNA by
replication inside bacterial cells provides a more effective way of obtaining large amounts
of DNA. The synthesis of new strands is achieved using the full system of DNA replication
provided by the host eg efficient proofreading activity.
Escherichia coli cloning vectors are highly useful for gene-cloning experiments. Bacterial
plasmids are double-stranded, circular DNA molecules that carry a number of genes
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responsible for useful characteristics when introduced into the host bacterium. Plasmids are
found in a variety of bacterial species, behaving as accessory genetic units, replicating
independently of the host chromosome. Plasmids rely on the host for proteins and enzymes
involved in replication and transcription. Advantageous or useful phenotypes produced in
plasmid-bearing hosts include antibiotic resistance, degradation of organic compounds, and
production of toxins and expression of cloned genes. The variety of cloning vectors
available for researches is immense, in particular E. coli cloning vectors. The huge amount
of information that exists concerning the biochemistry, microbiology and genetics of the E.
coli host provides a valuable tool for the study of gene structure and function. Molecular
biology research and gene cloning go hand in hand and provide an unlimited field and
scope for biological research (Brown, 2001).
The most common selectable marker used in plasmid vectors is an ampicillin resistance
gene (amp"), This attribute allows the host bacteria to grow comfortably in the presence of
the antibiotic ampicillin, allowing selection of only plasmid-containing hosts. Ampicillin
binds to inhibit enzymes in the bacterial membrane involved in cell wall synthesis. The
amp'' gene carried on the plasmid codes for an enzyme secreted into the periplasmic space
of the bacterium, catalysing hydrolysis of the ~-lactam ring, causing detoxification of the
antibiotic (Sykes and Mathew, 1976).
The success in cloning experiments in this study was due to the particular system for the
identification of recombinants known as lac selection or o-complementation. The plasmid
contains a gene call lacZ', which codes fora portion (the first 146 amino acids) of the
enzyme ~-galactosidase. The plasmid also contains the lac promoter, which is the sequence
that controls transcription of the facZ gene, and expression of ~-galactosidase.The multiple
cloning site of the vector is situated within the coding sequence for the lacZ' gene, and
cloning with the vector causes insertional inactivation of the facZ' gene. The strains of E.
coli used in these experiments contain a modified lacZ gene that lacks the lacZ' portion,
and codes for only the a-peptide portion of ~-galactosidase(carboxy-terminal). These cells
can only synthesise a functional ~-galactosidase enzyme when they contain plasmid DNA
coding for the rest of the enzyme, or facZ' region. Cells that harbour plasmid DNA are
rendered ampicillin resistant (amp"). Cells containing recombinant plasmids DNA are 13-
galactosidase deficient (~-gal} A lactose analogue called5-bromo-4-chloro-3-indolyl-P-D-
galactoside (X-gal) can be broken down by ~-galactosidase forming a deep blue product
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(Horwitz et al., 1967). If X-gal is included in the agar media, the bacteria containing
plasmid DNA (~-gal+) will form blue colonies due to the functional ~-galactosidase
enzyme. If the plasmid is recombinant the X-gal will not be broken down and the colonies
will possess a white phenotype. This system is used to effectively identify recombinant
colonies from a transformation plate without the need for time-consuming screening
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Figure 4.1 pMOSBlue vector map showing pMOSBlue polylinker region. (Taken
from pMOSBlue blunt ended cloning kit instruction manual, Amersham Biosciences).
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4.2 Results
4.2.1 Amplification of 757 bp target region in the Plasmodium falciparum acetyl-coA
carboxylase gene
Oligonucleotide primers ACCXpfl (GCT AAT AAT GGG ATG GCA GC) and ACCXpf2 (TTT
GTG TAG TAC AAT CAC GAC) were used to amplify a region within the biotin carboxylase
domain coding sequence ofthe ACC gene from the Plasmodiumfalciparum genomic DNA isolate
used in this study. Figure 4.2 shows agarose gel electrophoresis ofPCR samples obtained from this
reaction and verification ofproduct by restriction digestion analysis.













Figure 4.2 Amplification ofACC gene segment from Plasmodiumfalciparum genomic DNA.
Lane 1 - 100bp DNA ladder; lane 2 - no product; lane 3 - 757 bp PCR product; lane 4 - HindUI
digestion products of 757 bp PCR product.
These primers were previously designed to amplify this segment of DNA from isolated P.
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falciparum DNA supplied by ProfessorP. Doerig (INSERM,Paris). The reaction was used as a
. control for the DNA used in this study. Lane 3 (Figure 4.2) shows a band estimated to lie within
700 - 800 bp size range, as estimated using the 100 bp markers in lane 1. This correlates to the
expected size of757bp for this target region, as deduced from the genomic sequence available at
PlasmoDB. The fragments contain an internal HindUI site, which was used to confirm the identity
of this product. A restriction digestion reaction using the enzyme HindIII produces two bands
estimated to be 350 bp and 400 bp is size, which compares to the sizes of 344bp and 413bp as
predicted by sequence analysis.
These results show that the isolated Plasmodiumfalciparum genomic DNA as a good template for
further reactions. This DNA sample, and the components of the PCR reactions used in this study,
can effectively be used to amplify other target regions in the malaria genome.
4.2.2 Amplification of 817bp target region in the MAL3P6.11 gene from Plasmodium
falciparum genomic DNA
A region of the MAL3P6.l1 gene was amplified by PCR from Plasmodiumfalciparum genomic
DNA using the primers PfFOR2(BamHI) and PfREVI (see Table 3.1). Gel electrophoresis of the
PCR product showed an intense band, estimated using the molecular markers to be at roughly 800
bp. 'The amplification product was expected to be 817bp, based on the sequence of the target
region. This shows that the DNA fragments synthesised during amplification correspond closely to
that expected. As seen in lane 1 (Figure 4.3) there is an intense band at approximately 800 bp and
what appears to be a non-specific PCR product at approximately 500bp. To verify that the PCR
product obtained is the intended 817bp target sequence, restriction digestion analysis was
performed. This made use of an EcoRI and HindlII restriction site present within the target
sequence. The position of these sites is shown in Figure 3.2. The target sequence and position of
. the restriction sites in the sequence were used to calculate the sizes that would result from digestion
with these enzymes. As seen in lane 2 (Figure 4.3), digestion WIth EcoRI produces fragments
estimated at about 190bp and 620bp. Digestion of the sequence with EcoRI was predicted to
produces sizes of 193 bp and 624 bp respectively. The restriction digestion confirms the identity of
the amplification product. Sequence identity was confirmed with HindlII, which digests once
yielding fragments of 184bp and 633bp.








Figure 4.3 peR amplification of 822bp fragment in MAL3P6.ll gene from Plasmodium
falciparum genomic DNA. Agarose gel electrophoresis (1%). Lane I - 123bp Molecular markers;
lane 2 - 822bp PCR product; lane 3 - Digested PCR product (EcoRl) ; lane 4 - Digested PCR
product (HindJIl) (arrows show restriction fragments).
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I . . . . ..
aatctaaaaaacgaaaatgaaaaaaatgaattaattaaaataaataattttgaagaaatactcaaattaaaaaat
7351
I . . . .
aatctacaagataatgaaagttgtatacaaaacttaaataattatttaaaaaaaaatgaagaattaaataaaatt
7426
I . . . .
aatgtaaaaaatattttcaaatataaaggatatataattcatttaatacaacaaagtaatgtcttttgtaaaatt
7501
.I . . .
tttaaacattttaatgaaaataaaattattgatcaaagtattataaacaaattactttatttaaaaaaatccttt
7576
















CTTTTGCATGTTG 5' · . .
. Figure 4.4 DNA sequence of target region in MAL3P6.11 gene. The position of primers
designed for amplifying 817bp are shown in bold along with the primers on the sequence.
Restriction enzyme sites HindUI and EcoRI are highlighted.
4.2.3 Optimisation of PCR reaction (817bp) using different MgCh concentrations
In an attempt to optimise the PCR reaction that amplifies the 817bp target in the MAL3P6.l1 gene,
a range ofMgCh concentration was evaluated. The non-specific reaction product estimated to be
approximately 500 bp might be a non-specific reaction product caused by the amount ofMgCh in
the reaction. A range ofMgCh concentration was set up from 1 - 2.5 flM; Figure 4.3 shows the
agarose gel used to analyse the amplification products of the different peR reactions.
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Figure 4.5. Optimisation of PCR reaction with range of MgCh concentrations, for
amplification of 817bp target in MAL3P6.11. Agarose gel electrophoresis (1%) showing the
products ofPCR reactions 1-6 in the presence of lane 2 - 1JlMMgCh, lane 3 - 1.25JlMMgCh, lane
4 - 1.5JlMMgCh, lane 5 - 1.75JlM MgCh, lane 6 - 2JlM MgCh, lane 7 - 2.5JlM MgCh. Lane 1
shows the 123 bp molecular weight markers used.
There were amplification products in PCR reactions 2-4 (1.25-1.75JlM MgCh) and none in the
other lanes. It appears that MgCh concentrations below 1.25 JlM and above 1.75 JlM are
unfavourable for successful amplification. Varying the MgCh concentration did not affect the
presence of the 500 bp non-specific reaction product , indicating that the non-specificity of the
product is unrelated to MgCh concentrations and primer annealing defects.
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4.2.4 Further peR reactions tested using various primers designed
Attempts to amplify larger regions ofthe MAL3P6.ll gene were unsuccessful (Section 2.4.1). This
may be due to the length of the targets, and the difficulty in amplifying large regions. As can be
seen on Table 4.1, the elongation time in the PCR temperature cycles were adjusted according to
the target length.
Table 4.1 Alternative peR reactions performed using designed primers, showing intended













Optimisation of each of these attempted reactions was performed using a range of MgCh
. concentrations, as performed in section 4.5.2 for the successful reaction (817 bp), with no success
in amplification due to a change in stringency conditions. The annealing temperature was also
altered, to .account for the low (G+C) content in the target sequences, and the cycle numbers for
each reaction was increased to 40 compensating for possible late onset of amplification in the
reactions. In a further attempt, aliquots ofeach reaction product were re-introduced as template into
further reactions involving fresh Taq polymerase. These various optimisation attempts for these
target regions did not succeed in amplification.
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4.2.5 Preparation of insert DNA (817 bp PCR product) for Iigation reactions
As can be seen in Figure 4.6, the PCR product shows a distinct clear band of the required size
when visualised on an agarose gel. The PCR product was extracted with chloroform and
isoamy1 alcohol (24: 1) (ClAA) to inactivate the polymerase. After extraction the aqueous
phase was run alongside the untreated PCR product to assess the clean-up procedure. It was
noted that the PCR product after treatment, was less concentrated than in the original PCR
reaction due to loss of DNA in the ClAA extraction procedure. The product however, shows a










Figure 4.6 Clean-up of PCR product using chloroform / iso amyl alcohol (24:1) (CIAA)
treatment. Agarose gel electrophoresis (1%). Lane 1 - Untreated PCR product (5 ul); lane 2 _
ClAA treated PCR product (5 Ill). DNA was stained with ethidium bromide and photographed
under UV light.
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The concentration of : the PCR product before CIAA extraction, as determined
. .
spectrophotometrically (Section 2.3.1), was 760 ug/ml. After theclean up the concentration
was 500 ug/ml indicating a 65.8 % yield. The purity of the samples (A2601A28o) was measured
and showed an increase in purity after the procedure (Table 4.2). Protein contamination in the
original PCR reaction (Taq polymerase) was high and would interfere with :further
manipulations.









4.2.6 Direct ligation of 817 bp insert DNA into pGEX-4T-3
4.2.6.1 Restriction digestion of pGEX-4T-3 with BamID and Smal
. .
Figure 4.7 shows the BamHI and SmaI digestion of the pGEX-4T-3 vector in preparation for
ligation reactions. Agarose gel electrophoresis of the digestion products, determines the extent
and efficiency of these enzymes in the same buffer and the simultaneous digestion with
BamHI and SmaI. In comparison to the circular pGEX no-digested control , it is clear that the
DNA was cut as both enzymes linearised the vector DNA in the specific restriction buffer
used (Multi-core" buffer, Promega), it was assumed that a double digest with these enzymes
would result in vector fragments with terminal BamHI and SmaI sites. Lane 4 in Figure 4.7
shows the results ofa double digest reaction. Linear fragments of the plasmid were verified
using molecular markers. Sizes of the linearised plasmid resulted in single bands were
estimated to be approximately 4900 bp; correlating to the predicted size of the vector pGEX-
4T-3 (4900 bp). These reaction products were used for directional cloning of the insert into
the pGEX vector.










Figure 4.7 Restriction digestion of pGEX-4T-3 with BamHI and SmaI. Agarose gel
electrophoresis (1%) showing pGEX digestions: Lane 1 - Non-digested pGEX-4T-3; lane 2 -
BamHI digest; lane 3 - SmaI digest; lane 4 - BamHI and SmaI double digest.
4.2.6.2 Transformation of competent E. coli DHSa cells
Competent E. coli DH5a cells were transformed with the test and control ligations as
described in Section 2.5.4 and 2.5.5. The transformation resulted in over 300 colonies per
0.01 ng DNA, or 3.0 x 107 colony forming units (cfu) per ug DNA. This is comparable to the
expected transformation efficiency for E. coli DH5a (4 x 107 cfu/ug test plasmid). This is a
good indication that the cells were competent and transformation efficiencies for the ligation
reactions were likely to be sufficient. Table 4.3 shows the number of colonies obtained in
these transformation experiments.
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The ligation control (transformation 5) containing no insert DNA produced 31 colonies.
These colonies may have resulted from re-ligation of cut vector DNA, or vector DNA not cut
in the restriction digestion reactions, forming background colonies. The same approximate
number ofcolonies is seen in the test ligations (with insert DNA). There are no colonies seen
in the transformation of insert DNA only (no vector DNA) in the second ligation control
(transformation 6) showing that all colonies seen in the test ligations are due to pGEX vectors
providing ampicillin resistance to the host cells . There are unlikely to be contaminant colonies
as there are none seen in the mock transformation control (transformation 8) where no DNA
was transformed.
4.2.6.3 Screening for pGEX recombinantsby the isolation of plasmid DNA .
Figure 4.8 shows the niiniprep plasmid isolates from colonies picked and grown up in batch
culture from thetransfonnation plate. Analysis of the plasmid isolations using agarose gel
electrophoresis will indicate .recombinants by the increased size in plasmid, and decreased rate
of migration in an agarose gel. As can be seen, all the colonies appear to migrate at the same
rate, and compared to the control plasmid (non-recombinant pGEX transfonnant) (lane 1),
. ..
there are no recombinant plasmids. This method of screening was used for 30 colonies of the
transformation plate.
This method was not used to screen all the colonies, as the technique is time consuming. In
total, 40 colonies were screened in this manner, all non-recombinant. Due to the fact that the
proportion of recombinant colonies from these ligations may be very low, and the amount of
colonies to screen are too many; further more efficient methods must be used for screening,
that encompass many more colonies at the same time.
1 2 3 4 5 6 7 8 9 10
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Figure 4.8 Screening for recombinant pGEX plasmids using size analysis of plasmid
DNA. Lanes 1 to 10 shows the plasmid isolations from single colonies, lane 1 being the
control non-recombinant pGEX picked of the transformation control plate.
4.2.6.4 Screening for recombinant pGEX plasmids by colony peR
Colony PCR was performed using the method described in Section 2.3.7. Universal primers
specific to the pGEX plasmid were used to screen for insert DNA. The presence of insert
DNA was expected as part of the PCR product amplified, from the polylinker region in
pGEX. The PCR products were analysed using agarose gel electrophoresis (Figure 4.9).
Amplification of pGEX containing no insert using these universal primers results in a 173 bp
product due to the positioning of the primers flanking the multiple cloning sites. This is
evident in lane 2 by comparing the product size obtained to the molecular markers used in the
experiment
The positive control involves pGEX containing an insert approximately 1100 bp in size
resulting in a product less than 1300 bp using these primers. This was used to show that the
insert DNA can effectively be amplified with these primers and any insert DNA that may be
present in the form of recombinant pGEX, would be reflected in the same manner. Due to the
fact that the 817bp insert is being screened, the predicted product size for a positive clone will
be 990 bp in size. As can be seen on this gel in lanes 4 - 7, there were no inserts detected in
these samples . Prepared DNA from 5 colonies was pooled in one PCR reaction to increase the
amount of colonies to be screened, and four of these pools were evaluated.










Figure 4.9 Screening of colonies using peR with pGEX universal primers. Agarose gel
electrophoresis (1%) Lane 1 - 123 bp molecular markers; lane 2 - PCR of non-recombinant
pGEX; lane 3 - PCR of recombinant pGEX-GST-MAP2; lanes 4 to 8 are 20 colony DNA
samples pooled into four PCR reactions.
4.2.6.5 Screening for recombinant pGEX plasmids using DIG nucleic acid detection
Insert DNA can be directly detected from DNA prepared from a single colony, and so allows
for rapid screening of multiple colonies on a transformation plate. As a control for this
screening technique, an oligonucleotide probe was constructed specific to pGEX vector DNA,
independent of insert DNA. As described in Section 2.2.1, universal pGEX PCR and
sequencing primer pG-Seq1 (GGG CTG GCA AGC CAC GTT TGG TG) was tailed at the 3'
terminus with the DIG-ddUTP compound. Serial dilutions of purified pGEX-4T-3 plasmid
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resulting from transformation with the pGEX (non-recombinant) vector. The membrane was
probed using the DIG-labelled oligonucleotide, specific to pGEX vector DNA, to access the
degree of detection and sensitivity of this technique. Figure 4.10 shows the nylon membrane
with these samples , detected with anti-DIG antibody conjugated with alkaline phosphatase
and, and detected with the substrates NBT and BeIP (Section 2.2.2).
2 3
4 5 6 7 8 9 10
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Figure 4.10 DIG nucleic acid detection of DNA from colonies using pGEX specific
probe. 1 to 3 - 5 ul DNA prepared from single colonies of pGEX; 4 to 10 - 5 ul of the serial
dilution of purified vector DNA (1000 ng; 500 ng; 250 ng; 125 ng; 62.5 ng; 31.25 ng; 15.125
ng).
As can be seen in Figure 4.10, the colour reaction is more intense with a higher concentration
of DNA and gradually diminishes as the concentration is decreased sequentially. The crude
DNA preparation from the pGEX colonies showed positive colour reactions, and although not
as intense, is still visible against the background as a positive reaction. In comparison to the
serial dilution, the intensity of the colour reaction is similar to that of number 8, 9 and 10.
This indicates that the plasmid DNA in each colony is present in the approximate range of
15,125 - 62.5 ng. This result also shows that the screening can be performed in the same
manner, but replacing the vector specific probe with insert specific DIG-labelled
oligonucleotide, for the detection of insert DNA.
The oligonucleotide primer PfFOR2 (BamHI) used for the amplification of the 817 bp region
(Section 4.2.3) was tailed with DIG, and used as a probe for the detection of insert DNA in
colonies. A number of colonies were screened as shown in Figure 4.11. The control for the
immunochemical detection of DIG and the alkaline phosphatase .colour reaction was DIG-
labelled molecular weight markers. The hybridisation reaction was checked using the purified
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insert DNA as a positive control. As can be seen, both these samples showed a vigorous
colour reaction, indicating that the hybridisation reaction was working efficiently, and the
synthesised probe is specific to the 817 bp insert.
Figure 4.11 Screening by DIG nucleic acid detection using insert specific DIG-labelled
oligonucleotide probe. Cl - DIG labelled molecular weight markers; C2 - 817 bp insert
DNA ; C3 - pGEX (non-recombinant) DNA ; 1 to 47 - crude DNA preps from 47 colonies.
No colour reaction was detected for the pGEX control sample dotted , indicating that no false
positives were likely to occur due to non-specific hybridisation. There were no positive colour
reactions seen for any of the colonies screened. This experiment was repeated for a further
256 colonies, with no success in identifying a positive clone . Due to the fact that this method
of screening, allowed a great number of clones to be screened, it was assumed thatthe ligation
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. .
reactions with pGEX did not result in recombinants, A more efficient system of cloning the
817 bp insert was . attempted, using the pMOSBlue blunt-end cloning kit, for initially
obtaining a vector containing the insert DNA attempted in these experiments . .
4.2.7 Transformation of competent MOSblue cells
From this data (Table 4.4), the transformation efficiencyof the competent MOSBlue cells can
be assessed. The number .of transformants per ug of DNA is the universal .unit used for
transformation efficiency. Considering that 0.2 ng DNA was used to transform 100 ul cells,
plating 5 /!l of this reaction, would be plating 0.01 ng. As seen in Table 4, the amount of
colonies on the control transformation 8', was 390.
Table 4.4. The number and phenotype of pMOSBlue transformed E. coli colonies for
test and controlligations.
DNA source: Ligation reactions (1-6) pMOSBlue no DNA
Transformation number: 1 2 3 4 5 6 7 8 9
Volume spread (ul) 50 50 50 50 50 50 50 5 40
No. colonies (cfu) . 47 45 42 53 23 0 >500 390 0
No. (~-gan colonies 4 7 8 21 0 0 0 0 0
The transformation therefore produced 390 colonies per 0.01 ng DNA,or 3.9 x 107 colony
forming units (cfu) per ug DNA. This is comparable to the expected transformation efficiency
for MOSblue of 4 x 107 cfu/ug test plasmid.
The PK reaction, Ill . which the cleaned PCR product was blunt ended (Klenow) and
phosphorylated (T4 polynucleotide kinase), was evaluated using the control insert DNA
ligated after PK treatment, and no PK treatment. Transformation 4 (Table 4) is the ligation
reaction in which the controls insert DNA was PK treated, and transformation 5 the control
insert was not treated. As can be seen there are a number of white (recombinant) colonies seen
in no. 4, as a result of successful blunt-ending and phosphorylating of DNA termini, and
successfulligation with vector DNA. Transformation 5, contains less white colonies, as a
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result of the inability to ligate the insert with the vector, as the insert was not treated. This
shows that the PK reaction is efficient in preparing the DNA for cloning into pMOSBlue. It
also shows that the 23 colonies seen is the approximate amount of background colonies
expected from these experiments. This also serves as a control for the ligation reaction.
There are no white colonies seen in transformation 6 (Table 5.2), as no insert was included in
the ligation. This ensures that white colonies do not appear due to factors other than ligation
such as contamination. The appearance of white colonies in the test and control ligations are .
entirely due to the .addition of insert DNA to the ligationreactions, A mock transformation
(transformation 9) was performed ill which no DNA was transformed, to check for
contaminants in the competent cells that may form colonies and false positives. The
competent cells shouldn't form colonies, as they do not contain any plasmid DNA conferring
ampicillin resistance . .
4.2.8 Colony-P'Ck - screening for 817 bp insert in pMOSBiue plasmids.
PCR-screening was used to identify transformed E. coli colonies containing insert DNA.
Primers PfFOR2(BamHI} and PfREVl were used to amplify the 817bp insert directly from
crude preparations of bacterial DNA. After PCR, the samples were run an agarose gel. Figure
4.12 shows the PCR products from the colonies selected, lane 1 and 2 represent white
colonies and ablue colony was picked as a negative control{lane 3). A distinct amplification
product is seen forboth white colonies screened, and there is no visible product for the blue
colony. Lane 4 contains the PCR product of amplification using prepared insert DNA as the
template. As can be seen in this lane, the band is intense, showing an efficient PCR reaction,
. . .
serving as a positive control for the system. The size of the amplification products from PCR
of both insert DNA and from white colony DNA were identical, due to the two bands similar
migration rates. The size of the band was estimated to be approximately 800 bp, and due to
the evaluation of this PCR reaction in Chapter 3, it can be assumed that the product is the
predicted size of 817bp. This data confirms that the white colonies contain insert DNA
serving as template for the PCR reaction.










Figure 4.12 peR based screening for recombinants. Lane 1 -PCR product from white
colony, lane 2 - PCR product from white colony, lane 3 - blue colony (negative control - no
insert); lane 4 - PCR product (822bp template). Molecular markers are shown for size
analysis.
4.2.9 Preparation of plasmid DNA from transformant colonies for analysis of
recombinants
A number of independently transformed bacterial colonies representing both white and blue
phenotypes were picked and grown up in batch cultures. Plasmid DNA was isolated from
these cultures using the Nucleobond®AX kit (see section 2.3.5). Based on the results obtained
from colony PCR (Figure 4.12) the two white colonies identified as containing insert DNA
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were picked, along with a blue colony as a control for non-recombinant plasmid. Aliquots of
the isolated plasmid DNA were run on an agarose gel (Figure 4.13). The gel clearly shows
characteristic plasmid DNA bands (super-coiled, closed circular, and nicked conformations).
Molecular markers were not used in this gel as the different conformations of the plasmid
produce an inaccurate size on an agarose gel.
1 2 3
Figure 4.13 Isolation of pMOSBlue plasmid DNA for verification of recombinants.
Agarose gel electrophoresis (1%) showing isolated plasmid DNA from: lane 1 - blue colony
(non-recombinant control); lane 2 - white colony (recombinant); lane 3 - white colony. DNA
was stained with ethidium bromide and photographed under DV light.
It can be seen that for the two recombinant plasmids (lanes 2 and 3), the migration through the
gel has been slower, indicating that in comparison to the non-recombinant control in lane 1,
the size is larger. This shows that the pMOSBlue plasmid DNA has incorporated insert DNA,
and further verifies that the white colonies are indeed recombinant.
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4.2.10 Restriction digestion analysis of recombinant pMOSBlue plasmid DNA.
Characteristics of the recombinant pMOSBlue plasmid were analysed in order to verify the
effective ligation of the 817bp DNAinsert. Figure 4.14 shows agarose gel electrophoresis of
the various restriction digestions performed on pMOSBlue and recombinant plasmid DNA.
In order to estimate the size of plasmid DNA, the vector must be linearised by restriction
digestion with an enzyme that contains one site in the sequence. Restriction digestion of non-
recombinant pMOSBlue plasmid DNA with EeoR! (lane 2) yields a single band estimated to
be approximately 2900 bp. This correlates to the known size of the vector, 2887bp. For the
recombinant pMOSBlue DNA, the cloned insert contains an EeoR! site, and so the enzyme
Smal was chosen for restriction digestion and size estimation. This digestion, shown in lane
3, produces a single band with an estimated size of 3600 bp. If the DNA insert (817 bp) has
been ligated into pMOSBlue (2887), the expected size would be 3704 bp.
To verify that the insert DNA is 817 bp, the recombinant pMOSBlue DNA was digested with
BamHI, in an attempt to digest out a predicted 822 bp insert. The BamHI site in the insert,
and the BamHI site present in the pMOSBlue multiple cloning region would cut out a
fragment this size incorporating the cloned PCR product sequence . This assumes that the
restriction site was successfully incorporated into the PCR product, and that the orientation of
the insert DNA in the vector allows for the BamHI sites to lie on either side of the insert. In
lane 4 there are three bands seen, estimated to be 3600 bp, 2900 bp and 800 bp respectively.
These products of the reaction result from partial digestion of the vector DNA. This is due to
a proportion of the vector being digested at only one of the sites, ', at the .same time as
complete digestion yielding the 817 bp insert, and the pMOSBlue 2887 bp fragment. Vector
that only cuts once is predicted to be at 3704 bp, which accounts for the top band seen in lane
4. This confirms that the insert digested out ofpMOSBlue, is of approximate size to the insert
used for the cloning experiment. To verify that the insert is the intended 817 bp peR product. ".
restriction digestion was performed with one of the internal restriction sites in the insert that
is also in the vector. Based on the restriction sites of the insert and the vector, digestion with
EeoR! would result in fragments of 625 bp and 3079 bp. Lane 5 shows this digestion with
bands estimated to be approximately 650 bp and 3000 bp. The comparison of the estimated
sizes of the restriction fragments seen in lane 5 with the expected sizes of an EeoR!
digestion, confirms that the insert DNA in the recombinant pMOSBlue vector is the intended
insert (817bp peR product) used for cloning.











Figure 4.14 Restriction digestion analysis of recombinant pMOSBlue plasmid DNA.
Agarose gel electrophores is (1%). Lane 1 - Molecular markers (A DNA digested with EcoRI
and HindIII), lane 2 - Non-recombinant vector digested with EcoRI; lane 3 - recombinant
vector digested with SmaI ; lane 4 - recombinant vector digested with BamHI; lane 5 -
recombinant vector digested with EcoRI; lane 1 - molecular markers (A DNA digested with
EcoRI and HindUI).
4.3 Discussion and conclusion
A PCR reaction involving a 757 bp region of the acetyl-coA carboxylase gene in
Plasmodium falciparum , was performed using the specific malaria genomic DNA isolate
used in this study. The primers designed for this amplification was successful in amplifying a
757 bp band from isolated strain 3D7 DNA, and were used in this study to confirm the
viability of the DNA template DNA. Any PCR reaction failures can therefore not be
attributed to the template DNA, and are more likely to be the reaction itself. This
amplification served to ensure the effectiveness of the Taq polymerase and other reaction
components used in further experiments.
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In these experiments oligonucleotide PCR primers were designed to amplify three main
regions of the MAL3P6.11 gene (Figure 3.1) from isolated genomic Plasmodiumfalciparum
DNA. The first set, PfFORl and PfREV2(SalI) designed to flank: the open reading frame
(ORF) and amplify the whole gene, a 10532 bp region. The second set was designed to
amplify a 3202 bp target using primers PfFOR2(BamID) and PfREV2(SalI). Finally, primers
PfFOR2(BamHI) and PfREVl were designed to amplify a 817bp region. The 10532 bp and
3202 bp PCR reactions produced no amplification products that could be detected in an
agarose ge1. Due to the particularly long . target length, a number of different reaction
conditions were investigated. The elongation time was set at 10 min for the longer target, and
3 min for the 3202bp region. Increasing the elongation time, allows longer strands to be
synthesised at that particular temperature in the cycle. Primer extension usually occurs up to
100 bases/sec (funis and Gelfand, 1990), so a 3-minute elongation time would allow for this
length. The cycle numbers were also increased for both reactions to 40, to allow more
products to synthesise assuming that the reaction efficiency was low. The reactions were
repeated using an aliquot of the first PCR mixture as template for a new reaction, in case the
reaction components were depleted before sufficient amplification. The extension
temperature was lowered from 72°C to 60°C to account for the high (A+T) content of the
template DNA (Su et al., 1996). Although there are polymerase enzymes more suited
towards long targets such as Vent DNA Polymerase, these were not purchased due to
financial constraints in this project and it was decided to adopt a 'staggered' cloning
approach whereby several short targets would be amplified and studied, later to be cloned
together using cloning systems more suited towards expressing large proteins.
PCR amplification of the 817bp target was successfu1. The region amplified encodes a length
of amino acids whose sequence exhibits high homology to the Plasmodium chabaudi adami
antigen, Pc96. The target also encodes features of the protein such as predicted T cell
epitopes, a casein kinase II phosphorylation site, and various restriction sites, useful for
further cloning strategies. The PCR reaction was performed and an aliquot of the reaction
was evaluated on an agarose ge1. An intense DNA band was seen (Figure 4.3), and in
comparison to molecular markers, was estimated to be approximately the same size as the
intended target region (817 bp). However, the size of the fragment does not confirm that the
correct region has been amplified. Unique restriction sites within the sequence were used to
verify the identity of the product. As Figure 4.4 shows, the presence ofthese restriction sites
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at specific positions in the region being amplified, allows the synthesised DNA fragments to
be cleaved producing two fragments of a defined size. The fact that there are two such sites
(EcoRI and HindIII) ·increases the probability of verifying the expected product as being the
correct target, as there is very little chance that a non-intended product has the same size and
restriction sites. The results of these restriction digestion reactions on the PCR products
(Figure 3.3) confirm the identity of the amplification product. A MgCh profile was set up in
an attempt to optimise the PCR reaction and remove the non-specific reaction product seen.
The effect of altering the MgCh concentration had little influence on the nature of the PCR
product and amplification, except the fact that outsidethe range of 1.25 to 1.75 J.lM MgCh,
the amplification did not work. Figure 4.15 shows the PCR product obtained and the
incorporation of the BamIll site into the amplification product.
pMAL c2x multiple cloning region
lie Glu Gly Arg
5' ATC GAG GGA AGG ATT TCA GAA TTCGGA TCC TCT AGA GTC GAC CTG CAGGCA AGC TTG 3'
3' TAG CTC CCT TCC TAA AGT CTT AAG CCT AGG AGA TCT CAG CTG GAC GTC CGT TCG AAC 5'
EcoRI BamHI Xbal San Pstl Hindlll
Binding of forward primer PfFOR2(BamHI) to MAL3P6.11 target sequence
BamHI
5' GGA TCC AAC TAT CTT GTT AAT AAT CTT C 3'
3' ... taa cat eta taa ttg ttgata gaaeaa tta tta gaa gtt aat tta ttt etg ... 5'
7074 71 04
817 bp Amplification product incorporates 5' BamHI site
5'
3'
GGA TCC AAC TATCTT GTT AAT AAT CTT CAA TTA AAT AAA GAC




Figure 4.15 Diagram showing the incorporation of a BamID site ·into the 822 bp peR
product using primer PfFOR2(BamHI).
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For cloning experiments, the PCR product was treated with chloroform / iso amyl alcohol
(24:1) to remove impurities and contaminants remaining from the amplification reactions
(Taq polymerase, dNTP's etc.). Various attempts at cloning the PCR product directly into the
expression vector, pGEX-4T-3 was unsuccessful. ThePCR product was blunt ended, using
the Klenow enzyme, and then digested with BamHI to render the 5' terminus cohesive, for
directionalligation into the pGEX vector. The plasmid was digested with BamHI and SmaI
(blunt-end restriction enzyme) to accommodate the insert. It was found that this strategy
produced no recombinants. Hundreds of colonies were screened by colony PCR and
miniprep plasmid DNA isolation and analysis using agarose gel electrophoresis.
A method using DIG nucleic acid detection was used for large-scale screening. Tailing the
PCR oligonucleotide .primer with digoxigenin made an insert specific probe. An initial
experiment was performed to determine if DIG detection could be applied to crude
preparations of colony DNA, by using a pGEX specific probe (DIG-labelled universal pGEX
primer). There was significant detection seen, indicating that a positive clone, containing the
intended PCR product insert DNA, would produce a positive detection colour reaction. A
. .
total of 256 colonies were screened in the insert specific clone, and no positive clones were
detected.
The primary disadvantage of the pGEX system is the lack of u-complementation, which
would allow the blue and white phenotype selection of recombinant colonies. Incases where
. . . . . .
the extent of correctligation is low, this makes screening for recombinants difficult. Due to
the amount of reactions with the insert DNA, the final product may not be clean enough for
ligation (both .Klenow reactions and restriction digestions were performed with the insert .
DNA). Although heat- inactivated, these enzymes may inhibit the ligation reactions. The
problem may also be that the PCR product cannot be digested with BamHI as the site lies
directly at the termini of the fragments. The enzyme may not bind correctly to the termini as
the mode of action for cleaving the strand at this site depends on flanking DNA sequences,
stabilising the interaction (Kaufman and Evans, 1990). A solution to this problem is to first
blunt-end the fragments using the Klenow enzyme, to compensate for additional adenosine
overhangs resulting from the Taq polymerase activity, followed by blunt-end ligation into an
appropriate vector (Innis and Gelfand, 1990). This ensures that the BamHI site engineered
into the termini of the PCR products can be efficiently digested, in preparation for further
cloning. The pMOSBlue cloning vector was chosen for this strategy, due to unsuccessful
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attempts at cloning the PCR product directly into pGEX. This system would ensure efficient
digestion with BamHI .and would allow direct . screening of recombinants usmg u-
complementation. These experiments were shown to result in the successful blunt-end
cloning of the 817 bp PCR product into the cloning vector pMOSBlue. The PCR product
amplified from the MAL-3P6.11 gene in Plasm~dium jalciparum, was cleaned with
chloroform / iso amyl alcohol (24:1) and cloned into pMOSBlue to form the construct,
pMOS817. Figure 4.16 shows an outline and summary of the experiment detailing the
ligationofthe peR productinto the vector.
817 bp PCR product with 5' BamHI site (Klenow treated; phosphorylated)
5'
3'
GGA TCC AAC TAT CTT GTT AAT AAT CTT CAA TTA
CCT AGG TTG ATA GAA CAA TTA TTA GAA GTT AAT
BamHI
GAA AAC GTA CAA C
CTT TTG CAT GTT G
3'
5'
pMOSBlue multiple cloning region
5' ... GGA TCT ACT AGT CAT ATG GAT ATC GGA TCC CCG GGT ACC GAG CTC GAA TTC ACT 3'
3' .. ;CCT AGA TGA TCA GTA TAC CTA TAG CCT AGG GGC CCA .TGG CTC GAGCTT AAG TGA 5'
Spel Ndel EcoRV BamHI Kpnl Sacl EcoRI .
Smal
Restricted (EcoRV), and de-phosphorylated pMOSBlue vector with blunt ends
5' GGA TCT ACT AGT CAT ATG GAT
3' CCT AGA TGA TCA GTA TAC CTA
SpeI Ndel
ATC GGA TCC CCG GGT ACC GAG CTC GAA TTC 3'
TAG CCT AGGGGC CCA TGG CTC GAG CTT AAG 5'
BamHI Kpnl . Sacl EcoRI
Smal
Blunt-end Iigation of PCR product into restricted pMOSBlue vector .
817 bp peR QrQdllGt
5' .. ATG GAT gga tee aae
3' .. TAC CTA eot agg ttg
Ndel BamHI
eta eaa eAT CGG ATC CCC GGG TAC CGAGCT CGA ATT C..3'
gat gtt gTA GCC TAGGGG CCC ATG GCT CGA GCT TAA G.. 5'
BamH Kpnl Sacl EcoRI
Smal
Figure 4.16. Schematic diagram showing the construction of pMOS817 by blunt-end
ligation of the 817bp peR product into the EcoRV restriction site in pMOSBlue.
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The identification and screening of recombinant pMOSBlue vector, was performed in a
number of ways. Initially the u-complementation system provided by the lacZ' gene in
pMOSBlue was used, and direct observation of colonies (blue and white phenotypes).
Linearised (EcoRV digested) pMOSBlue vector that ligates with the PCR product, forms
circular intact plasmid DNA, that when transformed into the MOSBlue cells, forms white
colonies due to the truncated lacZ' gene. The system allows immediate indication of possible
recombinants, and provides an easier method for screening many colonies. This method
saves time, and further verification of recombinants allows rapid identification of positive
clones.
Colony PCR screening, developed in initial experiments to detect a recombinant pGEX
vector, was used to determine the presence of insert DNA in the colonies tested.
Representative blue and white colonies were chosen and the primers used to amplify the PCR
insert were used. Positive results were obtained for the white colonies tested and the blue
colonies were negative, confirming that the product was insert-specific. The results were
further verified as several studies have reported that false positives can arise using this
technique, due to transformation of trace amounts of insert DNA in the cells (Alvarez et al.,
2002). Primers specific to the pMOSBlue vector were unavailable, which would ensure that
vector specific DNA was amplified. Other experiments were needed to characterise and
identify the DNA in each ofthe white clones.
Further experiments required a large amount of purified plasmid DNA from each colony
tested. Colonies were grown up in LB culture and isolated using the Nucleobond" AX kit.
This was performed for three main reasons, to verify that the ampicillin resistant colonies
picked contained plasmid DNA, to prove that the recombinant plasmids have actually
incorporated extra DNA into its sequence by running the isolated preps on an agarose gel,
and assessing the relative rates of migration of the DNA, and to provide a stock of DNA for
further analysis and experiments. As can be seen in Figure 4.4, the white colonies plasmid
DNA does migrate slightly slower through the agarose gel, due to its increase in size
compared to the control (non-recombinant). Even though this stilldoes not conclusively
identify the inserts in these vectors to be the intended 817 bp region, two separate plasmid
isolations of white colonies were shown to migrate identically indicating similar sizes.
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The identity of the DNA insert sequence evaluated in thewhite colonies was verified using
restriction enzyme analysis and visualisation on agarose gels (Figure4.14). A theoretical map
was constructed using the restriction enzyme sites in the insert and the polyl~er region of
the vector. The plasmid DNA was digested using specific restriction enzymes that only cut at
one position in the vector, to form single linear fragments, which can then be compared to
molecular mass markers. The sizes of the fragments seen on the gel correspondedto that of
the actual sizes of pMOSBlue and recombinant pMOS817. The insert was also 'knocked out'
of the vector using BamHI which cuts on either side of the insert, producing two fragment
sizes, a 822 bp region containing the insert, and 2882 bp vector fragment (Figure 4.14). This
also verifies that the BamHI site is now being cut successfully as may not have been the case
during previous pGEX-4T-3 cloning attempts. The intemalEcoRIsite in the insert was used
to analyse the size of the digestion fragments, further establishing the identity of the insert
DNA.
These results show the positive identification of the insert DNA in the vector. The
. . ' . . . . .
constructed plasmid pMOS817 can now be used for further sub-cloning experiments with
expression vectors , and also provides a safe and easy method for .the storage and
. .
amplification of the 817 bp malaria DNA region, without a need for further peR and use of
isolated Plasmodiumfalciparum genomic DNA.
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CHAPTERS
SUB-CLONING OF 822 BP INSERT FROM pMOS817INTO pMAL-C2x AND
EXPRESSION OF MBP -Pf32.5 FUSION PROTEIN
5.1 Introduction
There are many factors that may influence the level of gene expression. Expression of a
protein relies on the presence of short sequences of nucleotides surrounding the gene that can .
be recognised by the host bacteria. These signals indicate the presence of a gene, providing
instructions for the transcription and translation of the gene by the cell. Eukaryotic
expression signals and their nucleotide sequences are not the same as those recognised in E.
coli. The solution to this problem has been the design of expression vectors, which introduces
the foreign gene in a manner where it is placed under control of E. coli expression signals.
The promoter region is highly important in expression vectors, due to its direct involvement
in gene expression and attachment to RNA polymerase. The promoter determines the rate at
which rnRNA is synthesized, and thus the yield of protein synthesised (Brown, 2001). The
lac promoter is the sequence of DNA that controls the transcription of the lacZ gene coding
for p-ga1actosidasein E. coli hosts. This promoter is induced chemically by
isopropylthiogalactoside (IPTG) and addition of this chemical into the E. coli growth media,
switches on transcription of the gene inserted downstream and in frame to that of the lac
promoter. This promoter has been used in a wide variety of expression vectors due to its
strength and efficiency in protein expression (Sambrook et al., 1989).
With a fusion protein the gene is inserted into the polylinker, which interrupts a segment of a
characterised E. coli gene in the plasmid. Insertion of the foreign gene into this position,
conserving the correct reading frame, produces a hybrid gene that starts with the E. coli
segment and joins into the foreign open reading frame without a break. The product of the
expression is therefore a hybrid protein and has many advantages. Due to the fact that the
attachment of the ribosome to its binding site depends largely on the nucleotide sequence at
the start of the coding region, the use of an E. coli protein ensures efficient translation of the
rnRNA produced from the clone gene. Foreign proteins lack characteristics of bacterial
proteins that prevent host degradation, and fusing the foreign protein to a host protein
protects and stabilises the foreign protein.
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pMAL™ vectors are highly useful for the .expression and purification of a recombinant
protein produced from a cloned gene or open reading frame. The cloned gene is ligated into
the multiple cloning region downstream from the malE gene of E. coli, which encodes
maltose-binding protein (MBP), resulting in the expression of a fusion protein (Guan et aI.,
1987). The strong tac promoter (a minor variation of the lac promoter) and the malE
translation initiation signals, provide a method of obtaining high-level expression of cloned
sequences (Maina et al., 1988). The system offers a one-step purification of the fusion
protein using MBP's affinity for maltose (Kellerman and Ferenci, 1982). The restriction sites
. in the multiple cloning region are positioned in between the malE and the lacZa gene. In non-
recombinant constructs the lacZa portion is expressed with the MBP protein, fulfilling the a-
complementation role of the lacZa portion. Inserting a coding region of interest, into the
multiple cloning site,inactivates the a-fragment activity of the malE-IacZa fusion, resulting
in the formation of white colonies when transformed into ana-complementing host such as .
TB1 or JM103.
A signal peptide is .present in some of the pMAL vectors (pMAL-P2x) directing fusion
proteins to the periplasm.In case this case, folding and disulphide bond formation are
allowed to take place in the periplasm of E. coli,allowing further purification from the
periplasm. ThepMAL-C2x vectors contain a deletion of the signal sequence, leading to
cytoplasmic expression of the protein. Generally this vector produces more protein the
pMAL-P2x, so the former is chosen for initial cloning experiments. lfthe fusion protein fails
to fold correctly in the cytoplasm, or if it requires disulfide bonding to fold correctly, pMAL-
P2x can be chosen . for expression. The pMAL vectors also carry. the origin of DNA
. . .
replication of E. coli bacteriophage M13, allowing the production of single-stranded DNA,
by infection of the host cells with a helper phage (Sambrook et al. , 1989).
These vectors also carry the lacfl gene, which encodes for the lac repressor. This keeps
expression from Ptac low when IPTG is not present, to minimise the effects of leaky
. . ' .
expression. The vectors also contain a sequence coding for a recognition site of the specific
protease factor Xa, located 5' to the polylinker mulitple cloning sites. This allows the MBP
protein to be cleaved from theprotein of interest after purification. Factor Xa is involved in
cleaving a four amino acid recognition sequence located directly after the malE gene. This
ensures that after cleavage, there are no remaining residues from the MBP protein present on
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the cleaved fusion protein, that may interfere with the .desired amino acid sequence of the
cloned gene.
pMAl-c2X. pMAL-p2X Polyllnker .
Xmn I· E~dt I 8,mtIl Xb, I Sal I PitI . HInd III .
I I I I I II II 11 I I I
malE..•ATe GAG GGA AGG ATT TCA GAA HC GGA Tee TCT AGA GTC GAC eTG CAG GCA AGe HG.•.tez«
lie Gla Gty Arg t .
_ Factor Xa
--- cleavage site
Figure 5.1 Map ofpMAL-2x (6648bp) vector showing the polylinkerregion and unique
plasmid features. Arrows show the direction of transcription (taken from the .pMAL™
Protein Fusion and Purification System instruction manual) e .
. . .
In order to produce a fusion protein using the pMAL vectors, the gene or open reading frame
of interest can be inserted in the same translational reading frame as the vectors malE gene.
As can be seen in Figure 5.1, the polylinker region is shown and the position of the BamHI
restriction site with regards to the translational reading frame of MBP. Due to the fact that a
BamHI site was incorporated into.the PCRproduct and clonedinto pMOSBlue, digestion of
pMOS817 will yield fragments with terminal BamHI cohesive ends. As the insert contains a
cohesive BamHI site at both ends of the molecule, the DNA can be inserted into pMAL in
both orientations. The site at the 5' end of the product will have to be cloned in frame with
MBP, in order to facilitate correct translation, and if ligated in the wrong way, the reading
frame will be lost andtranslatioIi will stop immediately downstream from the malE gene.
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These experiments describe the sub-cloning of the 822 bp region of the malaria MAL3 P6 .11
gene (in pMOSBlue) into the pMAL expression vector, for the synthesis of a MBP fusion
. .
protein. ·The plasmid construct was sequenced to confirm the recombination with insert
DNA, and preliminary induction and expression experiments were performed. .Furthermore,
two pGEX plasmids expressing malaria kinase fusion proteins (GST-MAPl and GST-
MAP2) were evaluated for their potential to be detected using antibodies raised against
peptides designed from within their respective sequences.
5.2 Results
5.2.1 Preparation of insert DNA (822 bp .PCR product) .
In order to prepare the insert DNA for cloning and ligation into pMAL:-C2x, the pMOS817 .
plasmid (Chapter 4) was digested with BamHI, to excise an 822 bp insert. The restriction
digestion reaction produced two products, the insert to be used for cloning, and the remainder
of thepMOSBlue vector. The 822 bp fragments were separated from the vector DNA, so that
the cut vector DNA did not interfere with cloning. For efficient ligation the insert was
purified and cleaned yielding sufficient pure DNA for use in ligations. Figure 5.2 shows low
. . . .
melting point agarose gel electrophoresis of the digestion products. As much as 2 ug were
digested (as in section 2.3.3) to ensure that enough insert DNA was present as a band at the
required size of 822 bp. Four reaction products (lanes 1 to 4) were used to maximise the yield
of DNA. As can be seen a single band representing the 822 bp product was isolated.
The bands seen at approximately 800 bp were taken as beingthe required 822 bp fragments
due to previous experimental evidence. The four bands were excised from the low melting
point gel and subjected to agarase treatment (section 2.7.1). The DNA was removed and
concentrated .from the sample by ethanol precipitation. .The final DNA pellet was
resuspended in 25 III sterile dist H20 at a fmal concentration of 180 ug/ml, as determined
spectrophotometrically (Section 2.3.1). An aliquot(1 Ill) was run on an agarose gel (lane 5)
and as can be seen in figure 5.2, the DNA was clean and only one product could be seen.
There were sufficient amounts of this DNA for further experiments such as .ligation.







Figure 5.2. BamHI restriction digestion of pMOS817, for the isolation of the 822 bp
product from low melting point agarose gel. Lanes 1 - 4 - pMOS817 digested with BamHI
(used for excising 822 bp band), lane 5 - 822bp fragment after isolation.
5.2.2 Preparation of vector DNA (pMAL-C2x) for ligation of 822bp insert
pMAL-C2x DNA was digested with BamHI (Section 2.3.3). Half of the reaction mixture was
evaluated on an agarose gel to ensure complete digestion, and the other half used for ligation
reactions. It is important that the vector DNA is completely linearised by BamHI, to avoid
background transformation colonies forming as a result of undigested plasmid. Figure 5.3
shows the results of the restriction enzyme digestion of pMAL-C2x with BamHI the digestion
of pMAL-C2x, and it can be seen that a single band is present , indicating complete
linearisation of the plasmid due to efficient digestion. An undigested control was included
(lane 1) for comparison of restriction digest products, and to ensure that the DNA had in fact
been digested.
1 2 3 4 5
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Figure 5.3. Restriction digestion of pMAL-C2x with BamHI for ligation with 822 bp
insert. Agarose gel electrophoresis (1%). Lane 1 - Non-digested pMAL-C2x DNA; lane 2 - 4
- pMALC2x digested with BamHI.
5.2.3 Transformation of competent JMI03 E. coli cells
Table 5.1 shows the results obtained after transformation with the test and controlligations as
described in section 2.7.2.
Table 5.1. The number and phenotype of pMAL-C2x transformed E. coli colonies for
test and controlligations.
DNA source: Ligation reactions pMAL-C2x none
Transformation no: 2 3 4 5 6 7 8 9
Volume spread (ul) 50 50 50 50 50 50 50 5 50
No. colonies (cfu) >400 >400 >400 >400 36 0 >500 260 0
No.(~-gar) colonies 8 5 22 0 0 0 0 0 0
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The frequency of background (p-ga1l colonies is very high in these transformations (Table
5.1). This is due to se1f-1igation of the BamHI digested pMAL vector. Background colony
numbers were expected to be this high, as the vector DNA was not dephosphory1ated with
calf intestinal alkaline phosphatase (CIAP). The vector is also only cut with one restriction
enzyme (BamHI), increasing the likelihood of re1igation. The extent of re1igation was tested
using transformations 4 and 5. The BamHI digested DNA, was included in a 1igationreaction
with no insert DNA, to assess the amount of re1igation, as reflected by ampicillin resistant
transformant colonies. In comparison to the same reaction, with no DNA ligase enzyme
included (transformation 5), the presence of ligase, results in over 400 colonies, indicating
that in a ligation reaction, the extent of se1f-1igation is high.
The 'no-ligase' control (transformation 5) also served as a positive control for the ligation
reaction, and comparing the amounts of colonies in transformations 4 and 5 (Table 5.1), it is
clearly evident that the ligase is efficient under these reaction conditions. The 36 colonies
formed in this control are also an indication ofbackground colonies resulting from undigested
DNA in the original vector BamHI restriction digestion. Transformation 6 represents the
1igation with no vector DNA, as a negative control. As can be seen there are no colonies
transformed from this 1igation.
The transformation efficiency was calculated for the competent JM103 E. coli cells used in
this experiment. As much as 0.2 ng of DNA circular pMAL DNA was transformed as per
Table 5.1 (transformation 7 and 8). When 5 III of this transformation was plated, 260 colonies
were counted, indicating that the transformation efficiency of these cells is 2.6 x 107 cfu/ug
DNA. The competent cells did not contain any ampicillin resistant contaminants, as there
were no colonies formed when no DNA was transformed (transformation 9). A total of 35
white colonies were counted on the test plates. There is a slight increase in the amount of
white colonies when the molar ratio ofvector:insert is 1:10 (transformation 3).
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5.2.4 Preparation of plasmid DNA from transformed colonies for analysis of
recombinants.
White and blue colonies were picked, and grown up in batch culture for the isolation of
plasmid DNA using the Nucleobond®AX kit (section 2.3.5). Figure 5.4 shows plasmid DNA
isolated from 3 white colonies and a blue colony (control), run on an agarose gel.
1 2 3 4
Figure 5.4 Analysis of isolated of pMAL-C2x plasmid DNA for verification of
recombinants. Agarose gel electrophoresis (1%) showing Lane 's 1,3 and 4 - white (p-gar)
colonies; lane 2 - blue colony (p-gal+) (non-recombinant control).
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These results show the slower migration of the plasmid DNA in lane's 1, 3 and 4
indicating that the circular DNA is a larger molecule than the original pMAL-C2x non-
recombinant DNA. This correlates to the fact that these plasmidswereisolated from colonies .
containing the p-gar or white phenotype (indicative of recombination). This indicates that the
white colonies are recombinant and have probably incorporated the 822·bp insert DNA used
for cloning. Further analysis of the plasmid DNA will confirm the identity of the ligated
insert. The size was not compared to molecular markers as the circular nature of the plasmid
DNA results in different .conformations, that cause a migration through the agarose gel,
disproportional to that of the linear marker bands.
5.2.5 Restriction digestion analysis of recombinant pMAL plasmid DNA.
The plasmid DNA that was isolated in the previous experiment (Figure 5.4) was used in
BamID digestions to confirm the size and ofthe insert DNA. Figure 5.5 shows an agarose gel
. .
electrophoresis of the digestion products. Lanes 3,5 and 6 each show a band ofa similar size
to the control (lane 2) (resulting from BamID digestion). If this was the insert used for cloning
then the fragment of DNA 'knocked out' of the recombinant vector should be the same size.
This can be seen on Figure 5.5 for the three recombinant colonies, in comparison to the
control. The vector DNA fragment after digestion was estimated to be roughly 6600 bp,
. which correlates to the actual size of the vector, 6648 bp. As can be seen (lane 4), plasmid
DNA isolated from a non-recombinant colony does not contain any insert DNA and when
digested with BamID, only one size is seen, that of linearised pMAL vector DNA. This
negative control validates the use of BamID to screen and verify recombinant colonies.
Together, this data suggests that the white colonies do contain insert the same size as the
intended 822 bp insert, and that the insert was successfully ligated into the BamID site in the
pMAL polylinker region.








Figure 5.5 Analysis of BamHI digestion of isolated pMAL DNA showing 822bp insert.
Agarose gel electrophoresis (1%) showing lane 1 - Molecular markers II; lane 2 - positive
control 822 bp DNA, lane 3, 5 and 6 - BamHI digested recombinant (p-gar) vector; lane 4 -
BamHI digested non-recombinant vector (p-gat).
To confirm the identity and orientation of the insert cloned in pMAL-C2x, the isolated
plasmid DNA from two separate white colonies were analysed. Figure 5.6 shows restrict ion
digestion analysis of two recombinants. As can be seen in lanes 2 and 3, the plasmid DNA
from the two colonies chosen contains a 800 bp band corresponding to the 822 bp insert.
These colonies were both digested with HindIII (lanes 4 and 5). HindIII occurs naturally in
the sequence of the insert (Chapter 4, Figure 4.4) originally cloned using PCR. Due to the fact
the HindIII is also present in the polylinker, downstream from the BamHI site, digestion of
recombinant DNA with this enzyme, determines the identity and orientation of the insert
DNA.










Figure 5.6 Analysis of recombinant pMAL clones using restriction enzyme digestion..
Agarose gel electrophoresis Cl %). Lane 1 - BamHI digested non-recombinant pMAL; lane 2 -
BamHI digestion of recombinant pMAL (white colony 1); lane 3 - BamHI digestion of
recombinant pMAL (white colony 2); lane 4 - HindUI digested pMAL (white colony 1); lane
5 - HindIII digested pMAL (white colony 2).
According to the sequence of the 822 bp insert cloned into pMAL, digesting with HindIII
should produce fragments of 629 bp and 7277 bp if the insert is in the desired orientation. If
the insert has been ligated in the opposite direction, the sizes were predicted to be 193 bp and
6841 bp. Colony 1 plasmid DNA digested with HindIII (lane 4) produces two bands. The size
of the smaller of these bands was estimated using the molecular markers , to be 615 bp. This
correlates to the sizes predicted for this digestion , and confirms the orientation of insert DNA.
The insert DNA can be verified as being the correct 822 bp insert, sub-cloned from
pMOS817. Lane 5 shows colony 2 plasmid DNA resulting in a band estimated to be 200 bp,
from a similar digestion with HindU!. This compares to the expected size when the insert is in
an incorrect orientation. The sizes of the high molecular weight bands could not be
effectively resolved at this gel percentage, although it can be seen that the degree of migration
is slower for vector with smaller fragments cleaved out, indicating an expected correlation
between the two reaction product sizes.
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5.2.6 Nucleotide sequencing of polylinker region and insert DNA in recombinant
pMAL plasmid
The insert in the pTS822 plasmid was sequenced using universal primers pMAL(F) (GGT
CGT CAG ACT GTC GAT GAA GCC) and pMAL(R) (CGC CAG GGT TTT CCC AGT
CAC GAC). The universal primer used for sequencing pMAL vectors (New England Biolabs)
initiates sequencing near the 3' end of the malE gene, roughly 78-81 bases upstream of the
polylinker site. Figure 5.7 shows the nucleotide sequence generated from the forward and
reverse cycle sequencing reactions of the insert in the pMAL vector.
GCGCGCAGAC TAATTCGAGC TCGAACAACA ACAACAATAA CAATAACAAC AACCTCGGGA
TCGAGGGAAG GATTTCAGAA TTCGGATCCA ACTATCTTGT TAATAATCTT CAATTAAATA
AAGACAATGA TAATATTATT ATTATTAAAT TTAATATTTT AAAACTATTC AAATTAGGTT
CATGCTATTT ATATATTATT AATCGTAATT TAAAAGAAAT CCAAATGTTG AAAAATCAAA
TCCTTTCCTT AGAAGAAAGC ATTAAAAGCT TAAATGAATT CATTAATAAT CTAAAAAACG
AAAATGAAAA AAATGAATTA ATTAAAATAA ATAATTTTGA AGAAATACTC AAATTAAAAA
ATAATCTACA AGATAATGAA AGTTGTATAC AAAACTTAAA TAATTATTTA AAAAAAAATG
AAGAATTAAA TAAAATTAAT GTAAAAAATA TTTTCAAATA TAAAGGATAT ATAATTCATT
TAATACAACA AAGTAATGTC TTTTGTAAAA TTTTTAAACA TTTTAATGAA AATAAAATTA
TTGATCAAAG TATTATAAAC AAATTACTTT ATTTAAAAAA ATCCTTTGAT TTTTATATGT
ATGATTCGGT TATACAAGAA ATAAGAGAAA ATAAAAATAT AATAATAAAT CAAGATTTTT
TAACAGATGA ATATTTTAAA CATATACAAA CCTTTACCAA AACATGTAAT GTATTAATTC
AAAGGGGATA TCTCAGCATC TTAAAAGATA CAAACAATGA TTTCTTTATA CAAAACAAAC
AAAGTAATCA ACAAGGAAAT CAAAATGGTA ACCATATAAA TATGTGTAAC ATATATCCAG
ATGATGAAAT CAATGTAACT GCTGATCAAC AAATTTTTGA TGGGACGGAA AACGTACCAC
ATCGGATCCT CTAGAGTCGA CCTGCAGGCA AGC'l'GGGCAC TGGCCG'l'CG'l' 'l''l''l'ACAACG'l'
CG'l'GACTGGG AAAACCCTGG CGTTACCCAA CTTAATCGCC TTGCAGCACA TCCCCCTT'l'C
GCCGC'l'GG
Figure 5.7. DNA sequence obtained from sequencing reaction of insert region in pMAL-
C2x. Vector specific DNA (polylinker region) is indicated in bold and the BamHI site used
for cloning is underlined.
Figure 5.8 show this sequence translated into ammo acids to verify the successful
incorporation of the insert DNA.
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A Q T N S S S N N N N N N N
5' GGC GCG CAG ACT AAT TCG AGC TCG AAC AAC AAC AAC AAT AAC AAT
N N N L G I E G R I S E F G S
AAC AAC AAC CTC GGG ATC GAG GGA AGG ATT TCA GAA TTC GGA TCC
N Y L V N N L Q L N K D N D N
AAC TAT CTT GTT AAT AAT CTT CAA TTA AAT AAA GAC AAT GAT AAT
I I I I K F N I L K L F K L G
ATT ATT ATT ATT AAA TTT AAT ATT TTA AAA CTA TTC AAA TTA GGT
S C Y L Y I I N R N L K E I Q
TCA TGe TAT TTA TAT ATT ATT AAT CGT AAT TTA AAA GAA ATC CAA
M L K N Q I L S L E E S I K S
ATG TTG AAA AAT CAA ATC CTT TCC TTA GAA GAA AGe ATT AAA AGC
L N E F I N N L K N E N E K N
TTA AAT GAA TTC ATT AAT AAT CTA AAA AAC GAA AAT GAA AAA AAT
E L I K I N N F E E I L K L K
GAA TTA ATT AAA ATA AAT AAT TTT GAA GAA ATA CTC AAA TTA AAA
N N L Q D N E S C I Q N L N N
AAT AAT CTA CAA GAT AAT GAA AGT TGT ATA CAA AAC TTA AAT AAT
y L K K N E E L N K I N V K N
TAT TTA AAA AAA AAT GAA GAA TTA AAT AAA ATT AAT GTA AAA AAT
I F K Y K G y I I H L I Q Q S
ATT TTC AAA TAT AAA GGA TAT ATA ATT CAT TTA ATA CAA CAA AGT
N V F C K I F K H F N E N K I
AAT GTC TTT TGT AAA ATT TTT AAA CAT TTT AAT GAA AAT AAA ATT
I D Q s I I N K L L Y L K K S
ATT GAT CAA AGT ATT ATA AAC AAA TTA CTT TAT TTA AAA AAA TCC
F D F Y M Y D S V I Q E I R E
TTT GAT TTT TAT ATG TAT GAT TCG GTT ATA CAA GAA ATA AGA GAA
N K N I I I N Q D F L T D E y
AAT AAA AAT ATA ATA ATA AAT CAA GAT TTT TTA ACA GAT GAA TAT
F K H I Q T F T K T C N V L I
TTT AAA CAT ATA CAA ACC TTT ACC AAA ACA TGT AAT GTA TTA ATT
Q R G y L S I L K D T N N D F
CAA AGG GGA TAT CTC AGe ATC TTA AAA GAT ACA AAC AAT GAT TTC
F I Q N K Q s N Q Q G N Q N G
TTT ATA CAA AAC AAA CAA AGT AAT CAA CAA GGA AAT CAA AAT GGT
N H I N M C N I Y P D D E I N
AAC CAT ATA AAT ATG TGT AAC ATA TAT CCA GAT GAT GAA ATC AAT
V T A D Q Q I F D G T E N V P
GTA ACT GCT GAT CAA CAA ATT TTT GAT GGG ACG GAA AAC GTA CCA
H R I L *CAT CGG ATC CTC TAG AGT CGA CCT GCA GGC AAG CTG GGC ACT GGC
CGT CGT TTT ACA ACG TCG TGA CTG GGA AAA CCC TGG CGT TAC CCA
ACT TAA TCG CCT TGC AGC ACA TCC CCC TTT CGC CGC TGG 3 '
Figure 5.8 Translation of DNA sequence obtained from sequencing reaction. The insert
DNA and protein is shown in bold, the BamHI sites are underlined, the T cell epitopes are
shown in red and the casein kinase phosphorylation site is shown in blue. * Denotes a stop
codon.
As can be seen (Figure 5.8) the reading frame is conserved as the cloned 822 bp open reading
frame is continuous with the 3' end of the malE gene. The introduction of the BamHI site in
the 5' end of the insert causes a glycine and a serine to replace the isoleucine and asparagine
residues in the orignal sequence. There are no other mutations of the DNA sequence region to
be expressed as a fusion protein, as checked by an alignment using this amino acid sequence
and that of the original sequence from the database.
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5.2.7 . Induction and expression ofMBP-Pf32.5 fusion protein .
. .
The presence of expressed fusion protein was evaluated using SDS-PAGE ofE. coli total cell
extract (Figure 5.9). Cells containing the pMAL-C2x non-recombinant plasmid, were induced
with 0.3mM IPTO (Section 2.8.1). A fusion protein of approximately 50 kDa is seen in lane 3
and the presence of a large dark band indicates the induction of the malE gene product to be
efficient, producing high yields ·of the MBP-~-gal-a. fusion protein (50.8 kDa). Three
recombinant colonies were chosen. pTS822A contains the 822 bp insert in the reverse
orientation (Figure 5.12), therefore disrupting the open reading frame upstream from the
lacZa. region. This plasmid was used as a control in this experiment. pTS822B and pTS822C
. contain insert DNA in the correct orientation and reading frame, as confirmed by restriction
analysis and DNA sequencing.
Lanes 4 and 5 are the non-induced and induced culture fractions respectively of clones
containing the insert in the wrong orientation. The MBP is expressed without the lacZa
fusion, as the open reading frame is disrupted. The MBP protein in this state is known as
MBP2 and has a molecular weight of 42,5 kDa. This is seen in lane 5 where upon induction
with IPTG there appears to be an expressed protein of approximately 40 kDa. In contrast the
constructs (lane 6- 9) with in-frame inserts, do not have expression protein bands atthis size..
There appears to bean increase in the density of the protein band estimated to be 75 kDa,
which can be seen more markedly in lanes 7 and 9(see arrow, Figure 5.9), in comparison to
that of the control lanes. The expected size of the MBP-Pf32.5 fusion expressed from this
plasmid is 75 kDa, as the cloned open reading frame codes for a 32,5 kDa region and the
MBP protein is 42,5 kDa. It can also be seen that some of the bands around 40 kDa appear to
be more intense, possibly due to .degradation of the fusion protein. The relative size of the
band at approximately 75 kDa is much larger and more evident in the correct clones than in
the incorrect plasmid. The 50 kDa, and at 42 kDa bands are absent from these two lanes
further indicating the identity of the 75 kDa protein.





Figure 5.9 SDS-PAGE analysis of induction and expression of MBP-Pf32.5 in E. coli
JM103. (7.5% running gel; 4% stacking gel). Lane 1 - Low weight molecular markers
(Phosphorylase b, 97.4 kDa; Bovine serum albumin, 68 kDa; Ovalbumin, 45 kDa), lane 2 -
Non-induced MBP control, lane 3 - induced MBP control, lane 4 - non-induced pTS822A,
lane 5 - induced pTS822A, lane 6 - non-induced pTS822B, lane 7 - induced pTS822B, lane 8
- non-induced pTS822C, lane 9 - induced pTS822C, lane 10 - Low weight molecular markers.
The arrows indicate the band thought to represent the MBP-Pf32,5 fusion protein.
5.2.8 Detection of fusion protein by western blot analysis using anti-MBP antibodies
The visualisation of expressed protein bands, in conditions of inefficient induction, is often
ambiguous due to the presence of many other E. coli proteins in the fractionate. One of the
methods for identifying which of the bands may be the expressed fusion protein is western
blotting, and immunochemical detection of the MBP protein using anti-MBP antibodies. The
antibodies can be used to label specific bands from fractions run on an SDS-PAGE gel. Figure
5.10 shows the detection of the MBP by western blotting using anti-MBP antibodies (as per
Section 2.2.1).








Figure 5.10 Western blot analysis of MBP and MBP-Pf32.5 expression using anti-MBP
anitbodies. (A). SDS-PAGE (7.5%; 4%) Lane 1 - non-induced MBP control, lane 2 -
induced MBP control, lane 3 - non-induced pTS822A, lane 4 - induced pTS822A, lane 5 -
non-induced pTS822B, lane 6 - induced pTS822B. (B) Western blot analysis of SDS-PAGE
gel in (A), using rabbit anti-MBP antibodies and goat anti-rabbit antibodies with HRPO
conjugate for substrate based detection. The arrow indicates the fusion protein MBP-Pf32.5.
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As can be seen in the control pMAL (no insert) lane 2, a large band was detected estimated to
be approximately 50 kDa (Figure 5.l0B). A band is also seen just below the 45 kDa marker.
Lanes 3 and 4 are the recombinant pMAL plasmid with the insert in the opposite orientation.
The expressed protein should be MBP2 (42,7 kDa) as the insert disrupts the reading frame
and the full MBP lacZa fusion (50,8 kDa) is not synthesised. A band in lane 4 of Figure
5.l0(A) corresponding to the size ofMBP2 was also detected by anti-MBP antibodies in the
western blot (Figure 6.10B). The band thought to represent the recombinant fusion protein,
induced with IPTG (estimated to be approximately 75:-80 kDa), was detected with anti-MBP
antibodies in the western blot. This confirms that this band is an MBP fusion protein, and due
to the size analysis, appears to be expressed at the expected size of74.99 kDa.
There also appears to be a protein band detected at about 60 kDa and minor bands lower down
in the gel. Due to the fact that the host E. coli strain is a: cloning strain and not an expression
strain (protease deficient), this may represent degradation products of the expressed protein
due to host proteases. This is also seen in the other lanes where there are several other sizes
detected. These lower molecular weight bands detected in the recombinant fractionate are
present in the control lanes (lane 4), and so are not as a result of the open reading frame,
Pf32.5 . The lowest molecular weight band seen detected in the western blot appears to be
present in the non-induced lanes, and so may be a non-specific detection.
5.2.9 Induction and expression of GST-fusion proteins MAP! and MAP7 and detection
using anti-peptide antibodies
Figure 5.11 shows analysis of fusion protein expression using SDS-PAGE, for the protein
kinases , MAPl and MAP2. These are GST fusions, previously cloned into pGEX-4T-3. GST-
MAPl is approximately 76 kDa, and GST-MAP2, 69 kDa. The GST protein is not shown in
this figure as it is approximately 27 kDa and is poorly resolved at a SDS-PAGE gel
percentage of 7.5% : The fusion proteins are seen to be expressed in the induced sample lanes,
at sizes estimated using the molecular markers to be 75 kDa and 70 kDa, for GST-MAPl and
GST-MAP2 respectively. Due to these estimated sizes corresponding to the predicted sizes for
these fusions, these expressed bands are suggested as being the fusion proteins of interest.









Figure 5.11. SDS-PAGE analysis of expressed MAPl and MAP2 GST-fusion proteins,
and detection of MAP2 on a Western blot. (7.5% running gel; 4% stacking gel). Lanes 1
and 5 - High weight molecular markers (Myosin. 212 kDa; a2-macroglobulin, 170 kDa; p-
Galactosidase, 116 kDa; Transferrin, 76 kDa; Glutamic dehydrogenase, 53 kDa); lane 2 - non-
induced GST-MAP2; lane 3 - induced GST-MAP2; lane 4 - western blot analysis using anti-
map-2 antibody; lane 6 - non-induced GST-MAPl ; lane 7 - induced GST-MAPI; lane 8 -
western blot analysis using anti-map-l antibody. The arrow shows the position where GST-
MAP I should be expressed.
Antibodies raised in chickens against peptides contained within the MAPI and MAP2
proteins (peptides VHE and CPQ) were used in a western blot experiment as the primary
antibody to detect the expressed proteins. As can be seen GST-MAP2 (lane 4) was detected,
verifying the expression seen for this construct. Though the MAP I protein is visibly
expressed (lane 7) the antibodies used did not give any positive detection band.
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5.3 Discussion and conclusion
These experiments describe the sub-cloning of the 822bp malaria insert from the
pMOS817 plasmid into the expression vector pMAL~C2x, to form pTS822. The white
colonies obtained in the transformations were screened and analysed, to identify the 'size
and verify the sequence of the insert DNA. Due to the fact that the insert DNA prepared
for cloning contains BamHI sites on either end of the fragments, the insert can be cloned
into the BamHI site ofpMAL-C2x in either orientation. Also, because only one restriction
site is used in the polylinker, there is a high degree ofre-circularisation of vector DNA
without the incorporation of insert. To reduce this, the vector DNA can be
dephosphorylated using calf intestinal alkaline phosphatase (ClAP), which removes the 5'
phosphates from the termini of DNA fragments, preventing self-ligation. Increasing the
amount of insert used in the reaction also increases the chances for recombination. As can
be seen from these experiments, the presence of several white colonies (~-gar) in the test
transformations, and the identification of a positive clone, negates the need to retry other
methods to increase the recombination efficiency.
It is interesting to note that in the 'no-ligase' control, there are still a number of colonies
seen, resulting from plasmid that were not digested in the initial BamHI digestion of
vector DNA. Even though there was no evidence of circular vector when the reaction was
visualised on an agarose gel, these background colonies result. The appearance of
hundreds of colonies when ligase was included in this reaction indicates the effectiveness
of the enzyme in ligating DNA termini. The transformation efficiency (2.6 x 107 cfu/ug
DNA) was high enough to conduct these experiments for the competent cells prepared by
the CaCh technique. Although this efficiency was lower than that of the MOSBlue cells
used for blunt-cloning the initial PCR product, this was expected as the transformation
efficiency decreases with an increase in the size of the plasmid DNA. The pMAL vectors
are 6648 bp, compared to the 2887 bp pMOSBlue vector. Due to the size of the vector it
is more difficult for the plasmid to be introduced into the cell, and smaller particles are
generally transformed more efficiently.
The method used to determine the orientation of the insert DNA cloned into the vector,
relied on restriction digestion analysis. This took advantage of the natural internal HindIII
site in the insert sequence. Figure 5.12 shows the basis for these analyses, and the sizes of
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the restriction fragments expected. As can be seen, digestion with HindUI will cleave at
the position in the multiple cloning site and the site within the 822 bp insert. This allows
the orientation of the insert to be determined. Digestion of the in-frame construct will
result in a 629 bp fragment. This analysis (section 5.2.5) allowed a clone with the desired
insert orientation to be identified and picked. The plasmid (PTS822) was grown up and
stock cultures made, to allow for further experimentation with the plasmid.
3'
SalI PstI HindIIIBamHI XbaIEeoRl BamHI EcoRl HindIII
5'_-l-__I--__.l--l- ~----+-----I----4-----lo---+--
Correct insertion
HindIII EcoRl BamHI XhaI SalI PstI HindIIIEeoRl BamHI
5'--I---+------------++--i--+--+---+--+_ 3'
Incorrect insertion
Figure 5.12 Restriction maps of pMAL ligated with 822 bp insert in both
orientations, showing restriction sites used for analysis.
Sequencing the insert in pTS822 using universal pMAL sequencing primers verified the
successfulligation of the insert, in frame with MBP. This also confirmed the sequence of
the insert and served to check for any mutations in the sequence introduced during the
original PCR reaction where the Taq polymerase may have caused mistakes in the
synthesis. It is also interesting to note that the DNA sequence cloned, is identical to that
obtained originally off the PlasmoDB (Plasmodium falciparum, 3D7) database. This
result allows further protein induction and expression experiments to be conducted using
this plasmid. The plasmid-containing insert DNA in the reverse orientation was also
sequenced. It was predicted from this sequence data that the incorrect reading frame
introduces a stop codon shortly after the start of the insert. IPTG was used to induce the
bacteria to express the MBP fusion protein. This was analysed using SDS-PAGE where
the protein bands between non-induced and induced cultures were compared (Figure 5.9).
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MEP by itself (non-recombinant plasmid) showed efficient expression of the MBP
protein and served as a control for the induction. Western blotting using antibodies raised
against MBP were used to detect the protein. The position of the detection band in
relation to the SDS-PAGE gel allows the identification of appropriate MEP fusion
proteins. There was a minimal amount of expression seen for the recombinant fusion
protein, MBP-Pf32S
In these experiments it was noted that some lower weight bands were thought to represent
degradation products. The E. coli strain JMl03 is primarily used for cloning experiments
while other strains are more suited towards expression, and are protease deficient,
reducing the degradation of fusion proteins. As levels of fusion protein expressed for the
recombinant plasmid were relatively low, further experimentation can be performed to
optimise the levels of expression. This plasmid, pTS822 can be re-transformed into a
protease deficient host such as the BL2l strain. Optimisation of growth and induction
temperatures and times, will determine and maximise protein expression. This degree of
degradation may also contribute towards reduced protein expression levels, and re-
transformation into an appropriate expression host, may increase the amount of fusion
protein synthesised.
In a separate experiment, recombinant malaria protein kinases map-I and map-2, were
used to futher evaluate recombinant gene expression in E. coli, involving cloned malaria
open reading frames. Two pGEX expression vectors were evaluated for their expression,
GST-MAPl and GST-MAP2. SDS-PAGE analysis was used to visualise the induction
and expression of these proteins. Affinity purified antibodies raised in chickens against
peptides from immunodominant regions contained in the sequences of these proteins were
used to detect the fusion protein by western blot analysis. The anti-map-2 antibodies were
successful in the detection of MAP2 whilst under the same conditions MAPl was not
detected. Theseresults show how antibodies raised against peptides designed from the
proteins sequence, can be used to positively identify recombinantexpression. Where
MBP fusion proteins were detected using antibodies specific to MBP,.this method shows
the specific detection of the malaria protein cloned.
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pMOS817 construct - 817bp PCR product cloned into pMOSBlue vector
817 bp peR product
5' ATG GAT gga tee aae aac tat ctt
3 ' TAC CTA eet agg ttg aae tat ctt
Ndel BamHI
aae eta eaa cAT CGG ATC CCC GGG TAC CGA 3 '
ttg gat gtt gTA GCC TAG GGG CCC ATG GCT 5'
BamH Kpnl
Smal




GA TCC AAC AAC TAT CTT
G TTG TGG ATA GAA
AAC CTA CAA CAT CG
TTG CAT GTT GTA GCC TAG
3 '
5 '
pMAL c2x multiple cloning region
lie Glu Gly Arg
5 ' ATC GAG GGA AGG ATT TCA GAA TTC GGA TCC TCT AGA GTC GAC CTG CAG GCA AGC TTG 3'
3' TAG CTC CCT Tec TAA AGT CTT AAG CCT AGG AGA TCT CAG CTG GAC GTC CGT TCG AAC 5'
EcoRI BamHI Xbal san Pstl Hlndlll
GA TCC TCT AGA GTC GAC CTG CAG GCA C 3 '
G AGA TCT CAG CTG GAC GTC CGT T 5 '
Restriction digestion of pMAL c2x with BamHI
lie Glu Gly Arg lie Ser Glu
5' C GAG GGA AGG ATT TCA GAA TTC G
3 ' G CTC CCT TCC TAA AGT CTT AAG CCT AG
EcoRI Xbal san Pstl Hind III
Cohesive-end ligation of insert DNA into restricted pMAL-c2x vector in correct
orientation
Arg lie Ser Glu Phe Gly Ser Asn Asn Tyr Leu
5 ' ATT TCA GAA TTC Gg a tee aae aac tat ett aae eta eaa eat egG ATC CTC TAG 3 '
3 ' TAA AGT CTT AAG CCT Agg ttg ttg ata gaa . . . ttg gat gtt gta gee tag GAG ATC 5 '
EcoRI BamHI Xbal
Figure 5.13. Schematic diagram showing the construction of pTS822 by cohesive-
end ligation of sub-cloned insert (pMOS817) into the pMAL-C2x expression vector.
149
The detection of expressed fusion protein MBP-Pf32.5, combined with the results
obtained from sequencing, verify the successful synthesis of recombinant protein coded
by the 822 bp insert (276 amino acids) cloned in these experiments. Figure 5.13 shows an
overall summary of thecloningscheme used for these experiments, based on the insert
obtained from the pMOS817 plasmid. The diagram also indicates how the correct
translational reading frame is preserved in the ligation of the foreign open reading frame
into pMAL-C2x. This plasmid can now be used as a tool for investigating properties of
this region of Pf403 (amino acids 2355 - 2631). Analysis on the various features within
the protein sequence (T cell epitopes, phosphorylation sites etc.) can be performed. The
recombinant protein can be used to raise antibodies, for further immunological studies.
These in turn can be used to identify the presence and localisation of the protein using
immunofluorescent microscopy. This clone serves as the first of several overlapping
regions to be expressed for studies on antigenic properties. It codes for the region of




Over four thousand humans die from malaria every day in sub-Saharan Africa, mostly due to
the spread of drug resistance in P. jalciparum, the parasite responsible for the majority of
deaths, particularly in infants (Merckx et al., 2003). To reduce the number of fatalities, there is
an urgent need for control of the disease and the development of new effective
chemotherapeutic agents and vaccines (Ridley, 2002). The availability of databases containing
the sequenced genomes of P. jalciparum and the rodent malaria P. yoelii yoelii has
revolutionised the study of malaria. A wealth of molecular biological information can be
gained from utilisation of this sequence data, providing insights into the .genetic and
biochemical mechanisms within the parasite. The DNA sequencing of both the human
pathogen P. falciparum and the rodent model P. yoelii yoelii, has allowed research into
possible drug and vaccine targets. Homologues ofnovel proteins of interest can be identified,
cloned and expressed for further characterization.
Efforts based on the development of a human malaria vaccine have largely been based on the
assumption that antibodies mediate protection. However it is evident that cell-mediated
mechanisms play a significant role in resistance to malaria (Grun and Weidanz, 1981). T cell
epitopes on the parasite antigens, providing protective cellular immune responses have been
considered as potential immunizing agents. The purpose of this study was the identification of
P. jalciparum malaria proteins that may share homology to Pc96, due to the unique
immunological properties of this mouse antigen (Wanidworanun et al., 1989). The protein has
been shown to be associated with the outer membrane of mouse erythrocytes, using antibodies
raised against Pc96. A T cell clone that provided protection when grafted into nude mice
challenged with P. chabaudi adami (Brake et al., 1988) proliferated in the presence of
recombinant and native Pc96. The mice produced antibodies against an array of parasite
antigens, similar to those seen in infected euthymic mice. This was unexpected due to the
restricted ability of the clone to recognise diverse antigenic epitopes. This may suggest that
this T cell clone was capable of providing help to a variety of B cell clonotypes, specific to a
range of malaria antigens (Goldring et al., 1989). It was therefore of interest to identify the P.
jalciparum homolog and to obtain recombinant protein material to begin characterization of
the protein, and the role that the protein may have in promoting a human immune response.
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In the experiments described in Chapter 3, open reading frames containing overlapping
identity to the amino acid sequence of Pc96 (P. chabaudi adami) were identified in P.
jalciparum and P. yoelii yoelii. The sequences were obtained from the PlasmoDB database
and relate to Pc96 at the primary and secondary structure levels, with the identification of
possible tertiary structure and function. Pyy84 andPyy178 were shown to resemble regions of
Pf403, the P. jalciparum homologue of Pc96. Pc96 was evaluated for the presence of T cell
epitopes using the online T cell epitope recognition software, SYFPEITHI. Three of the
peptides identified were shown to be conserved in the homologous regions of Pf403 and
Pyy178 identified in Plasmodium jalciparum and Plasmodium yoelii yoelii respectively, and
may play a role in cell-mediated immunity. To evaluate the possible presence of these
epitopes in other malaria proteins, the P. jalciparum database (PlasmoDB) was screened using
the epitope sequences in a BLAST search for short nearly exact matches. In particular one
epitope (LIKYKFNII) conserved in Pc96, Pf403 and Pyy178 was aligned with several other
malaria proteins.
In an effort to elucidate features of structural homology in these proteins, the sequences were
screened against a database (3DPSSM) of known tertiary structure profiles. Two regions of
Pf403 were found to resemble the catalytic domain of the Botulinum neurotoxin, a zinc
metalloprotease, and several other features were found to indicate membrane association and
DNA binding. No other homologues were identified in other organisms providing functional
information.
In order to further study Pf403 to establish a possible function for the protein and its
interaction with the human host immune system, a series of PCR reactions were designed. A
range of oligonucleotide primers were designed for the in vitro amplification of the gene using
PCR, from purified P. jalciparum DNA, in preparation for cloning and recombinant
expression. The strategy for cloning in these studies was based on PCR-cloning, in which
restriction enzyme sites are included into the primer design for digestion and ligation into the
vectors (Kaufman and Evans, 1990). A number of open reading frames were successfully
cloned in this way. Cloning and recombinant expression of a variety of protein kinases
involved in the regulation of parasite development and programming of the cell cycle, was
achieved. PCR-cloning strategies were primarily used, resulting in the production and
isolation of fusion proteins in E. coli expression systems. Two mitogen-activated protein
kinase homologues, Pfmap-l and Pfmap-2, were cloned into the pGEX expression vector
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(GST fusion proteins) and were shown to be activated by phosphorylation. This indicates that
the open reading frame cloned, results in the correct folding and synthesis of the protein in an
active form. Methods used for the induction and expression of these two fusion proteins were
used in this study as a control for expression of malaria proteins in E. coli expression systems.
Recently, three novel cyclin-related proteins from P. jalciparum were identified and
characterised by molecular cloning and bacterial expression (Merckx et a!., 2003). In this
study, these pGEX plasmids, expressing pfmap-I and pfmap-2 were used as controls for
protein expression and evaluation on western blots with specific antibodies.
Recombinant malaria proteins can be used to determine the interactions of the proteins with
components of the immune system. In Chapter 5, the pfmap-l and pfmap-2 GST fusion
proteins were detected in a western blot system. Antibodies were previously raised in chickens
against peptides contained within the amino acid sequence of the proteins. The successful
detection of pfmap-2 using anti-peptide antibodies, allows the antibodies to be used in further
experiments such as localisation of the native proteins using immunofluorescent microscopy.
The antibodies can be used to screen expression libraries, identify the cross-reactivity of the
. antibodies , and for the isolation of native protein using affmity chromatography . Further
experiments will involve the evaluation of antibodies isolated from the sera of humans
infected with P. jalciparum, with regard to the recognition of the recombinant proteins. The
extent of recognition of proteins by the human immune system can be evaluated using
western-blotting and enzyme-linked immunosorbent assay (ELISA)-based techniques. This
approach will form a basis for the evaluation of recombinant proteins related to the Pc96
antigen, and their natural effect on infected populations of humans.
Due to the unknown function of the Pc96 protein, and the difficulty in identifying domains
and regions of specific 3D conformation, the region ofPf403 corresponding to, or overlapping
Pc96 and Pyy178 was initially chosen for cloning. This region includes the two conserved
putative predicted T cell epitopes along with other features such as the leucine zipper
conformation, and a casein kinase phosphorylation site, in the hopes that the conserved nature
and extended region of similarity to Pc96 would render a region of the protein with a specific
structure, conformation and function. Studies on this expressed protein will provide useful
information about Pf403, and the Pyy178 and Pc96 proteins. Certain immunological
experimentation is not possible using human malaria, due to the difficulty in obtaining human
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material from malaria patients and complex regulations involving human studies. With
Pyy178in Plasmodium yoelii yoelii , studies using the rodent model of infection are possible.
An initial study of the amplification of target malaria genes was performed using PCR
amplification of a 757 bp target from Plasmodium falciparum. The primers were designed to
amplify this region of the acetyl-coA carboxylase gene. Previously isolated genomic P.
jalciparum (3D?) DNA was used as a template for the reaction, and resulted in the
amplification of the 757 bp sequence, as verified by agarose gel electrophoresis. The
amplicons identity was confirmed using restriction digestion analysis. This PCR reaction was
used as a control for many of the reactions attempted for the amplification of target regions in
MAL3P6.11, encoding Pf403. One pair of oligonucleotides resulted in the amplification of a
817 bp target region. A Bamffi restriction site was included into the design of the forward
primer, to facilitate directional cloning into plasmid expression vectors. The PCR product was
identified by restriction digestion analysis, using restriction sites based within the sequence.
Attempts at directly cloning the 817 bp PCR product into pGEX were unsuccessful (Chapter
4). The strategy involved the blunt ending of the PCR product using the Klenow enzyme,
followed by restriction digestion with BamHI to generate a 5' cohesive overhang. These
fragments would have contained a cohesive and a blunt end for directional ligation into the
BamHI and SmaI sites in the poly-cloning region. It may have been that the BamHI site was
not digested, preventing ligation with pGEX, or that the extent of ligationwas too low to
identify recombinants with the screening methods used. The use of the pMOSBlue-c1oning
vector, introduced the c-complementation system of screening where colonies of the white
phenotype are selected as recombinants. This is observed directly off the transformation plate
allowing immediate selection of putative positive clones, in a system where the extent of
recombination may be too low to detect using conventional screening procedures. The
incorporation of the insert in the cloning vector allowed the BamHI sites to become
internalised, allowing complete and efficient digestion with restriction enzymes, as analysed
by agarose gel electrophoresis. The introduction of this step allowed the sub-cloning of the
insert DNA into the pMAL expression vector.
The pMAL expression vector (New England Biolabs) was chosen in this study due to its
success in previous cloning experiments. These involved PCR amplification of open reading
frames from P. falciparum, in particularly several protein kinases, by Doerig's group over the
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last number of years (Merckx et al., 2003). The vector offers the blue/white screening
capabilities, simplifying the process of the identification and screening of recombinants , and
enabling the isolation of fusion proteins using affinity chromatography (Guan et al., 1987).
The clones obtained were analysed using various restriction enzyme cleavage sites contained
within the vector and the insert DNA. The insert was sub-cloned from pMOS, containing
BamHI sites on either termini, one within the forward primer sequence used for the original
amplification, and the other derived from the pMOS polylinker region. The designed BamHI
site in the insert served to clone the fragment in frame to the lacZ coding sequence of pMAL,
forming a fusion protein with MBP. Successful in frame ligation depended on the inserts
orientation, which could have been in either direction due to the BamHI sites at both termini
(Figure 5.12, Chapter 5). The polylinker region in the recombinant pMAL plasmid was
sequenced to confirm that the insert had ligated in frame with the MBP coding sequence. The
recombinant pMAL vector was named pTS822 and was used in a series of studies on protein
expression.
The fusion protein encoded by pTS822 includes a 32,5 kDa region of the Plasmodium
jalciparum open reading frame, Pf403 ·and a 42,5 kDa MBP protein. The theoretical mass of
the MBP fusion protein is 75 kDa. In initial experiments, using standard growth and induction
conditions, and SDS-PAGE, it appears as if there is low expression of a fusion protein
estimated to be at a similar size to that expected. Anti-MBP antibodies raised against the
MBP protein were used to detect fusion proteins more sensitively by western blotting. This
was performed directly from the SDS-PAGE gels used to resolve the E. coli cellular proteins.
The antibodies detected the control and non-recombinant pMAL MBP protein, as well as the
fusion protein seen at approximately 75 kDa. Although several products of other sizes were
detected, these are a result of protein degradation effects, and are seen in the controls. These
degradation products can be removed by further optimisation of expression with this plasmid.
Isolated pTS822 DNA can be used to re-transfonnan E. coli host strain more suited to protein
expression than cloning .experiments. The strain used for these expression experiments was
JM103, a strain more genetically suited to cloning experiments (Chapter 5). Strains such as
BI2l and DH5a. may be more suited towards expression of the fusion protein, due to the lack
of host protease enzymes. The induction experiments can also be optimised for temperature
and time and .duration of induction. The amounts of expression in relation to other E. coli
proteins will obviously influence the amount that can be isolated from an affinity column
using MBP's affinity for maltose. As the PCR product was initially cloned into the pMOSBlue
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vector (Chapter 3), and the insert cloned further into the pMAL vector (Chapter 4), it should
be possible to sub clone the insert into the pGEX vector using a similar strategy. Although
MEP has been succesful in the expression of foreign proteins, fusion with an alternative
protein such as GST might improve the expression of the recombinant protein.
The cloned region (homologous to Pc96) of the gene encoding Pf403 in Plasmodium
falciparum (Pt32 .5) will be used in further studies to validate certain features previously
investigated in the protein sequence (Chapter 3) that may be used to study the nature of the
recombinant protein and its possible involvement in an immune response in humans. T cell
epitopes predicted within the sequence can be studied further, by synthesising peptides and
studying MHC binding (Vogt et al., 1994). A further approach can be the identification of T
cells that may recognised the antigen, once processed naturally. Several assays are available
that measure the response of T cells to antigens, such as the detection of cytokines and
proliferation studies. Antibodies raised against IL-2 and IFN-y, can be used in an ELISA
system to measure T cell responses (Troye-Blomberg et al., 1985). The MHC heavy chain has
been engineered to allow the biotinylation of the MHC-peptide complex and subsequently
detected by dye-bound avidin (Crawford et al., 1998). This indicates the proportion of T cells
specific to the antigen or T cell epitope studied. Another method for detecting cytokine
production is the amplification of induced cytokine mRNA using quantitative real time reverse
transcriptase polymerase chain reaction (RT-PCR). This has allowed the relative expression of
cytokines to be quantitated in a reproducible and sensitive fashion in disease. This is also
highly useful during vaccination studies with the peptides or antigen, as.a determination of the
recognition and activation of cytokine producing T cells (Schirle et al., 2001).
The region of the Pf403 protein was chosen due to its similarity to the Pc96 antigen. Regions
of the Pyy178 protein overlapping with Pc96 canbe similarly cloned and expressed. This will
provide further material to study the Pt32.5 recombinant protein, and any further regions of
Pf403 expressed due to the availability of a mouse model for parallel in vivo experiments on
the P. yoelii yoelii homolog. The establishment of mouse malaria with P. yoelii yoelii , will
also provide opportunities to further study the function of Pyy178 in malaria possibly
indicating a role for Pf403 in P. falciparum. The 817 bp PCR product amplified in this study
from P. falciparum DNA, or similar targets amplified from Pyy178, can be used to screen
various stages of parasite development, by the evaluation of mRNA in each stage. cDNA
libraries can be generated allowing further detection and cloning studies to be performed. .
156
To further study the Pf403 protein, B ·cell epitopes can be selected within the amino acid
sequence and synthesised as peptides, which can be used to raise antibodies. This has been
used successfully by Merckx et al (2003) in studies involving malaria protein kinases.
Peptides were chosen within the sequences of recombinant Pfcyc-1, Pfcyc-2, Pfcyc-3 and
Pfcyc-4, and synthesised, and used to raise antibodies in chickens. IgY was isolated from the
chicken egg yolks according the method used by Polson et al. (1985) using polyethy1ene
glycol (pEG) precipitation. The antibodies were affinity purified using the peptides, and used
in various pull-down experiments involving malaria kinase proteins in lysed malaria material.
Parasite extracts were exposed to the anti-peptide antibodies and native malaria proteins were
immunoprecipitated, allowing an evaluation of kinase activity within the extract. The anti-
peptide antibodies can be used in similar pull-down experiments, involving the isolation of
native Pf403 protein, and comparisons to the recombinant Pf32.5. These antibodies can be
further used in experiments such as immunofluorescent microscopy, for the detection of the
protein in various organelles. As the Pc96 protein was identified in the surface membrane of
red blood cells, this technique can be used to determine whether Pf403.is distributed similarly.
The expression of recombinant malaria proteins has played a vital role in understanding the
biology, metabolism and immunology of malaria. Due to the relative difficulty in the isolation
of pure native proteins from malaria extracts, this technique has been widely used for the
production and isolation of recombinant proteins. The recombinant forms of these proteins
have been shown to exhibit functional activity in many studies discussed. Recombinant
malaria proteins show potential for use in vaccine research, as particular regions or features of
proteins can be chosen according to their particular immunogenic .characterisitics. Genetic
engineering of recombinant antigens has allowed the synthesis of different components,
hoping to achieve an effective multi-component response.
In these experiments a region of a P. falciparum protein Pf403, which was shown to exhibit
close homology to the P. chabaudi adami antigen Pc96, was cloned and expressed in E. coli.
The pMAL expression vector was used to clone and express a MBP fusion protein (MBP-
Pf32.5). This recombinant protein could be used as a tool for evaluating its role in the P.
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